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CHAPTER 1 INTRODUCTION 
Parts of this chapter have been published in Clinical Lipidology, Vol. 9, No. 5, Pages 
533-551, 2014. 
 
Despite decades of studies, little is known about the molecular mechanisms 
underlying the neuropsychiatric disorders schizophrenia, depression, anxiety, and 
bipolar disorder (BD), which contribute about 14% of the global burden of disease 
(Prince et al., 2007). The development of effective treatments for these devastating 
illnesses is hampered by the failure so far to elucidate the molecular mechanisms 
underlying their pathologies.  Recent findings suggest that sphingolipids may play an 
important role in the pathophysiology of psychiatric disorders. Because sphingolipids 
are abundant in the brain and are involved in the regulation of processes essential for 
normal brain function, sphingolipids and sphingolipid metabolites may be promising 
targets for new treatments of psychiatric disorders.  
Lipids constitute about 50% of the dry weight of the brain, which has the second 
highest lipid composition after adipose tissue (Watkins et al., 2001; Morrel and Toews, 
1993). The mammalian nervous system is rich in sphingomyelin, glycosphingolipids, 
and molecules with ceramide backbones (Cutler and Mattson, 2001; Tettamanati, 
2004). Sphingolipids are a ubiquitous, highly conserved, diverse group of bioactive 
lipids, comprising about 10-20% of cellular lipids (van Meer et al., 2008). Technical 
advances in lipidomics and mass spectrometry in the past two decades have greatly 
facilitated the quantification and characterization of sphingolipids (Ejsing et al., 2009; 
Skevchenko and Simons, 2010). The yeast model has been invaluable in identifying 
and characterizing the genes and enzymes that mediate sphingolipid metabolism 
(Dickson and Lester, 2002), and elucidating the role of sphingolipids in the regulation of 
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essential cellular functions, including growth, endocytosis, protein trafficking, calcium 
homeostasis, aging, nutrient uptake, maintenance of lipid rafts, regulation of heat 
stress, actin cytoskeleton, and cell wall synthesis and repair (Dickson et al., 2006; 
Funato et al., 2002; Cowart and Hannun, 2004; Sims et al., 2004). Several of these 
functions have been associated with psychiatric disorders, including cellular signaling, 
endocytosis, inflammation, secretion, apoptosis, and proliferation (Breslow, 2013). The 
new lipidomic technologies, combined with the powerful yeast system to generate 
genetic and molecular models of sphingolipid functions that can be tested in relevant 
mammalian systems may offer promising new avenues for drug design.   
We begin with a comparison of sphingolipid metabolism in yeast and mammals. 
The very high degree of conservation of sphingolipid biosynthetic enzymes and of the 
functions of individual sphingolipids and metabolites underscores the utility of yeast to 
elucidate molecular mechanisms underlying sphingolipid function. We then discuss 
studies associating perturbation of sphingolipids with schizophrenia, depression, 
anxiety and BD. Finally, we suggest avenues whereby yeast can be exploited further to 
design drugs that may be used to modulate sphingolipid targets that are implicated in 
these disorders.  
1. Sphingolipid structure 
Sphingolipids contain two hydrophobic tails, including a long chain base (LCB) 
and a fatty acid chain, linked to a hydrophilic polar head group. The fatty acid is linked 
to the C-2 of the LCB via an amide bond, and the polar head group is linked to C-1 of 
the LCB via an OH group (Kihara et al., 2007). The basic sphingolipid structure is 
shown in Fig. 1.1. 
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In the yeast Saccharomyces cerevisiae, LCBs are linear alkanes containing 
hydroxyl groups on C-1 and C-3 and an amino group on C-2. The two major LCBs 
found in yeast are dihydrosphingosine (DHS) and phytosphingosine (PHS). PHS 
contains an extra hydroxyl group on C-4 compared to DHS. DHS in yeast contains 16, 
18 or 20 carbons, and PHS contains 18 or 20 carbons (Lester and Dickson 2001). 
Sphingosine, the major LCB of mammals, is not found in yeast. Mammals also have 
minor amounts of DHS (Dickson and Lester 2002). The mammalian LCB, sphingosine, 
contains a 4,5- trans double bond, which is not found in yeast (Dickson and Lester, 
1999).  
The fatty acid linked to the LCB in yeast is generally a C26 saturated fatty acid 
containing zero to three hydroxyl groups, whereas the fatty acids in mammalian 
sphingolipids vary in chain length, degree of hydroxylation and saturation (Dickson et 
al., 2006). The hydrophilic polar head group also varies. In yeast, these groups are 
myo-inositol containing namely, phosphorylinositol, mannosyl phosphorylinositol, or 
mannosyl diphosphorylinositol. In mammals, the polar groups are mostly 
phosphorylcholine (sphingomyelin), galactose (galactosylceramide) or glucose 
(glucosylceramide). Mammals contain more than 100 classes complex sphingolipids, 
while yeast contain only three (Kihara et al., 2007). 
2. Comparative sphingolipid metabolism in yeast and mammals 
Sphingolipids have long been known to play a structural role in cell membranes 
(Obeid et al., 2002). In addition, studies in yeast and mammals have shown that 
sphingolipids act as secondary messengers in several signaling pathways (Dickson et 
al., 1998). The sphingolipid synthesis pathway in yeast and mammals is highly 
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conserved through the synthesis of ceramide, with minor variations in chain length, 
hydroxylation and saturation (Epstein and Riezman, 2013). Ceramide is synthesized in 
the endoplasmic reticulum (ER) and transported to the Golgi, where complex 
sphingolipids are synthesized in both yeast and mammals (Breslow, 2013). The 
sphingolipid biosynthetic pathways of yeast and mammals are shown in Fig. 1.3.    
2.1 Synthesis of long chain bases (LCBs)  
The synthesis of LCBs, the precursors of sphingolipids, is highly conserved from 
yeast to mammals. Sphingolipid synthesis begins in the ER with the condensation of L-
serine with fatty acyl-coenzyme A (CoA), primarily palmitoyl-CoA (but also stearoyl-
CoA), catalyzed by serine palmitoyl transferase (SPT), which produces 3-
ketodihydrosphingosine (KDHS) (Gable et al., 2003; Hanada, 2003; Lowther et al., 
2012). The genes encoding these enzymes are shown in Table 1.1. 
In the second reaction of sphingolipid synthesis, the short-lived product KDHS is 
reduced to DHS in an NADPH-dependent reaction catalyzed by 3-
ketodihydrosphingosine reductase (Dickson 2008; Beeler et al., 1998; Kihara and 
Igarashi 2004). PHS is synthesized in yeast via hydroxylation of C-4 of DHS, catalyzed 
by sphinganine C4-hydroxylase (Dickson, 2008). The reverse reaction, conversion of 
PHS to DHS, does not occur. PHS is also found in the skin epidermis of mammals 
where it regulates important functions such as apoptosis, inflammation, and 
differentiation (Kim et al., 2014).  
2.2 Ceramide synthesis  
Ceramide is the central intermediate of sphingolipid metabolism. Interestingly, 
altered ceramide levels have been associated with schizophrenia, depression, and BD, 
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as discussed below (Schwartzet al., 2008; Kornhuber et al., 2005). Ceramide exists as 
dihydroceramide or phytoceramide. DHS is linked to mostly a C26 fatty acid via an 
amide linkage at the C-2 position to form dihydroceramide. The ER-localized ceramide 
synthase catalyzes this reaction. In yeast, dihydroceramide is hydroxylated to 
phytoceramide by sphinganine C4-hydroxylase. Phytoceramide can also be 
synthesized by hydroxylating DHS to PHS, which is amide-linked to a C26 fatty acid 
(Dickson 2008). The yeast ceramide synthases Lag1 and Lac1 have overlapping 
functions, as single mutants of Lag1 and Lac1 are viable, while the double mutant is 
not (Cowart and Obeid 2007). Mammals contain six ceramide synthases, CerS1-6, 
which exhibit specificity for fatty acyl-CoAs.  CerS1 exhibits specificity for C18, CerS2 
and CerS4 for C22 and C24, and CerS5 and CerS6 for C16, while CerS3 utilizes a 
broad range of substrates (Mizutani et al., 2006). In mammals, dihydroceramide is 
desaturated by Δ4-desaturase between C-4 and C-5 to phytoceramide (Ternes et al., 
2002; Mizutani et al., 2004; Omae et al., 2004). 
2.3 Fatty acid elongation pathway 
Very long chain fatty acids required for ceramide synthesis are synthesized in 
the ER by the fatty acid elongation pathway. The fatty acid elongase complex adds two 
carbons to fatty acyl CoAs per cycle (Jakobsson et al., 2006). Each isoform of fatty 
acid elongase synthesizes a very long chain fatty acyl CoA of a characteristic length 
(Denic and Weissman 2007). The four steps of fatty acid elongation in yeast and 
mammals include condensation, reduction, dehydration, and a second reduction, as 
shown in Fig. 1.2. Malonyl-CoA is first condensed with acyl-CoA to synthesize 3-
ketoacyl-CoA, catalyzed by the highly conserved fatty acid elongase (Jakobsson et al.,  
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Figure 1.1. Sphingolipid structure. The sphingolipid backbone consists of a long 
chain base linked to a fatty acid chain via an amide link A polar head group R is linked 
to the OH of C-1 of the LCB via a OH bond R=H in a ceramide molecule; R= 
Phosphocholine in sphingomyelin; R= Sugar in glycosphingolipids.       Represents 
variations in the chain length.  
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2006). Three elongases in yeast exhibit specificity for fatty acids of specific chain 
length (Table 1.1). Elo1 catalyzes elongation of C14 to C16, Elo2/ Fen1 catalyzes 
elongation of C20 to C22 and C22 to C24, and Elo3/Sur4 catalyzes the elongation of 
C24 to C26 and, with a lower efficiency C22 to C24 (Oh et al., 1997). Mammalian fatty 
acid elongases are encoded by seven genes, ELOVL1-7, which also exhibit acyl chain 
specificity (Table 1.1). 
ELOVL6 elongates saturated fatty acyl-CoA chains of C16 or shorter. ELOVL3 
and ELOVL7 elongate both saturated and unsaturated fatty acyl-CoAs of C16 to C22 
but have highest activity for C18 (Ohno et al., 2010). ELOVL1 elongates saturated 
C18-C26 and monounsaturated C20:1 n-9 and C22:1 n-9 (Ohno et al., 2010). ELOVL1 
is the major elongase responsible for the synthesis of C24 containing sphingolipids, 
which are present in high amounts in mammals (Kihara, 2012). ELOVL4 elongates 
very long saturated fatty acids or polyunsaturated fatty acids with chains longer than 
C26. ELOVL2 and ELOVL5 exhibit specificity for polyunsaturated fatty acyl-CoAs. 
ELOVL2 elongates polyunsaturated fatty acyl CoAs with C22 and ELOVL5 with C18, 
and both can elongate polyunsaturated fatty acyl CoAs with C20 (Kihara, 2012). 3-
ketoacyl-CoA is reduced by 3-ketoacyl-CoA reductase to 3-hyroxyacyl-CoA, which is 
dehydrated to 2,3-trans-enoyl-CoA by 3-hydroxyacyl-CoA dehydratase. 3-hydroxyacyl-
CoA undergoes another round of reduction catalyzed by enoyl reductase to yield an 
acyl-CoA with 2 more carbon chains than the original acyl-CoA (Kihara, 2012). The 
steps in the fatty acid elongation pathway as well as the fatty acid elongases are 
conserved from yeast to mammals (Kihara, 2012).  
2.4 Complex sphingolipid synthesis   
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Complex sphingolipids differ from yeast to mammals primarily in their head 
groups. Mammals contain more than 100 different sphingolipid classes due to diverse 
head groups linked to ceramide, while yeast contain only three types of complex 
sphingolipids.  Yeast sphingolipids are derived mostly from phytoceramide and, to a 
lesser extent, dihydroceramide (Perry et al., 2005; Vallee and Reizman 2005). In yeast, 
ceramides are transported to the Golgi via vesicular or nonvesicular ATP-independent 
transport (Funato et al., 2002). The ER and the Golgi membranes must be in contact 
with each other for transport to occur (Funato et al., 2002). It is proposed that an ATP-
independent translocation protein transports ceramide to the Golgi at the contact sites 
(Funato et al., 2002). In the Golgi, a polar, hydrophilic head group is transferred to 
ceramide to form complex sphingolipids, which are transported to the plasma 
membrane where they are abundant (Dickson 2008; Sims et al., 2004; Funato et al., 
2002). The three types of complex sphingolipids synthesized in the yeast Golgi are 
inositol phosphoceramide (IPC), mannose inositol phosphoceramide (MIPC), and 
mannose (inositol-P)2 ceramide (M(IP)2 C).   
The synthesis of IPC, catalyzed by IPC synthase, occurs by the addition of 
phosphorylinositol to ceramide (Dickson 2008; Sims et al., 2004; Funato et al., 2002). 
MIPC is synthesized by the addition of mannose from guanosine diphosphate 
mannose to IPC via MIPC synthase. There are two MIPC synthase complexes in 
yeast, one containing Sur1p and Csg2p and the other composed of Csh1p and Csg2p 
(Dickson 2008; Sims et al., 2004). The most abundant complex sphingolipid, M(IP)2C, 
is formed by the addition of a second phosphorylinositol to MIPC, catalyzed by 
inositolphosphotransferase (Dickson 2008; Sims et al., 2004). 
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Figure 1.2. Fatty acid elongation pathway. Step 1: Malonyl-CoA is condensed with 
acyl-CoA to synthesize 3-ketoacyl-CoA. Step 2: 3-ketoacyl-CoA is reduced by 3-
ketoacyl-CoA reductase to 3-hydroxyacyl-CoA. Step 3: 3-hydroxyacyl-CoA is 
dehydrated to 2,3-trans-enoyl-CoA by 3-hydroxyacyl-CoA dehydratase. Step 4: 3-
hydroxyacyl-CoA undergoes a round of reduction catalyzed by enoyl reductase to yield 
an acyl-CoA with 2 more carbon chains than the original acyl-CoA. 
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In mammals, the C-1 position of ceramide is linked to a hydrophilic group such 
as phosphorylcholine, galactose, or glucose to form complex sphingolipids. Mammalian 
cells also exhibit both vesicular and non-vesicular ceramide transport. Vesicular 
transport involves coat protein complex II (COPII), which mediates vesicular transport 
of ceramides from the ER to the Golgi (Perry and Ridgway, 2005; Van Meer and 
Holthius, 2000). Non-vesicular transport of ceramides from the lumenal surface of the 
ER to the outer leaflet of the Golgi is mediated by the transporter ceramide transfer 
protein (CERT) (Hanada et al., 2003; Kumagai et al., 2005). Ceramide is primarily 
converted to sphingomyelin via the addition of a phosphorylcholine to the ceramide 
backbone by sphingomyelin synthase. There are two sphingomyelin synthases SMS1 
catalyzes the synthesis of SM in the Golgi. SMS2 is mainly responsible for the 
synthesis of sphingomyelin in the plasma membrane. In addition to its activity in the 
plasma membrane, SMS2 functions redundantly with SMS1 in the Golgi  (Hanada et 
al., 2007). Ceramide can also be galactosylated to produce galactosylceramide in the 
ER by galactosyltransferase (Holthuis et al., 2001). Galactosylceramide 
(galactocerebroside) is one of the predominant glycosphingolipid in the brain 
(Svennerholm et al., 1968).  
Ceramide transported via vesicular or non-vesicular transport to the Golgi, is 
glucosylated to glucosylceramide via glucosylceramide synthase (Schulte and Stoffel 
1993). Glucosylceramide and glycosylceramide act as precursors for the synthesis of 
glycosphingolipids, catalyzed by Golgi glycosyltransferases (Maccioni et al., 2011; 
Merill et al., 2011). These glycosyltransferases transfer a specific carbohydrate from a 
sugar nucleotide namely UDP-glucose, UDP-galactose, CMP-sialic acid to the 
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acceptor molecule, ceramide or the non reducing end of a growing carbohydrate chain 
attached to a ceramide molecule. Glucosylceramide, is galactosylated to produce 
lactosylceramide by galactosyltransferase (Perry and Ridgway, 2005; Hanada et al., 
2007). Lactosylceramide acts as a precursor for the synthesis of a number of complex 
glycosphingolipids such as GA2 (Nagata et al., 1992; Hidari et al., 1994), GM3 (Ishii et 
al., 1998), Gb3 (Kojima et al., 2000); and Lc3 (Merrill, 2011; Biellmann et al., 2008). 
GA2, GM3, Gb3 and Lc3 are then precursors for the synthesis of other complex 
glycosphingosphingolipids (Merrill, 2011). In addition, galactosylceramide is sialylated 
to produce GM4 ganglioside, or sulfated to produce sulfatides (Merrill, 2011). Sulfate 
esters of galactosylceramide, or sulfatides are thought to play a role in the function of 
myelin. Perturbation of complex sphingolipid synthesis (especially GM1 and sulfatides) 
has been described in schizophrenia, as discussed below. 
2.5 Long chain base phosphate (LCBP) 
 In yeast, the LCBs, DHS and PHS are phosphorylated to dihydrosphingosine 
phosphate (DHS-1P) or phytosphingosine phosphate (PHS-1P) by sphingolipid base 
kinases Lcb4 and Lcb5 (Nagiec et al., 1998). Lcb4 contributes about 97% of the kinase 
activity. Lcb5, which contributes about 3% of activity, is important for phosphorylation 
during heat stress (Nagiec et al., 1998; Ferguson-Yankey et al., 2002). Although the 
double mutant lacking both kinases has aberrant sphingolipid base content, it is viable 
(Cowart and Obeid, 2007).  
In mammals, sphingosine bases are phosphorylated at C-1 by two sphingosine 
kinases that are homologous to the yeast enzyme. Sphingosine-1-phosphate (S1P) is 
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the major product of the kinase but DHS-1P also exists (Kihara et al., 2007). S1P is an 
important signaling molecule, as discussed in 3.11.2.  
2.6 Ceramide-1- phosphate (C1P) 
In mammals, ceramides are phosphorylated at the C-1 position by the calcium-
stimulated ceramide kinase (CERK) to form ceramide-1-phosphate (C1P). C1P is a 
bioactive signaling molecule involved in macrophage migration, inflammation and 
vesicular transport  (Chalfant and Spiegel, 2005; Misutake et al., 2005; Kihara et al., 
2007). Ceramide kinase and C1P are not found in yeast (Sugiura et al., 2002). 
2.7 Catabolism of complex sphingolipids 
Isc1, the only sphingomyelinase (SMase) identified in yeast, hydrolyzes all three 
complex sphingolipids to phytoceramide. Isc1 is homologous to mammalian neutral 
SMase (Sawai et al., 2000). In mammals, five types of SMases degrade complex 
sphingolipids to ceramide. These include acid (aSMase), secretory (sSMase), alkaline  
(alk-SMase), Mg2+-independent neutral (nSMase), and Mg2+-dependent neutral 
SMases (Samet and Barenholz, 1999). A single gene, ASM/SMPD1, encodes both 
aSMase, which is targeted to the lysosomes, and sSMase, which is present in 
secretory vesicles (Wu et al., 2005; Duan, 2006). Alk-SMase is expressed in bile and 
intestinal tract (Wu et al., 2005; Duan, 2006). Very little is known about Mg2+-
independent neutral SMase, and the gene encoding this enzyme has not been 
identified. Three Mg2+-dependent neutral SMases have been identified (Tomiuk et al., 
1998, Hofmann et al., 2000; Krut et al., 2006). 
 2.8 Catabolism of ceramides 
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Figure 1.3. Synthesis and metabolism of sphingolipids in yeast and mammals. 
Common synthesis pathway: Sphingolipid synthesis begins in the ER in both yeast 
and mammals. Acyl-CoA is condensed with serine to form 3-ketohydrosphingosine, 
which is further reduced to dihydrosphingosine (DHS). C26 fatty acid is transferred to 
DHS to yield dihydroceramide. In yeast: DHS is hydroxylated to phytosphingosine 
(PHS), which is attached to a C26 fatty acid to synthesize phytoceramide. 
Dihydroceramide can also be hydroxylated to phytoceramide. Phosphatidylinositol is 
transferred to phytoceramide to produce inositolphosphorylceramide (IPC), which is 
mannosylated to mannoylinositolphosphorylceramide (MIPC). Another 
phosphatidylinositol group is added to MIPC to yield mannosyl(inositolphosphoryl)2 
ceramide [M(IP)2C]. In mammals: DHS is N-acetylated to dihydroceramide, which is 
converted to ceramide. Different polar groups are added to the ceramide backbone to 
synthesize complex sphingolipids, including phosphorylcholine to produce 
sphingomyelin, and galactose and glucose to synthesize galactosylceramide and 
glucosylceramide, respectively. Glucosylceramide can be modified by the addition of 
sugars such as fucose, galactose, sialic acid, N-acetylglucosamine and N-
acetylgalactosamine to produce several glycosphingolipids. Common cleavage 
pathway: Complex sphingolipids are catabolized to ceramide, which is cleaved to 
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LCBs. LCBs are phosphorylated to form LCBPs, which are dephosphorylated to LCBs 
or further cleaved to fatty aldehyde and phosphatidylethanolamine. In mammals, 
ceramide is phosphorylated to ceramide-1-phosphate (C1P). In yeast, Rsb1 transports 
sphingosine bases from the cytoplasmic side to the extra-cytoplasmic side of the 
membrane. 
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Ceramide that is synthesized de novo from sphingolipid bases or produced via the 
hydrolysis of complex sphingolipids is cleaved by ceramidases to LCBs, which can be 
phosphorylated or recycled for synthesis of ceramides (Ogretmen et al., 2002; Sultan e 
al., 2006). Reacylation of the cleaved sphingolipid bases to form ceramide is reported 
to be less efficient than the de novo synthesized sphingolipid bases, but it has been 
suggested that these cleaved bases can aid in the formation of ceramide with fatty 
acids of varying N-acyl chain length (Ogretmen et al., 2002; Sultan et al., 2006). Yeast 
contain two ceramidases, Ydc1 and Ypc1, while mammals contain three pH-dependent 
ceramidases. Acid ceramidases are located in the lysosomes (Koch et al 1996; Ferlinz 
et al., 2001). Neutral ceramidases are in the plasma membrane or secreted to the 
extracellular fluid following cleavage of the transmembrane region (Tani et al., 2003; 
Mao et al., 2001). Two alkaline ceramidases have been identified, one in the ER/Golgi, 
which selectively degrades phytoceramides (Mao et al., 2001), and one in the ER, 
which degrades N-acylsphingosine (Mao et al., 2003).  
2.9 Catabolism of LCBPs 
In yeast, DHS-1P and PHS-1P are cleaved by the sphingolipid lyase Dpl1 to 
generate ethanolamine phosphate and fatty aldehydes (Saba et al., 1997). This is the 
only known route whereby a sphingolipid can be converted to a non-sphingolipid. 
Ethanolamine phosphate is shuttled to synthesize phosphatidylethanolamine through 
the Kennedy pathway (Panwar and Scott- Moye Rowley, 2006). DHS-1P and PHS-1P 
are dephosphorylated to DHS and PHS. In mammals, S1P is catabolized to fatty 
aldehyde and phosphatidylethanolamine by S1P lyase encoded by SPL, which is 
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homologous to yeast DPL1 (Kihara et al., 2007).  S1P regulates cell survival, cell 
proliferation and migration, and neurotransmitter release  (Okada et al., 2009). 
2.10 Sphingolipid base transporter 
In yeast, deletion of sphingolipid lyase DPL1 leads to accumulation of 
sphingosine base phosphates and inhibits cell growth (Kim et al., 2000). In a screen to 
identify suppressors of the dpl1 mutant growth defect caused by the accumulation of 
sphingosine phosphates, the ATP dependent sphingosine transporter Rsb1p was 
identified (Kihara and Igarashi 2002). Rsb1p is thought to be a transporter or flippase 
that transports sphingosine bases from the cytoplasmic side to the extra cytoplasmic 
side of the membrane in order to maintain normal intracellular levels of LCBs and 
membrane composition (Kihara and Igarashi 2002). Homologs of Rsb1p have not been 
found in mammals.  
2.11  Sphingolipids regulate essential functions  
Metabolites and intermediates of sphingolipid metabolism, including (but not 
limited to) LCBs, ceramide, S1P, and C1P, are signaling molecules that regulate 
essential cellular processes that are required for the regulation for neuronal processes  
(Hannun and Obeid, 2008). These include SNARE complex formation, synaptic vesicle 
exocytosis at nerve terminals, neurogenesis, neural tube closure, apoptosis, 
neurodegeneration, and neurotransmitter release (Okada et al., 2009; Shinghal et al., 
1993; Kajimoto et al., 2007; Van Brocklyn et al., 2012; Mizugishi et al., 2005; Darios et 
al., 2009).  
2.11.1 LCBs and sphingosine  
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 LCBs regulate actin cytoskeleton, heat stress, and endocytosis (Hannun and 
Obeid, 2008). Heat stress causes a transient 2-3-fold increase in the levels C18 DHS 
and C18 PHS and a 100-fold increase in levels of C20 DHS and C20 PHS (Dickson et 
al., 1997; Jenkins et al., 1997). LCBs are required for proper actin cytoskeleton 
organization (Schmelze et a., 2002) and for the regulation of endocytosis (deHart et al., 
2002). LCBs also play a role in inhibiting uptake of uracil and amino acids tryptophan, 
leucine, and histidine (Chung et al., 2001). It is not understood how LCBs regulate 
amino acid transport, but PHS is important for ubiquitin-mediated breakdown of the 
uracil transporter Fur4 (Chung et al., 2000). 
Sphingosine activates synaptobrevin in synaptic vesicles, facilitating SNARE 
complex assembly, implicated in membrane fusion. In addition, sphingosine increases 
synaptic vesicle exocytosis in nerve terminals and neuromuscular junctions (Darios et 
al., 2009).  
2.11.2 S1P 
 S1P regulates cell survival, cell proliferation, migration and neurotransmitter 
release (Okada et al., 2009; Kajimoto et al., 2007), and rescues cells from ceramide-
induced apoptosis (Cuvillier et al., 1996). The effect of S1P depends on the level of 
neuronal differentiation. Thus, S1P induces proliferation in neural undifferentiated 
progenitor cells (Harada et al., 2004) but it increases apoptosis in well-differentiated 
neurons (Moore et al., 1999). In addition to its role in cell proliferation, S1P is important 
for neural and vascular development (Mizugishi et al., 2005). Sphingosine kinase 
mutants (SphK1 and SphK2) do not show any abnormalities, but the double mutant 
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exhibits embryonic lethality, perturbed neurogenesis, neural tube closure, and 
angiogenesis in mice (Mizugishi et al., 2005).  
2.11.3 Ceramide 
Ceramides are anti-proliferative and promote apoptosis (Van Brocklyn and 
Williams, 2012). Increased levels of ceramide cause cell death (Obeid et al., 1993), 
while depletion of ceramide reduces progression of apoptosis (Bose et al., 2005; 
Santana et al., 1996). Altered ceramide levels are linked to cancer, neurodegeneration 
and inflammation (Echten-Deckert and Herget, 2006). Maintaining normal ceramide 
levels is crucial for brain function. Ceramide is also known to regulate cell senescence. 
The genes LAG1 and LAC1, which encode ceramide synthase, regulate yeast life span 
(Schorling et al., 2005). The mammalian homolog of LAG1 (CerS1) is highly expressed 
in the brain (Pewzner-Jung et al., 2006). Overexpression of CerS1 leads to increased 
levels of C18 ceramide and induces apoptosis (Pewzner-Jung et al., 2006). CerS1- 
generated C18 ceramide negatively regulates the human telomerase reverse 
transcriptase promoter (Blasco et al., 1995; Menacarelli and Martinez-Martinez, 2012).  
Telomerase is expressed in neurons in the early stages of development, in neural stem 
cells and progenitors, but is downregulated in developed cells.  Telomerase protects 
post-mitotic neurons from stress-induced apoptosis and is important for survival of 
neurons in the developing brain. Therefore, C18 ceramide very likely contributes to 
neuronal vulnerability in age related neurodegenerative disorders (Menacarelli and 
Martinez-Martinez, 2012). Ceramide affects several signal transduction pathways.  The 
signaling molecules Akt serine/threonine kinase and PP2A are known targets of 
ceramide (Mora et al., 2002; Qin et al., 2012; Wolff et al., 1994). Ceramide was shown  
	  	  	  
19	  
	  
 
Table 1.1. Yeast and mammalian genes involved in sphingolipid metabolism  
Enzymes Genes References 
Yeast Mammals 
Serine palmitoyl 
transferase 
LCB1, LCB2, 
LCB3 
SPTLC1, SPTLC2, 
SPTLC3 
(Gable et al., 
2003; Hanada 
2003; Lowther et 
al., 2012) 
3-
ketodihydrosphingosine 
reductase 
TSC10 FVT-1 (Dickson 2008; 
Beeler et al., 
19998; Kihara 
and Igarashi 
2004) 
Sphinganine C4-
hydroxylase 
SUR2 - (Dickson 2008) 
Ceramide synthase LAG1, LAC1 
LIP1 
CERS1-6 (Cowart and 
Obeid 2006; 
Mizutani et al., 
2006) 
Dihydroceramide 
desaturase 
- DES1, DES2 (Ternes et al., 
2002; Mizutani et 
al., 2004; Omae 
et al., 2004) 
Fatty acid elongases ELO1, 
ELO2/FEN1, 
ELO3 SUR4 
ELOVL1-7 (Jakobsson et al., 
2006; Ohno et al., 
2010; Kihara 
2011; Kihara, 
2012) 
3-ketoacyl-CoA 
reductase 
Ybr159w, AYR1 KAR (Kihara 2011) 
3-hydroxyacyl-CoA 
dehydratase 
PHS1 HACD1-4 (Kihara 2011) 
Enoyl reductase TSC13 TER (Kihara 2011) 
IPC synthase AUR1 - (Dickson 2008; 
Sims et al., 2004; 
Funato et al., 
2002) 
Sphingolipid alpha-
hydroxylase 
SCS7 - (Dickson 2008; 
Sims et al., 2004; 
Funato et al., 
2002) 
MIPC synthase SUR1, CSH1 
and CSG2 
- (Dickson 2008; 
Sims et al., 2004) 
Inositolphosphotransfer
ase 
IPT1 - (Dickson 2008; 
Sims et al., 2004) 
Sphingomyelin 
synthase 
 SMS1 and SMS2 (Hanada et al., 
2007) 
Glucosylceramide - GlcT-1 (Schulte and 
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synthase Stoffel 1993) 
Galactosyltransferase - CGT (Schulte and 
Stoffel 1993) 
Long chain base kinase LCB4, LCB5 SPHK1 and 
SPKH2 
(Kihara et al., 
2007) 
Ceramide kinase  CERK (Sugira et al., 
2002) 
Sphingomyelinase ISC1 aSMase, sSMase: 
ASM/SMPD1 
alk-SMase: NPP7 
Mg2+ dependent 
neutral SMase: 
SMPD3, SMPD4, 
SMPD5 
Mg2+ independent 
neutral SMase: 
not known 
 
 
(Sawai et al., 
2000; Wu et al., 
2005; Duan, 
2006; Tomiuk et 
al., 1998, 
Hofmann et al., 
2000; Krut et al., 
2006) 
Ceramidase YDC1, YPC1 Acidic: 
ASAH1/AC 
Neutral: 
ASAH2/NCDase 
Alkaline: PHC, 
CER1/AAH3 
(Ogretmen et al., 
2002; Sultan e 
al., 2006; Koch et 
al 1996; Ferlinz et 
al., 2001). Tani et 
al., 2003; Mao et 
al., 2001; Mao et 
al., 2003) 
Sphingolipid-1-P lyase DPL1 SPL (Kim et al., 2000; 
Kihara et al., 
2007) 
Long chain base 
phosphatase 
LCB3, YSR3 SPP1, SPP2, 
LPP1-3 
(Panwar et 
al.,2006; Kihara et 
al., 2007). 
 
Sphingolipid transporter RSB1 - (Kihara and 
Igarashi 2002). 
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to reduce Akt phosphorylation at Ser473; this dephosphorylation was reversed after 
treatment with antidepressants (Gulbins et al., 2013). Ceramide induces mitochondrial 
outer membrane permeabilization (MOMP), important for induction of apoptosis, by 
forming ceramide channels. In addition, ceramide enhances the autophosphorylation of 
the kinase suppressor of Ras (KSR), which activates the RAF1/MEK/ERK MAPK 
cascade, inducing apoptosis (Zhang et al., 1997; Basu et al., 1998). Several studies 
have demonstrated that ceramide activates the JNK pathway (Westwick et al., 1995; 
Verheij et al., 1996; Nica et al., 2008). JNK activation regulates proteins of the Bcl-2 
family, involved in apoptosis (Bogoyevitch et al., 2006). Ceramide also activates PKC-
zeta and inhibits PKC-alpha (Muller et al., 1995), phenotypes that are reversed by 
antidepressants imipramine and amitriptyline (Kornhuber et al., 2005). These findings 
suggest that antidepressants may restore normal signaling that is perturbed by 
increased ceramide levels. 
2.11.4 Ceramide-1-phosphate (C1P) 
Phosphorylation of ceramide produces C1P, which decreases apoptosis in 
several ways.  C1P blocks ceramide synthesis by inhibiting acid sphingomyelinase 
(Gomez-Munoz et al., 2004) and SPT activity (Granado et al., 2009). C1P also 
enhances the activity of anti-apoptotic protein kinase B and NF-kappaB (NF-kB) 
(Granado et al., 2009). While the function of C1P has not been definitively elucidated, 
an early study proposed that it plays a role in synaptic vesicle functioning and release 
of neurotransmitters (Shinghal et al., 1993).  
3.  Sphingolipid metabolism in psychiatric disorders  
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As discussed above, sphingolipids affect essential cellular processes that are 
crucial not only for cellular homeostasis such as apoptosis, cell survival and 
development, but also for neuronal functions.  In particular, sphingosine is required for 
activation of exocytosis of the synaptic vesicles at the nerve terminal. Ceramide, S1P, 
and C1P regulate apoptosis, neurogenesis, and neurotransmitter release. In view of 
the key role of sphingolipids in neurogenesis, neuronal cell death and 
neurotransmission. It is not surprising that perturbation of sphingolipid metabolism is 
observed in depression, anxiety, schizophrenia, and BD. 
3.1 Depression 
Depression is a chronic, severe, life-threatening disorder characterized by 
depressed mood, insomnia, weight loss, loss of interest or pleasure in normal activities, 
feelings of worthlessness, and a high risk of suicide. The worldwide prevalence of 
depression is 10% (Belmaker and Agam, 2008). Recent studies suggest that 
depression is linked to a change in the levels of neurogenic and apoptotic factors in the 
hippocampus, leading to hippocampal atrophy and neurodegeneration (Santarelli, et 
al., 2003; David et al., 2009).  
A number of studies indicate that depression is associated with altered 
sphingolipid synthesis.  A recent lipidomic analysis identified significant alterations in 
plasma sphingomyelin species in patients with depression (Demirkan et al., 2013).  
Several studies, summarized below, report increased levels of ceramide and/or 
aSMase in depression, and decreased levels of these components following 
antidepressant treatment.  
3.1.1 Increased ceramide and acid sphingomyelinase in depression  
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Several studies suggest that increased ceramide levels are associated with 
depression.  Increased aSMase activity was observed in peripheral blood mononuclear 
cells of patients suffering from major depressive disorder who were free of therapy for 
at least 10 days (Kornhuber et al., 2005). As discussed above, aSMase converts 
sphingomyelin to ceramide and phosphorylcholine (Gublins and Kolesnick 2003; 
Perrotta et al., 2010). Therefore, this finding suggested that increased levels of 
ceramide might be associated with depression.  Consistent with this possibility, 
increasing the levels of ceramide by injecting C16 ceramide directly in the 
hippocampus or by administrating D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-
1-propanol (PDMP, a glycosyltransferase inhibitor that increases ceramide levels by 
inhibiting glycosylation of ceramide) induced depressive disorder-like symptoms in 
mice (Gulbins et al., 2013). Plasma ceramide levels were analyzed in Alzheimer 
disease patients with recent depression, past depression and no depression. 
Interestingly, ceramide levels were elevated in patients with recent depression 
compared to patients with past or no depression (Garcia-Garcia et al., 2011). Indirect 
evidence associating ceramide with depression comes from a report of increased 
activity of phospholipase A2, which is stimulated by ceramide, in patients with major 
depression (Nopnenm et al., 1993).  
3.1.2 Antidepressants inhibit aSMase activity and decrease ceramide levels  
If ceramide plays a causal role in depression, as suggested by the correlational 
studies cited above, antidepressants may exert their therapeutic effects by inhibiting 
aSMase, thus decreasing the release of ceramide from sphingomyelin. Consistent with 
this, treatment with antidepressants imipramine and amitriptyline caused a rapid 
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reduction of aSMase activity in peripheral blood mononuclear cells of depressive 
patients (Kornhuber et al., 2005). In addition, a therapeutic concentration of 
antidepressants amitriptyline and fluoxetine inhibited aSMase activity in cultured 
neurons (Gulbins et al., 2013). Wild type mice treated with antidepressants amitriptyline 
(a tricyclic drug) or fluoxetine (a serotonin reuptake inhibitor) exhibited decreased 
aSMase protein levels and activity (Gulbins et al., 2013). The high levels of ceramide 
present in mice heterozygous for mutant ceramidase were also decreased by 
antidepressants amitriptyline and fluoxetine (Gulbins et al., 2013). These studies 
suggest that antidepressants inhibit aSMase activity via the following mechanism. The 
inner leaflet of the lysosomal membrane is negatively charged due to the presence of 
the anionic lipid bis(monoacylglycero)phosphate (Schulze et al., 2009). Positively 
charged aSMase adheres to the inner lysosomal membrane leaflet electrostatically 
(Kolzer et al., 2004). Lipophilic compounds and weak bases such as antidepressants in 
the neutral form can pass passively through the cell and lysosomal membranes and 
accumulate in the lysosome, where they become protonated thus, trapped in the 
lysososme, increasing the antidepressant concentration in the lysosome (Duve et al., 
1974; Trapp et al., 2008). This changes the physiology of the lysosome. The lipophilic 
part of the drug adheres to the membrane, and the positively charged part of the drug is 
facing the lumen. Accumulation of the drug prevents the aSMase from adhering to the 
lysosomal membrane (Kolzer et al., 2004). This results in proteolytic cleavage of the 
enzyme, thus inhibition of the aSMase activity and increasing the levels of ceramide in 
the lysosome (Hurwitz et al., 1994). This suggests that antidepressants decrease levels 
of ceramide due to inhibition of aSMase activity via degradation of the aSMase protein, 
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which normalizes the reduced neurogeneisis and neuronal maturation caused by 
increased ceramide levels.    
 Interestingly, amitriptyline and fluoxetine increased neurogenesis, neuronal 
maturation and survival in wild type but not in aSMase-deficient mice, suggesting that 
the mechanism of action of the drugs is by affecting aSMase. Treatment of 
antidepressants amitriptyline and fluoxetine or the aSMase inhibitor fendiline 
attenuated corticosterone-induced depressive-like behavior in wild type mice but had 
no effect on corticosterone-treated aSMase-deficient mice (Gulbins et al., 2013). These 
studies suggest that increased levels of ceramide may play a causal role in the 
pathophysiology of depression, and that a potential therapeutic mechanism underlying 
antidepressant efficacy is the reduction of ceramide levels by inhibition of aSMase 
activity. Reducing ceramide levels could be the central goal for the development of new 
antidepressants.  
3.2 Anxiety 
Anxiety disorders are characterized by severe and prolonged distress and fear 
with physiological symptoms, which are manifested early and recur throughout life 
(Baxter et al., 2014). They are the sixth leading cause of disability in both low and high-
income countries (Baxter et al., 2014). Several studies suggest that sphingolipids may 
play a role in the pathophysiology of anxiety disorder.  In particular, increased levels of 
S1P are associated with anxiety-like behavior while increased levels of GM1 may 
reduce anxiety and cause neuroprotection.  
3.2.1 Increased levels of S1P  
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Chronic stress is known to cause anxiety-like behavior. In several models of 
stress-induced anxiety in rats, including daily immobilization for 3 weeks or electric 
shock followed by immobilization, serum S1P levels were increased (Jang et at., 2011). 
In the former model, increased expression of protein markers of neurodegeneration 
were also observed, including iNOS (inducible nitric oxide synthase), GFAP (glial 
fibrillary acidic protein) and NR1 (N-methyl-D-aspartate receptor channel). Infusion of 
S1P into the lateral cerebroventricle also led to increased expression of these protein 
markers, suggesting that stress-induced anxiety causes increased S1P, which leads to 
degeneration (Jang et al., 2008). However, an alternative possibility comes from a 
study using an elevated plus maze model of anxiety, in which S1P-treated animals 
spent significantly less time in the open arms of the maze, suggesting that S1P induces 
anxiety (Jang et al., 2011).  
3.2.2 Perturbation of glycosphingolipid levels   
 Precocious weaning is known to induce anxiety-like behavior in male mice, 
which is more pronounced than that observed in precocious weaned female or normal 
weaned mice (Ono et al., 2008). Interestingly, precocious weaned male mice exhibited 
an accumulation of galactosylceramide in the amygdala (but not in the hippocampus or 
prefrontal cortex), along with an increase in number and reduction in the diameter of 
myelinated axons at 5 weeks. Galactosylceramide and sulfatide contribute about 30% 
of the lipid content of the myelin sheath (Noton, 1984). The developmental time of 
myelin formation differs for each brain region (Akiyama et al., 2002). In normal-weaned 
male mice, galactosylceramide increases linearly until 8 weeks of age in the amygdala, 
and saturates by 5 weeks in the prefrontal cortex and hippocampus. Therefore, early 
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weaning may induce precocious myelination. Decreased axonal diameter could be 
caused by precocious myelination induced by early weaning. This can cause changes 
in axonal structure and neural circuts in basolateral amygdala, a site controlling anxiety 
like behavior (LeDoux, 1993; Schafe et al., 2001; Spiga et al.,2006). Therefore, 
precocious myelination of the amygdala in early-weaned male mice might affect the 
development of an anxiety-related network and thereby increase anxiety-related 
behavior. 
GM1 (monoamine ganglioside) is a neuroprotective sialic acid-containing 
glycosphingolipid (Ariga et al., 2008; Wallis et al., 1995). An early study suggested that 
GM1 improved memory but not anxiety. GM1 was administered to male rats containing 
electrolytic lesions in the left cortex. (Electrolytic lesions produce transient behavioral 
deficits (Reeves et al., 1997; Loesche et al., 1977). Working memory was measured in 
a Morris water maze and anxiety levels were tested in a plus maze. GM1 treatment led 
to improvement in the working memory, but not in the anxiety levels (Glasier et al., 
1995). However, GM1 was effective in blocking anxiety-related responses to ethanol 
withdrawal, including hypolocomotion, tremors and other anxiety-like behavior (Wallis 
et al., 1995). Pretreatment with GM1 or its constituent sialic acid was also effective in 
reducing effects of ethanol intoxication, such as nose-poke exploration, decreased 
locomotion, and anxiety (Wallis et al., 1995). Pretreatment with ganglioside or sialic 
acid also improved staircase climbing by 22%, consistent with lower anxiety (Wallis et 
al., 1995).  
These studies suggest that cerebrosides may play a role in anxiety, as 
galactosylceramide accumulates in at least one model of anxiety. Galactosylceramide 
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and GM1 are required for proper myelination of the axon, thus exerting a protective 
role. 
3.3 Schizophrenia 
Schizophrenia is a debilitating mental disorder with drastic psychosocial 
consequences. It is characterized by defects in synaptic connectivity in the white 
matter tracts, leading to cognitive abnormalities (Fitzsimmons et al., 2013). 
Schizophrenic patients exhibit both positive symptoms (delusions and hallucinations) 
and negative symptoms (social withdrawal and loss of motivation) (Liddle, 1987). 
Schizophrenia is known to affect 1% of the world population (Capuano et al., 2002; 
Merikangas et al., 2007). Several neurochemical and neuropathlogical theories have 
been proposed to explain the pathology of schizophrenia, including perturbations in 
GABAergic (Lewis et al., 2005), dopaminergic (Carlsson, 1980), and glutamatergic 
signaling (Kim et al., 1980; Olney and Farber, 1985), and aberrations in 
neurodevelopment (Weinberger, 1987), prefrontal cortex function (Andreasen et al., 
1986; Ingvar and Franzén, 1974), and inflammatory response (Lin et al., 1998; 
Rothermundt et al., 2001).  
3.3.1 Perturbation of complex sphingolipids  
 Complex sphingolipids are required for myelination of neurons (Boggs et al., 
2010). They play a role in carbohydrate-carbohydrate interactions between opposing 
membranes, cell-cell adhesion and transmembrane signaling, and communication 
between the axon and myelin sheath, which affects axonal and myelin functions and 
neurodegeneration (Boggs et al., 2008).  
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Decreased levels of complex sphingolipids, including sulfatides and 
cerebrosides were first observed in a postmortem schizophrenic brain in 1969 
(Cherayil 1969). Subsequently, decreased levels of sphingomyelin and 
galactocerebrosides, which are required for myelin synthesis in the brain, were 
observed in post mortem brain samples of chronic schizophrenic patients (Schmitt et 
al., 2004). Consistent with decreased sphingomyelin, increased levels of 
phosphatidylserine, an activator of neutral sphingomyelinase, was observed in post 
mortem schizophrenic samples (Schmitt et al., 2004). Decreased levels of 
glycosphingolipids could result in decreased myelination and altered cell-cell adhesion 
and transmembrane signaling, leading to neurodegeneration. However, this conclusion 
is obscured by studies reporting increased levels of complex sphingolipids in 
schizophrenia, including glycosphingolipids, and gangliosides GM3 and GD3 
(Haselhorst et al., 1988). 
In a microarray analysis comparing post mortem brain samples of prefrontal 
cortex from schizophrenic patients and healthy controls, expression of a number of 
genes that encode enzymes of sphingolipid metabolism were observed. Changes were 
most notable in the early stages of the disorder (within 5 years of diagnosis) (Narayan 
et al., 2009). A significant reduction was observed in the expression of seven genes 
related to sphingolipid metabolism, including UDP glycosyltransferase 8 (UGT8), serine 
palmitoyltransferase, long-chain base subunit 2 (SGPP1), UDP-
Gal:betaGlcNAcbeta1,4-galactosyltransferase polypeptide 6 (B4GALT6), 
galactosylceramidase (GALC), galactose-3-O-sulfotransferase 1(GAL3ST1), serine 
palmitoyltransferase, long-chain base subunit 2 (SPTLC2), and N-acylsphingosine 
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amidohydrolase (acid ceramidase)1 (ASAH) (Narayan et al., 2009). UGT8 encodes 
UDP glycosyltransferase, which converts ceramide to galactosylceramide. The 
GAL3ST1-encoded enzyme, galactose-3-O-sulfotransferase, catalyzing the synthesis 
of sulfatides, Sulfatides and galactosylceramide are components of the myelin sheath, 
and altered levels of these lipids may lead to impaired myelination.  Postmortem 
studies of schizophrenic patients have revealed abnormalities in myelination of 
oligodendrocytes (Davis et al., 2003). Consistent with the hypothesis of impaired 
myelination, oligodendrocyte dysfunction was observed in schizophrenic patients 
(Kubicki et al., 2005). However, chronic treatment with haloperidol was associated with 
decreased expression of myelin oligodendrocyte related genes in the white matter of 
mouse brain samples (Narayan et al., 2007).  Therefore, the role of abnormal 
myelination in schizophrenia remains to be elucidated. 
3.3.2 Aberrant ceramide levels  
Several reports indicate that ceramide levels are altered in schizophrenia, 
although a consistent pattern of alteration is not apparent. In a study comparing 
epidermal lipid profiles of drug naïve (first episode) schizophrenics and healthy 
controls, several classes of ceramide were altered (Smesny et al., 2012). A significant 
increase of α-hydroxy and 6-hydroxysphingosine with C26 or C28 and nonhydroxy 6-
hydroxysphingosine/ α-hyroxysphingosine with C26 or C28 fatty acid chains, and a 
decrease in ceramide containing ω-hydroxylated fatty acid greater than C30 esterified 
to linoleic acid and nonhydroxy phytosphingosine with C26 or C28 were observed in 
patients compared to the healthy controls (Smesny et al., 2012).  
	  	  	  
31	  
	  
A high throughput mass spectrometry profile of lipid levels in prefrontal cortex 
white and grey matter showed significant changes in the levels of ceramides in 
samples from schizophrenic vs. normal controls (Schwarz et al., 2008). Levels of 
ceramides were increased in the white matter. However, ceramide 34:1 was decreased 
in RBC samples from first onset patients (Schwarz et al., 2008). This study only 
analyzed one species of ceramide in RBCs, therefore the data of ceramide levels is not 
conclusive. In addition, ceramides were significantly increased with drug treatment 
(Schwarz et al., 2008). Cationic amphiphilic drugs used for the treatment inhibit acid 
ceramidase activity. Acid ceramidase catalyses the breakdown of ceramide. Inhibition 
by these drugs could lead to an increase in the ceramide levels (Elojemy et al., 2006).   
The microarray analysis of postmortem brain samples of schizophrenic patients 
discussed in the previous section identified altered expression of genes that metabolize 
ceramide (Narayan et al., 2009). Interestingly, genes encoding enzymes that decrease 
ceramide levels were downregulated in chronic schizophrenia, including UGT8, 
GAL3ST1, and ASAH1. ASAH1 was also found to have strong linkage to schizophrenia 
in a genome wide metascan study (Lewis et al., 2003). In addition, two single 
nucleotide polymorphisms in ASAH1 were found to be associated with schizophrenia 
(Zhang et al., 2012). In summary, while some studies suggest that increased ceramide 
may play a role in schizophrenia, conflicting findings preclude a definitive conclusion. 
3.4 Bipolar disorder (BD)  
BD, which is characterized by depression and mania, is a severe mood disorder 
that affects 1-2% of the world population (Weissman et al., 1988).  A high throughput 
lipidomics study of postmortem brain samples from bipolar patients and normal 
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controls revealed statistically significant increased levels of ceramide in the white 
matter, not accompanied by decreased levels of phosphatidylcholine, suggesting that 
the increase in ceramide results from increased synthesis rather than increased 
breakdown of sphingomyelin (Schwarz et al., 2008). While these studies are very 
preliminary, they suggest that BD may be associated with altered ceramide levels and 
ceramide signaling. However, whether ceramide plays a role in the development and 
progression of BD or is simply an outcome of the disease remains unknown.      
4. Future perspective: Exploiting yeast to elucidate sphingolipid functions and 
develop sphingolipid-modifying therapeutics 
 While the studies summarized above suggest that sphingolipid metabolism is 
perturbed in psychiatric disorders, the fundamental question – does perturbation of 
sphingolipid metabolism play a causal role, or is it a secondary effect of the disorder? – 
remains to be elucidated.  The complexity of mammalian systems and the lack of 
suitable animal models that accurately reflect human psychiatric illness complicate the 
ability to effectively address this question.  How, then, can a unicellular eukaryote shed 
light on these complex processes? The genetic tractability of yeast offers powerful 
advantages that can be exploited to elucidate the role of sphingolipids in essential and 
highly conserved cellular processes, as follows: 1) All the genes encoding the enzymes 
of the sphingolipid metabolism in yeast are well characterized, and most of the 
enzymes of sphingolipid metabolism have homologs or orthologs in mammals, as 
discussed above. The homology of yeast and mammalian genes has been exploited to 
clone mammalian sphingolipid genes by complementation of yeast mutants (Dickson, 
2006; Modrak et al., 2006; Hannun and Obeid, 2002). The signaling pathways and 
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cellular processes that are controlled by sphingolipids are also conserved. 
Conservation of sphingolipid synthesis and function suggests that knowledge gleaned 
from the yeast system can shed light on similar processes in human cells.  2) A wealth 
of well-characterized yeast mutants can be exploited in in vivo experiments to address 
the role of specific sphingolipids in essential cellular processes, and to ascertain the 
global effects of targeted sphingolipid perturbations. 3) Yeast bioassays utilizing 
sphingolipid mutants can be developed to screen for drugs that target specific 
sphingolipid components. 4) Yeast genetic and metabolic databases can be utilized for 
in vivo and in silico experiments to determine the effects of sphingolipid perturbation on 
cell function. 
4.1 Identifying inhibitors of ceramide and S1P synthesis 
Increased levels of ceramide in depression, schizophrenia, and BD suggest that 
ceramide synthesis may be a potential therapeutic target. As discussed above, 
mammals have six different ceramide synthase enzymes that exhibit tissue specificity 
as well as specificity for fatty acyl CoAs  (Levy et al., 2005). Creating and analyzing the 
effects of ceramide synthase knockouts would help to elucidate the role of specific 
ceramide species. Several knockout mice have already been described (Ebel et al., 
2013; Imgrund et al., 2009). CerS6 knockout mice exhibited a decrease in C16:0 
containing ceramide species relative to wild type mice.  These knockout mice exhibit 
behavioural abnormalities, such as habituation deficit and clasping abnormalities of 
their hind limbs (Ebel et al., 2013).  In addition, CerS2-deficient mice exhibit myelin 
sheath defects, cerebellar degeneration, and hepatocarcinomas (Imgrund et al., 2009). 
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Creating other CerS knockouts will enable the study of functional roles of the specific 
ceramide synthase and their products, ceramide species with fatty acyl CoA.     
The available ceramide synthase inhibitors (fumonisin B, austalifugin) target the 
enzymes nonspecifically, but specific inhibitors would be useful in elucidating the 
functions of each enzyme. Yeast ceramide synthase mutants (lag1, lac1) exhibit 
growth defects that can be functionally complemented with mammalian homologs 
(Guillas et al., 2003). Therefore, inhibitors of specific ceramide synthases could be 
identified by inhibiting growth of yeast lag1 or lac1 mutants expressing the mammalian 
enzyme.   
A similar approach could be used to identify inhibitors of S1P, the levels of which 
are increased in anxiety.  FTY720, a sphingolipid analog, is currently approved for the 
treatment of the autoimmune disorder multiple sclerosis. In vertebrates, FTY720 is 
phosphorylated by sphingosine kinase 2 and acts as a S1P mimic (Hla et al., 2011). 
FTY720 inhibits sphingosine kinase 1 (Lim et al., 2011). Yeast was used to study the 
metabolism and possible cellular targets of FTY720 (Welsch et al., 2003). In yeast, 
FTY720 phosphorylation is not required for its action, suggesting that FTY720 may have 
other cellular effects, including mimicking sphingolipid bases, and controlling the 
ubiquitin pathway and amino acid permease trafficking (Lee et al., 2011; Welsch et al., 
2004). In addition, FTY720 inhibits sphingosine phosphate lyase but it is not understood 
if this inhibition has a role in the mechanism of action of FTY720. In addition, 
siponimoid, a S1P1 agonist designed using FTY720 is currently completed phase 2 
clinical trails for the treatment of relapsing-remiting multiple sclerosis (Pan et al., 2013). 
Identification of specific inhibitors of S1P kinase will help elucidate the cellular functions 
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of S1P. In addition, these molecules could act as potential drugs for the treatment of 
psychiatric disorders.  
Therefore, there is a need to identify new inhibitors of sphingosine kinases or 
sphingosine phosphatases.  Inhibitors of these enzymes may be identified by loss of 
rescue of growth defects of yeast lcb4 and lcb5 mutants expressing the mammalian 
homologs.  
Inhibitors of these specific steps in sphingolipid metabolism would be powerful 
tools to elucidate the cellular roles of ceramide and S1P, just as studies with the SPT 
and ceramide synthase inhibitors myriocin and fumonisin B1, respectively, have 
contributed greatly to our understanding of the roles of sphingolipids in autophagy, heat 
stress, life span, and apoptosis (Daquinag et al., 2007; Huang et al., 2013).  
4.2 Mathematical modeling the effects of perturbation of ceramide and S1P on 
yeast cell homeostasis 
 Mathematical modeling is a powerful tool to organize and analyze high 
throughput data pertaining to biochemical pathways (Alvarez-Vasquez et al., 2005). 
Mathematical modeling has been exploited to generate complex network maps of 
sphingolipid metabolism in yeast (Alvarez-Vasquez et al., 2004; 2005; 2007). For 
example, a recent study simulated the action of drugs affecting sphingolipid metabolism 
in the ER to determine the effects of the drugs on ergosterol in the plasma membrane 
(Alvarez-Vasquez et al. 2011). Simulation of inhibition of IPC synthase, a step inhibited 
by aerobasidin, suggested that vesicular co-transport of ergosterol and complex 
sphingolipids is impaired, resulting in redistribution of ergosterol from the outer to the 
inner leaflet of the plasma membrane. Similarly, simulations with drugs such as 
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myriocin, an inhibitor of serine palmitoyltransferase (SPT), suggested a decrease in 
vesicular ergosterol transport flux and an increase of the non-vesicular ergosterol flux. 
Mathematical modeling can be used to simulate perturbation of ceramide and S1P 
levels, generating in silico disease models in yeast. The predictions of these models can 
be validated easily in yeast and then translated to complex mammalian systems 
(Kemmmer et al., 2009).  
4.3 Elucidating the global in vivo effects of perturbation of ceramide and S1P 
levels  
Altered levels of ceramide or S1P in yeast can be achieved by genetic 
manipulation using mutants of ceramide synthase (LAG1, LAC1), sphingosine base 
kinases (LCB4 and LCB5), and sphingosine base phosphate (LCB3 and YSR3). The 
effects of perturbation can be analyzed in the context of the available yeast 
metabolome, transcriptome, proteome and interactome data (Ge et al., 2001; Humston 
et al., 2011; Ptacek et al., 2005; Schwikowski et al., 2000; Velculescu et al., 1997). 
Lipidomic analyses may identify specific (and unexpected) metabolites important in 
maintaining homeostasis that may be altered in disease conditions (Kemmer et al., 
2009). Recent advances with mass spectrometric tools in the field of lipidomics have 
made it possible to identify and quantify several species of sphingolipids. In addition, 
recent developments in shotgun lipidomics enables the identification and quantification 
individual lipid species directly from lipid extracts of biological samples (Blanksby et al., 
2010). Alterations in specific sphingolipid species may provide insights into the role in 
pathogenesis (Han et al., 2007). The results from these studies can be investigated 
and validated in mammalian systems.  
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5. Conclusion 
There is a profound need to elucidate the molecular mechanisms underlying 
psychiatric disorders and to develop effective therapies to treat them. While many 
studies associate aberrant sphingolipid metabolism with the pathophysiology of 
psychiatric illnesses, the role of sphingolipids in the etiology of these disorders has not 
been established. The yeast model can be exploited to characterize the regulation of 
sphingolipid metabolism, the roles of specific sphingolipids in essential cell functions, 
and the global cellular consequences of perturbation of their synthesis. Because of the 
very high degree of conservation of function of these lipids between yeast and human 
cells, the data from studies in yeast can be used to generate testable hypotheses that 
can be experimentally addressed in appropriate mammalian systems. This knowledge 
has the potential to contribute to our understanding of the mechanisms underlying the 
pathophysiology of psychiatric disorders and to the development of new drugs that can 
be used in their treatment. 
6. Project outline  
The objective of the studies described in this thesis was to identify and 
characterize molecular targets of Valproic acid (VPA), a drug used for the treatment of 
BD, in order to gain insight into the therapeutic mechanism of action of the drug. 
Several pathways have been hypothesized to play a role in the therapeutic action of 
VPA, but the molecular mechanism is not understood. In order to accomplish this goal, I 
carried out the following studies: 
Utilizing a genome-wide microarray analysis, I identified molecular targets and 
pathways that are affected by acute and chronic VPA treatment, as described in 
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Chapter 2. In this screen, I identified sphingolipid metabolism as a possible novel target 
of VPA, as further discussed in Chapters 3 and 4.   
Studies in Chapter 3 focused on the chronic effects of VPA on sphingolipid 
metabolism. Chronic VPA-mediated inositol depletion increased expression of fatty 
acid elongases, which catalyze the synthesis of C24-C26 fatty acids utilized in 
ceramide synthesis. Consistent with this, phytoceramide with C24-C26 fatty acids were 
increased, and the expression of nutrient transporters decreased, inducing stress and 
activating the unfolded protein stress response (UPR) pathway.  This study identified 
the UPR pathway as a possible new target of VPA, which could be important for the 
therapeutic action of the drug.  
In experiments described in Chapter 4, I characterized the acute effects of VPA 
on sphingolipid metabolism. The gene RSB1, which encodes a transporter of the long 
chain bases (LCBs) dihydrosphingosine (DHS) and phytosphingosine (PHS), showed a 
striking high level of upregulation following acute VPA treatment.  The rsb1Δ mutant 
exhibited sensitivity to PHS. This suggested that acute VPA causes accumulation of 
LCBs. In fact, I showed that ino1Δ starvation and acute VPA increase PHS levels, 
suggesting that VPA-mediated inositol depletion increases de novo synthesis of PHS.  
LCB phosphates are lipid signaling molecules that are crucial for cell 
proliferation and differentiation. However, the role of these molecules in cellular 
functions is not understood. In the Appendix, I described a synthetic lethality screen 
with the major LCB kinase mutant, lcb4Δ. Among many synthetic interactions 
observed, an interesting category of mutants identified genes required for transport 
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from the endoplasmic reticulum (ER) to the Golgi, suggesting for the first time that LCB 
phosphates play a role in ER-Golgi transport.  
The studies described in this dissertation identified sphingolipid metabolism as a 
potential new target of VPA, characterized effects of chronic and acute treatment of 
VPA on sphingolipid metabolism, and identified new genetic interactions with the 
sphingosine kinase, Lcb4. Many interesting questions emerged from my work and 
remain unanswered. Chapter 5 summarizes potential exciting directions for future 
studies.  
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CHAPTER 2 IDENTIFICATION OF GENES AND CELLULAR PATHWAYS AFFECTED 
BY ACUTE AND CHRONIC TREATMENT WITH VALPROIC ACID 
 
INTRODUCTION 
Bipolar disorder (BD) is a psychiatric disease characterized by recurrent manic 
and depressive episodes. The World Health Organization (Cheng et al., 2005) ranks BD 
as the sixth leading cause of disability worldwide. BD affects at least 1% of the 
population and leads to suicide in 15% of the cases (Bostwick and Pankratz, 2000). 
Valproic acid (VPA), an FDA approved drug used for the treatment of BD, is a short-
branched chain fatty acid that was first synthesized by Burton in 1882. It was used as 
an organic solvent for about eighty years, and was serendipitously discovered to be an 
effective anticonvulsant (Meunier et al., 1963). VPA was first approved for the treatment 
of epilepsy in 1967, and since then has been used for the treatment of generalized and 
partial epilepsies. Later, VPA was found to be effective for the treatment BD (Calabresi 
et al., 2007; Emrich et al., 1981). VPA is effective in only 40-60% of BD cases and 
sometimes causes severe side effects, including hepatotoxicity and teratogenicity 
(Henry, 2003). The molecular targets underlying the therapeutic action of VPA are not 
known, nor are the underlying causes of the disease (Gould et al., 2004; Williams et al., 
2002).  
The inositol depletion hypothesis of the therapeutic action of drugs used for the 
treatment of BD was first proposed by Berridge, who showed that lithium inhibits inositol 
synthesis, possibly resulting in decreased inositol 1,4,5- triphosphate mediated 
signaling (Berridge, 1989). Our laboratory has shown that VPA, another drug used for 
the treatment of BD also decreases intracellular inositol in yeast and mammalian cells  
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(Vaden et al., 2001; Ye and Greenberg, 2015). The finding that both lithium and VPA, 
two structurally dissimilar drugs, cause inositol depletion suggests that this outcome 
may be important for the therapeutic action.  
In yeast, VPA causes a decrease in intracellular inositol and a dramatic increase 
in expression of INO1, the gene encoding the enzyme catalyzing the rate-limiting step of 
de novo biosynthesis of inositol (Vaden et al., 2001). Interestingly, the drug exerts 
differential acute and chronic effects on INO1 expression, although inositol depletion 
was apparent during both acute and chronic treatment (Ju and Greenberg, 2003). The 
expression of INO1 decreased during acute treatment (30 minutes -1 hour), while 
chronic exposure to VPA resulted in increased expression of INO1 (Ju and Greenberg, 
2003). These data led me to speculate that acute and chronic treatment with VPA elicit 
differential effects on expression of target genes. I hypothesized that acute treatment 
affects the expression of signaling molecules while chronic treatment perturbs 
downstream pathways controlled by these signaling molecules. 
In order to get a global picture of the effects of VPA, my study compared whole 
genome expression in response to acute and chronic treatment of VPA. To determine if 
the effect of VPA target gene expression was dependent on inositol depletion, the 
effects of VPA were determined in yeast cells grown in the presence or absence of 
inositol.   
MATERIALS AND METHODS 
VPA treatment   
 Wild type cells were pre-cultured in I+ (inositol-containing) medium, harvested, 
washed twice with sterile water, and grown in I+ medium until the cells reached the mid 
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log phase (A550= 0.5). Cells were pelleted, washed twice with sterile water and 
inoculated in synthetic minimal I+ or I- to a final A550 of 0.05, and cultured until the cells 
reached the mid log phase (A550= 0.5). Cells were then pelleted and suspended in fresh 
I+ or I- with or without 0.6 mM VPA and incubated for 30 minutes (acute treatment) or 5 
hours (chronic treatment). Cells were pelleted and stored at -80°C. Each sample was 
processed in duplicate. 
RNA extraction and microarray  
Total RNA was isolated by hot phenol extraction (Kohrer and Domdey, 1991) and 
purified using an RNeasy kit from Qiagen. The quality of the RNA was determined using 
the Agilent 2100 Bioanalyzer. RNA was labeled using the Agilent Low Input Quick-Amp 
labeling kit (Agilent Technologies). Cy3 labeled cRNA was then hybridized to the 8x15K 
Agilent Yeast V2 Arrays (design ID 016322). Slides were scanned on an Agilent 
G2505B microarray scanner and the resulting image files were processed with Agilent 
Feature Extraction software (version 9.5.1). All procedures were carried out according 
to the manufacturer’s protocols. Subsequent analysis was performed using the 
GeneSpring (v10.0) software. Microarray analysis was carried out at the Research 
Technology Support Facility in Michigan State University.   
Data analysis 
 The Gene Spring 10.0 software package was used for data analysis. The fold 
change for each gene was calculated using the expression levels in the control (i.e. 
cells grown in medium without VPA under similar conditions) as the basal level. Genes 
that showed more than a two-fold change compared to the respective control were 
considered for further analysis. The gene list was subjected to a statistical Student T 
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test and genes were grouped based on their biological function using the GO Slim 
Mapper program available on the Saccharomyces cerevisiae genome database (SGD). 
 Validation by qRT-PCR  
Total RNA was extracted using the hot phenol method (Kohrer and Domdey, 
1991) and purified using an RNeasy mini plus kit (Qiagen, Valencia, CA). 
Complementary DNA (cDNA) was synthesized using the first strand cDNA synthesis kit 
from Roche Applied Science as described in the manufacturer's manuals. qRT-PCR 
reactions were done in a 20 µl volume reaction using Brilliant III Ultra-Faster SYBR 
Green qPCR master mix (Agilent Technologies, Santa Clara, CA). Each reaction was 
done in triplicate. RNA levels were normalized to ACT1 levels (internal control). Relative 
values of mRNA transcripts are shown as fold change relative to that of the indicated 
controls. Primers were validated as suggested in the Methods and Applications Guide 
(Agilent Technologies). All primers used in this study had primer efficiency between 85 
and 105%. Optimal primer concentrations were determined, and primer specificity of a 
single product was monitored by a melt curve following the amplification reaction. PCR 
reactions were initiated at 95°C for 10 min for denaturation followed by 40 cycles 
consisting of 30 s at 95°C and 60 s at 55°C. 
RESULTS AND DISCUSSION 
  The microarray analysis confirmed our earlier findings that acute and chronic 
VPA exhibit differential expression of INO1, which showed downregulation with acute 
VPA and upregulation with chronic VPA (Ju and Greenberg, 2003). The findings 
suggested intriguing possible targets of VPA, including sphingolipid metabolism, the 
unfolded protein response (UPR) pathway, and glycolysis, as discussed below. This 
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study identified sphingolipid metabolism for the first time as a target of VPA and showed 
that VPA exerts differential effects on this pathway. Chronic VPA-mediated inositol 
depletion upregulates the UPR pathway, suggesting that this pathway may be a new 
target for future drug development.  In addition, this screen suggests that VPA increases 
glycolytic flux, which suggests that it may inhibit inositol synthesis by channeling the 
common substrate, glucose-6-phosphate, towards glycolysis. 
a. Sphingolipid metabolism 
  This study revealed for the first time that sphingolipid metabolism is altered by 
VPA. Upon acute exposure, the gene that was most strikingly upregulated was RSB1, a 
long chain base (LCB) transporter (Table 2.1), which showed a 158-fold upregulation in 
I- and 108-fold upregulation in I+. In the studies described in Chapter 4, I characterized 
the acute effects of VPA and showed that acute VPA-mediated inositol depletion 
increases the levels of PHS (phytosphingosine), a signaling lipid molecule.  In response 
to chronic VPA, FEN1 and SUR4, which code for fatty acid elongases, exhibited about 2-
fold upregulation in both I+ and I- (Table 2.2). Further studies show that chronic VPA-
mediated inositol depletion increases the intracellular levels of ceramide, which induces 
the UPR pathway, suggesting a possible new target for drug development  (Chapter 3).  
b. The UPR pathway 
  As described in Chapter 3, chronic VPA induces the UPR pathway by depleting 
intracellular inositol. Interestingly, the microarray data revealed that ER chaperone 
proteins KAR2, JEM1, LHS1, EUG1, PDI1, and SEC63, markers of the UPR pathway, 
exhibited 2- to 5-fold increased expression with chronic VPA treatment in I- medium, but 
not in I+, further supporting that UPR induction was likely due to inositol depletion. 
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Previously, Shulin Ju showed that overexpression of Ubi4, which ubiquitinylates 
misfolded proteins and targets them for degradation, conferred VPA resistance. These 
studies indicate that VPA could induce the UPR pathway by inhibiting degradation of 
unfolded proteins (PhD thesis 2005).  
  Several studies support that the UPR dysfunction might be involved in the 
pathophysiology of BD. Expression of ER stress proteins such as GRP78, GRP94 and 
calreticulin are upregulated in rat brain samples in response to chronic treatment with 
VPA (Shao et al., 2005). In addition, the UPR pathway induction is impaired in 
lymphoblastoid cell lines derived from bipolar patients (So et al., 2007). The expression 
of genes coding for proteins of the ubiquitin–proteasome system that ubiqutinlyate and 
mark misfolded proteins for degradation is greatly decreased in the hippocampus of 
bipolar patients (Hayashi et al., 2009). In summary, these studies suggest that the 
antibipolar drugs induce the UPR pathway by depleting intracellular inositol levels. 
c. Glycolysis 
  Glycolysis genes ERR2, ENO2, HXK2, LAT1, ENO1, PFK1, TPI1, ERR3, ERR1, 
PFK2, GPM1 showed increased expression with chronic VPA treatment, suggesting that 
chronic VPA may increase glycolysis flux. Several other studies in our laboratory support 
an effect of VPA on glycolysis. Shi et al. (2005) showed that VPA increases 
accumulation of two glycolytic intermediates, dihydroxyacetone phosphate (DHAP) and 
glyceraldehyde3-phosphate (G-3‐P), which inhibit the activity of MIPS, decreasing 
inositol synthesis. In addition, a cDNA overexpression screen showed that 
overexpression of glycolytic genes increased sensitivity to VPA (Rania Deranieh, 2014). 
Based on these data, as well as his finding that VPA causes increased production of 
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ethanol (unpublished), Michael Salsaa’ hypothesized that VPA affects the metabolic flux 
of glucose-6-P to glycolysis, thereby decreasing inositol synthesis and causing inositol 
depletion. These studies suggest that inhibiting inositol synthesis may be a regulatory 
mechanism whereby cells respond to an increased requirement for glycolysis. 
d. Other pathways 
  After acute VPA treatment, 597 genes exhibited more than a two-fold change in 
gene expression in I-, and 545 genes in I+ (Table 2.1). A functional classification of 
genes showing more than 2-fold change in response to VPA using GO SLIM MAPPER 
(SGD) is shown in Fig. 2.3 (VPA I-) and Fig. 2.4 (VPA I+). Genes required for amino acid 
metabolism, transmembrane transport, lipid metabolism, protein modification, and the 
cell cycle, exhibited a significant change in expression with acute VPA. Further analysis 
showed that 129 genes were upregulated only in I-, 136 only in I+, and 273 in both I+ 
and I-. 129 genes were down regulated only in I-, 70 only in I+, and 66 genes in both I+ 
and I- (Fig. 2.1). The relatively large number of that genes exhibited altered expression 
only in I- likely represent pathways that are regulated by inositol. In addition, a large 
number of genes exhibited upregulation in both I+ and I- in response to VPA, but the 
upregulation was higher in I- than in I+, suggesting that expression is partially dependent 
on inositol.  
  After chronic VPA treatment, 413 genes exhibited more than a two-fold change in 
gene expression when grown in I-, and 324 genes in I+ (Table 2.2). Classification of 
genes showing more than 2 fold change using GO SLIM MAPPER (SGD) is shown in 
Fig. 2.5 (VPA I-) and 2.6 (VPA I+). The highest number of genes belonged to transport, 
cellular amino acid metabolic process, and cell cycle in I-, and   cell cycle, DNA repair, 
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transport, and protein modification in I+.  Further analysis showed that 108 genes were 
upregulated only in I-, 119 only in I+, and 60 in both I+ and I- and 184 genes were 
downregulated only in I-, 84 only in I+ and 64 genes in both, I+ and I- (Fig. 2.2).  
  In studies described in Chapters 3 and 4, I characterized the effects of VPA on 
sphingolipid metabolism. This study unraveled possible novel targets of VPA that can be 
further used to develop newer and better drugs for the treatment of BD.  
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Figure 2.1. Differential effects on the regulation of gene expression in response 
to acute VPA treatment in the presence and absence of inositol (I). Genes 
showing differential expression (more than 2 fold), upregulated (A) and downregulated 
(B) in response to acute VPA treatment.  
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Figure 2.2. Differential effects on the regulation of gene expression in 
response to chronic VPA treatment in the presence and absence of inositol 
(I).Genes showing differential expression (more than 2 fold), upregulated (A) and 
downregulated (B) in response to chronic VPA treatment.   
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Figure 2.3. Genes that show more than 2 fold change in response to acute VPA 
treatment in I- 
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Figure 2.4. Genes that show more than 2 fold change in response to acute VPA 
treatment in I+ 
91	  44	  43	  
38	  29	  26	  
26	  26	  14	  
48	  24	  24	  
19	  28	  15	  
14	  14	  13	  
12	  11	  11	  
8	  8	  8	  
30	  24	  14	  
7	  6	  6	  
10	  5	  5	  
4	  4	  4	  
4	  3	  3	  
3	  3	  3	  
3	  3	  3	  
3	  4	  3	  
2	  2	  2	  
2	  2	  2	  
1	  1	  1	  
1	  0	  
Transport	  	  Response	  to	  chemical	  stimulus	  
	  Cellular	  amino	  acid	  metabolic	  process	  Transcription	  	  
	  Sporulation	  	  Carbohydrate	  metabolic	  process	  
	  Lipid	  metabolic	  process	  	  Cofactor	  metabolic	  process	  
RNA	  modiGication	  and	  processing	  	  Cell	  cycle	  
	  	  Cell	  wall	  organization	  or	  biogenesis	  Nucleobase-­‐containing	  small	  molecule	  
	  Generation	  of	  precursor	  metabolites	  and	  DNA	  repair	  
Vitamin	  metabolic	  process	  DNA	  recombination	  
rRNA	  processing	  Conjugation	  
Cellular	  ion	  homeostasis	  	  Response	  to	  oxidative	  stress	  
Signaling	  Protein	  targeting	  
Cellular	  respiration	  	  Chromosome	  segregation	  
Protein	  modiGication	  	  Ribosomal	  	  biogenesis	  
	  Cytoskeleton	  and	  chromatin	  organization	  	  Organelle	  Gission	  
	  DNA	  replication	  Response	  to	  starvation	  
Organelle	  organization	  	  Membrane	  invagination	  
	  Nucleobase-­‐containing	  compound	  	  Protein	  complex	  biogenesis	  
	  tRNA	  processing	  	  Proteolysis	  involved	  in	  cellular	  protein	  
Telomere	  organization	  Histone	  modiGication	  
Nucleus	  organization	  Cell	  morphogenesis	  
Protein	  folding	  Regulation	  of	  DNA	  metabolic	  process	  
	  Mitochondrion	  organization	  Oligosaccharide	  metabolic	  process	  
Pseudohyphal	  growth	  Endocytosis	  
	  Translation	  Organelle	  fusion	  
	  Response	  to	  osmotic	  stress	  	  Cytokinesis	  
Vacuole	  organization	  Invasive	  growth	  in	  response	  to	  glucose	  
	  Peroxisome	  organization	  Membrane	  fusion	  
	  Cell	  budding	  Organelle	  inheritance	  
	  Vesicle	  organization	  	  Response	  to	  heat	  
	  Exocytosis	  
I+	  
Acute	  VPA	  
	  	  	  
52	  
	  
 
Figure 2.5. Genes that show more than 2 fold change in response to chronic 
VPA treatment in I-  
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Figure 2.6. Genes that show more than 2 fold change in response to chronic 
VPA treatment in I+ 
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Table 2.1. Genes showing more than 2 fold change in response to acute VPA 
treatment. (Gene descriptions are from Saccharomyces Genome Database). 
 
 Gene 
name 
Description Fold change VPA+/VPA- 
Inositol+ Inositol- 
YOR049C RSB1 Suppressor of sphingoid long chain 
base (LCB) sensitivity of an LCB-
lyase mutation 
108.14 158.2 
YPL033C SRL4 Protein of unknown function 70.44 68.69 
YNR002C ATO2 Putative transmembrane protein 
involved in export of ammonia 
56 50.29 
YAL018C YAL018
C 
Putative protein of unknown function 45.39 25.76 
YPL058C PDR12 Plasma membrane ATP-binding 
cassette (ABC) transporter 
36.14 34.12 
YGR035C YGR035
C 
Putative protein of unknown function, 
potential Cdc28p substrate 
33.96 25.4 
YCL026C-
A 
FRM2 Protein of unknown function, involved 
in the integration of lipid signaling 
pathways with cellular homeostasis 
20.19 21.39 
YGR224
W 
AZR1 Plasma membrane transporter of the 
major facilitator superfamily, involved 
in resistance to azole drugs such as 
ketoconazole and fluconazole 
18.78 − 
YPR001W CIT3 Dual specificity mitochondrial citrate 
and methylcitrate synthase 
18.78 31.46 
YOR153
W 
PDR5 Plasma membrane ATP-binding 
cassette (ABC) transporter 
18.78 19.34 
YLR346C YLR346
C 
Putative protein of unknown function 
found in mitochondria 
18.78 13.93 
YHR126C ANS1 Putative protein of unknown function; 
transcription dependent upon Azf1p 
18.78 − 
YMR279C YMR279
C 
Putative paralog of ATR1, but not 
required for boron tolerance 
18.78 − 
YBR040W FIG1 Integral membrane protein required 
for efficient mating 
18.78 − 
YIR017C MET28 Basic leucine zipper (bZIP) 
transcriptional activator in the Cbf1p-
Met4p-Met28p complex, participates 
in the regulation of sulfur metabolism 
11.35 13.04 
YIL056W VHR1 Transcriptional activator 10.74 13.74 
YGR213C RTA1 Protein involved in 7-
aminocholesterol resistance 
10.17 7.07 
YLR099C ICT1 Lysophosphatidic acid 
acyltransferase 
10.06 9.41 
YGL205W POX1 Fatty-acyl coenzyme A oxidase, 
involved in the fatty acid beta-
oxidation pathway; localized to the 
9.55 6.08 
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peroxisomal matrix 
YHR139C SPS100 Protein required for spore wall 
maturation 
9.40 19.68 
YBL005W PDR3 Transcriptional activator of the 
pleiotropic drug resistance network 
9.30 10.21 
YNR058W BIO3 7,8-diamino-pelargonic acid 
aminotransferase (DAPA 
8.54 10.49 
YHR140W YHR140
W 
Putative integral membrane protein 
of unknown function 
8.05 9.14 
YKL217W JEN1 Lactate transporter 8.03 12.70 
YBR047W FMP23 Putative protein of unknown function 8.01 8.99 
YBR045C GIP1 Meiosis-specific regulatory subunit of 
the Glc7p protein phosphatase 
7.96 8.62 
YKL132C RMA1 Putative dihydrofolate synthetase 7.91 8.92 
YAL061W BDH2 Putative medium-chain alcohol 
dehydrogenase with similarity to 
BDH1 
7.89 12.72 
YER024W YAT2 Carnitine acetyltransferase 7.76 9.32 
YGL184C STR3 Cystathionine beta-lyase, converts 
cystathionine into homocysteine 
7.71 − 
YPR078C YPR078
C 
Putative protein of unknown function 7.54 − 
YOR100C CRC1 Mitochondrial inner membrane 
carnitine transporter 
7.41 13.67 
YOR365C YOR365
C 
Putative protein of unknown function 7.40 4.16 
YLL028W TPO1 Polyamine transporter that 
recognizes spermine, putrescine, 
and spermidine 
7.14 9.33 
YDR446W ECM11 Non-essential protein apparently 
involved in meiosis 
7.04 − 
YBR180W DTR1 Putative dityrosine transporter 6.86 3.34 
YLR307W CDA1 Chitin deacetylase 6.74 6.37 
YOR388C FDH1 NAD(+)-dependent formate 
dehydrogenase 
6.66 2.83 
YOR152C YOR152
C 
Putative protein of unknown function 6.63 7.17 
YBR250W SPO23 Protein of unknown function 6.55 7.63 
YGR281
W 
YOR1 Plasma membrane ATP-binding 
cassette (ABC) transporter 
6.53 5.75 
YHL042W YHL042
W 
Putative protein of unknown function; 
member of the DUP380 subfamily of 
conserved, often subtelomerically-
encoded proteins 
6.49 − 
YNR056C BIO5 Putative transmembrane protein 
involved in the biotin biosynthesis 
pathway 
6.40 8.21 
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YDR011W SNQ2 Plasma membrane ATP-binding 
cassette (ABC) transporter 
6.39 7.67 
YOR351C MEK1 Meiosis-specific serine/threonine 
protein kinase 
6.19 5.64 
YLR348C DIC1 Mitochondrial dicarboxylate carrier  6.11 6.91 
YMR322C SNO4 Possible chaperone and cysteine 
protease  
6.09 6.62 
YPL280W HSP32 Possible chaperone and cysteine 
protease 
5.89 6.13 
YKR015C YKR015
C 
Putative protein of unknown function 5.86 6.24 
YFR023W PES4 Poly(A) binding protein, suppressor 
of DNA polymerase epsilon mutation, 
similar to Mip6p 
5.85 7.40 
YNR044W AGA1 Anchorage subunit of a-agglutinin of 
a-cells, highly O-glycosylated protein 
with N-terminal secretion signal and 
C-terminal signal for addition of GPI 
anchor to cell wall, linked to adhesion 
subunit Aga2p via two disulfide 
bonds 
5.77 − 
YPL088W YPL088
W 
Putative aryl alcohol dehydrogenase 5.77 5.78 
YOL151W GRE2 3-methylbutanal reductase and 
NADPH-dependent methylglyoxal 
reductase (D-lactaldehyde 
dehydrogenase 
5.76 4.38 
YHR214C
-D 
YHR214
C-D 
Putative protein of unknown function 5.75 5.21 
YNL231C PDR16 Phosphatidylinositol transfer protein 
(PITP) controlled by the multiple drug 
resistance regulator Pdr1p 
5.73 6.13 
YCR020C PET18 Protein of unknown function, has 
weak similarity to proteins involved in 
thiamin metabolism; expression is 
induced in the absence of thiamin 
5.62 6.23 
YGL015C YGL015
C 
Putative protein of unknown function 5.60 − 
YDR406W PDR15 Plasma membrane ATP binding 
cassette (ABC) transporter 
5.55 7.67 
YOR011
W 
AUS1 Transporter of the ATP-binding 
cassette family 
5.47 7.02 
YMR017
W 
SPO20 Meiosis-specific subunit of the t-
SNARE complex 
5.46 4.49 
YGR087C PDC6 Minor isoform of pyruvate 
decarboxylase 
5.35 5.74 
YJL160C YJL160
C 
Putative protein of unknown function 5.20 6.79 
YBR019C GAL10 UDP-glucose-4-epimerase 5.19 − 
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YKL070W YKL070
W 
Putative protein of unknown function 5.19 − 
YER106W MAM1 Monopolin, kinetochore associated 
protein involved in chromosome 
attachment to meiotic spindle 
5.18 − 
YBR018C GAL7 Galactose-1-phosphate uridyl 
transferase 
5.17 6.81 
YCL027W FUS1 Membrane protein localized to the 
shmoo tip 
5.04 5.61 
YPL250C ICY2 Protein of unknown function 5.04 − 
YNL036W NCE103 Carbonic anhydrase 4.97 5.35 
YAL064W YAL064
W 
Protein of unknown function 4.95 4.87 
YDR536W STL1 Glycerol proton symporter of the 
plasma membrane 
4.80 − 
YER185W PUG1 Plasma membrane protein with roles 
in the uptake of protoprophyrin IX 
and the efflux of heme 
4.78 − 
YNL279W PRM1 Pheromone-regulated multispanning 
membrane protein involved in 
membrane fusion during mating 
4.75 6.22 
YDL138W RGT2 Plasma membrane high glucose 
sensor that regulates glucose 
transport 
4.72 5.59 
YML066C SMA2 Meiosis-specific prospore membrane 
protein 
4.70 − 
YDL114W YDL114
W 
Putative protein of unknown function 
with similarity to acyl-carrier-protein 
reductases 
4.70 3.18 
YDR402C DIT2 N-formyltyrosine oxidase 4.61 4.80 
YJL037W IRC18 Putative protein of unknown function 4.60 7.55 
YIL060W YIL060
W 
Putative protein of unknown function 4.41 3.74 
YNR070W PDR18 Putative transporter of the ATP-
binding cassette (ABC) family, 
implicated in pleiotropic drug 
resistance 
4.39 5.96 
YHL043W ECM34 Putative protein of unknown function 4.37 − 
YAR029W YAR029
W 
Member of DUP240 gene family but 
contains no transmembrane domains 
4.34 4.15 
YDR242W AMD2 Putative amidase 4.32 − 
YOR186
W 
YOR186
W 
Putative protein of unknown function 4.31 5.12 
YKL071W YKL071
W 
Putative protein of unknown function 4.29 − 
YMR042
W 
ARG80 Transcription factor involved in 
regulation of arginine-responsive 
genes; acts with Arg81p and Arg82p 
4.27 − 
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YPL264C YPL264
C 
Putative membrane protein of 
unknown function 
4.24 5.24 
YGR059
W 
SPR3 Sporulation-specific homolog of the 
yeast CDC3/10/11/12 family of bud 
neck microfilament genes 
4.24 − 
YML116W ATR1 Multidrug efflux pump of the major 
facilitator superfamily, required for 
resistance to aminotriazole and 4-
nitroquinoline-N-oxide 
4.22 5.05 
YDL243C AAD4 Putative aryl-alcohol dehydrogenase 
with similarity to P. chrysosporium 
aryl-alcohol dehydrogenase 
4.21 − 
YMR018
W 
YMR018
W 
Putative protein of unknown function 
with similarity to human PEX5Rp 
(peroxin protein 5 related protein) 
4.18 5.45 
YCR061W YCR061
W 
Protein of unknown function 4.17 3.78 
YIL164C NIT1 Nitrilase, member of the nitrilase 
branch of the nitrilase superfamily 
4.17 5.58 
YJL071W ARG2 Acetylglutamate synthase  4.16 5.35 
YFL003C MSH4 Protein involved in meiotic 
recombination 
4.13 6.05 
YNL277W MET2 L-homoserine-O-acetyltransferase 4.13 7.01 
YPR167C MET16 3'-phosphoadenylsulfate reductase, 
reduces 3'-phosphoadenylyl sulfate 
to adenosine-3',5'-bisphosphate and 
free sulfite using reduced thioredoxin 
as cosubstrate, involved in sulfate 
assimilation and methionine 
metabolism 
4.11 3.97 
YER187W YER187
W 
Putative protein of unknown function; 
induced in respiratory-deficient cells 
4.04 7.16 
YDR043C NRG1 Transcriptional repressor that recruits 
the Cyc8p-Tup1p complex to 
promoters 
4.03 3.73 
YEL057C YEL057
C 
Protein of unknown function involved 
in telomere maintenance 
4.02 − 
YDR403W DIT1 Sporulation-specific enzyme required 
for spore wall maturation 
4.01 4.74 
YDR317W HIM1 Protein of unknown function involved 
in DNA repair 
4.00 − 
YNL117W MLS1 Malate synthase, enzyme of the 
glyoxylate cycle 
4.00 11.00 
YDL170W UGA3 Transcriptional activator necessary 
for gamma-aminobutyrate (GABA)-
dependent induction of GABA genes  
3.99 4.85 
YHR015W MIP6 Putative RNA-binding protein, 
interacts with Mex67p, which is a 
component of the nuclear pore 
3.99 4.00 
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involved in nuclear mRNA export 
YLL056C YLL056
C 
Putative protein of unknown function, 
transcription is activated by 
paralogous transcription factors 
Yrm1p and Yrr1p and genes involved 
in pleiotropic drug resistance (PDR 
3.98 5.77 
YOR393
W 
ERR1 Protein of unknown function, has 
similarity to enolases 
3.96 − 
YDL054C MCH1 Protein with similarity to mammalian 
monocarboxylate permeases 
3.96 4.43 
YML083C YML083
C 
Putative protein of unknown function 3.96 − 
YJL089W SIP4 C6 zinc cluster transcriptional 
activator that binds to the carbon 
source-responsive element (CSRE) 
of gluconeogenic genes 
3.95 − 
YPL281C ERR2 Protein of unknown function, has 
similarity to enolases 
3.93 4.29 
YAR031W PRM9 Pheromone-regulated protein with 3 
predicted transmembrane segments 
and an FF sequence, a motif 
involved in COPII binding; member of 
DUP240 gene family 
3.92 4.00 
YJR155W AAD10 Putative aryl-alcohol dehydrogenase 
with similarity to P. chrysosporium 
aryl-alcohol dehydrogenase 
3.90 4.86 
YGR251
W 
YGR251
W 
Essential protein required for 
maturation of 18S rRNA; green 
fluorescent protein (GFP)-fusion 
protein localizes to both the nucleus 
and the nucleolus 
3.80 4.43 
YDR223W CRF1 Transcriptional corepressor involved 
in repression of ribosomal protein 
(RP) gene transcription via the TOR 
signaling pathway which promotes 
accumulation of Crf1p in the nucleus 
3.80 − 
YPR007C REC8 Meiosis-specific component of sister 
chromatid cohesion complex 
3.80 4.53 
YNR071C YNR071
C 
Putative protein of unknown function 3.79 4.25 
YMR102C YMR102
C 
Protein of unknown function 3.75 5.19 
YIL165C YIL165C Putative protein of unknown function 3.74 5.28 
YOR192C THI72 Transporter of thiamine or related 
compound 
3.71 4.03 
YER085C YER085
C 
Putative protein of unknown function 3.70 − 
YML042W CAT2 Carnitine acetyl-CoA transferase 
present in both mitochondria and 
3.70 5.11 
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peroxisomes 
YOL162W YOL162
W 
Putative protein of unknown function 3.68 − 
YJR130C STR2 Cystathionine gamma-synthase, 
converts cysteine into cystathionine 
3.64 4.17 
YER174C GRX4 Hydroperoxide and superoxide-
radical responsive glutathione-
dependent oxidoreductase 
3.63 − 
YDL020C RPN4 Transcription factor that stimulates 
expression of proteasome genes 
3.62 3.31 
YMR118C YMR118
C 
Protein of unknown function with 
similarity to succinate 
dehydrogenase cytochrome b 
subunit; YMR118C is not an 
essential gene 
3.61 − 
YLR004C THI73 Putative plasma membrane 
permease proposed to be involved in 
carboxylic acid uptake and repressed 
by thiamine 
3.61 4.43 
YNL128W TEP1 Homolog of human tumor suppressor 
gene PTEN/MMAC1/TEP1 that has 
lipid phosphatase activity and is 
linked to the phosphatidylinositol 
signaling pathway 
3.61 3.39 
YLL057C JLP1 Fe(II)-dependent sulfonate/alpha-
ketoglutarate dioxygenase 
3.60 5.09 
YOL024W YOL024
W 
Putative protein of unknown function; 
predicted to have thiol-disulfide 
oxidoreductase active site 
3.58 3.33 
YDR534C FIT1 Mannoprotein that is incorporated 
into the cell wall via a 
glycosylphosphatidylinositol (GPI) 
anchor 
3.57 3.26 
YOR269
W 
PAC1 Protein involved in nuclear migration, 
part of the dynein/dynactin pathway 
3.56 4.21 
YDR218C SPR28 Sporulation-specific homolog of the 
yeast CDC3/10/11/12 family of bud 
neck microfilament genes 
3.56 − 
YER176W ECM32 DNA dependent ATPase/DNA 
helicase belonging to the Dna2p- and 
Nam7p-like family of helicases that is 
involved in modulating translation 
termination 
3.54 4.33 
YNL095C YNL095
C 
Putative protein of unknown function 
predicted to contain a 
transmembrane domain 
3.52 4.36 
YMR195
W 
ICY1 Protein of unknown function 3.52 4.64 
YCR104W PAU3 Member of the seripauperin 3.50 − 
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multigene family encoded mainly in 
subtelomeric regions, active during 
alcoholic fermentation 
YOR391C HSP33 Possible chaperone and cysteine 
protease with similarity to E. coli 
Hsp31 and S. cerevisiae Hsp31p, 
Hsp32p, and Sno4p 
3.49 4.02 
YEL048C TCA17 Protein that interacts with subunits of 
the TRAPP complex and may play a 
role its assembly or stability 
3.48 − 
YLL046C RNP1 Ribonucleoprotein that contains two 
RNA recognition motifs (RRM) 
3.48 4.58 
YKL187C YKL187
C 
Putative protein of unknown function 3.45 − 
YMR323
W 
ERR3 Protein of unknown function, has 
similarity to enolases 
3.43 − 
YHR022C YHR022
C 
Putative protein of unknown function 3.41 3.86 
YJR120W YJR120
W 
Protein of unknown function 3.39 2.94 
YNR068C YNR068
C 
Putative protein of unknown function 3.39 3.96 
YGR144
W 
THI4 Thiazole synthase 3.37 3.30 
YDL245C HXT15 Protein of unknown function with 
similarity to hexose transporter family 
members, expression is induced by 
low levels of glucose and repressed 
by high levels of glucose 
3.36 − 
YNL269W BSC4 Protein of unknown function 3.35 4.07 
YHL044W YHL044
W 
Putative integral membrane protein 3.35 3.67 
YBR104W YMC2 Mitochondrial protein, putative inner 
membrane transporter with a role in 
oleate metabolism and glutamate 
biosynthesis 
3.35 4.69 
YGR142
W 
BTN2 v-SNARE binding protein that 
facilitates specific protein retrieval 
from a late endosome to the Golgi 
3.34 3.36 
YIL037C PRM2 Pheromone-regulated protein 3.32 4.13 
YJL106W IME2 Serine/threonine protein kinase 
involved in activation of meiosis,  
3.32 3.93 
YCR045C RRT12 Probable subtilisin-family protease 
with a role in formation of the 
dityrosine layer of spore walls 
3.32 − 
YHR048W YHK8 Presumed antiporter of the DHA1 
family of multidrug resistance 
transporters 
3.30 − 
YMR325 PAU19 Protein of unknown function 3.28 − 
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W 
YOR394
W 
PAU21 Protein of unknown function 3.28 − 
YJL077C ICS3 Protein of unknown function 3.28 − 
YPL282C PAU22 Protein of unknown function 3.27 − 
YPL095C EEB1 Acyl-coenzymeA:ethanol O-
acyltransferase  
3.26 2.03 
YGL192W IME4 Probable mRNA N6-adenosine 
methyltransferase  
3.26 − 
YDR076W RAD55 Protein that stimulates strand 
exchange by stabilizing the binding 
of Rad51p to single-stranded DNA 
3.24 3.44 
YNL211C YNL211
C 
Putative protein of unknown function 3.23 3.94 
YBL103C RTG3 Basic helix-loop-helix-leucine zipper 
(bHLH/Zip) transcription factor that 
forms a complex with another 
bHLH/Zip protein, Rtg1p, to activate 
the retrograde (RTG) and TOR 
pathways 
3.23 4.27 
YAL067C SEO1 Putative permease, member of the 
allantoate transporter subfamily of 
the major facilitator superfamily 
3.23 − 
YCR099C YCR099
C 
Putative protein of unknown function 3.22 4.73 
YCR100C YCR100
C 
Putative protein of unknown function 3.22 4.53 
YNR066C YNR066
C 
Putative membrane-localized protein 
of unknown function 
3.22 3.85 
YOR273C TPO4 Polyamine transport protein, 
recognizes spermine, putrescine, 
and spermidine 
3.22 2.39 
YNL270C ALP1 Arginine transporter 3.21 3.95 
YDL214C PRR2 Serine/threonine protein kinase that 
inhibits pheromone induced 
signalling downstream of MAPK, 
possibly at the level of the Ste12p 
transcription factor 
3.20 2.83 
YDR114C YDR114
C 
Putative protein of unknown function 3.19 − 
YDR256C CTA1 Catalase A, breaks down hydrogen 
peroxide in the peroxisomal matrix 
formed by acyl-CoA oxidase (Pox1p) 
during fatty acid beta-oxidation 
3.18 − 
YML007C
-A 
YML007
C-A 
Putative protein of unknown function 3.18 − 
YOR130C ORT1 Ornithine transporter of the 
mitochondrial inner membrane, 
exports ornithine from mitochondria 
3.17 3.73 
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as part of arginine biosynthesis 
YPL201C YIG1 Protein that interacts with glycerol 3-
phosphatase and plays a role in 
anaerobic glycerol production 
3.16 4.15 
YFR030W MET10 Subunit alpha of assimilatory sulfite 
reductase 
3.16 3.82 
YOR302
W 
YOR302
W 
CPA1 uORF, Arginine attenuator 
peptide 
3.13 3.08 
YIR041W PAU15 Protein of unknown function 3.13 − 
YJR078W BNA2 Putative tryptophan 2,3-dioxygenase 
or indoleamine 2,3-dioxygenase, 
required for de novo biosynthesis of 
NAD from tryptophan via kynurenine 
3.10 − 
YFR022W ROG3 Protein that binds the ubiquitin ligase 
Rsp5p via its 2 PY motifs 
3.09 3.55 
YBR148W YSW1 Protein required for normal prospore 
membrane formation 
3.09 4.11 
YCR023C YCR023
C 
Vacuolar membrane protein of 
unknown function 
3.08 3.48 
YIR018W YAP5 Basic leucine zipper (bZIP) 
transcription factor 
3.07 − 
YLL053C YLL053
C 
Putative protein; in the Sigma 1278B 
strain background YLL053C is 
contiguous with AQY2 which 
encodes an aquaporin 
3.06 2.56 
YOR339C UBC11 Ubiquitin-conjugating enzyme most 
similar in sequence to Xenopus 
ubiquitin-conjugating enzyme E2-C 
3.06 2.94 
YLR164W YLR164
W 
Mitochondrial inner membrane of 
unknown function 
3.05 3.80 
YNR060W FRE4 Ferric reductase 3.04 − 
YPL188W POS5 Mitochondrial NADH kinase 3.03 3.59 
YOR328
W 
PDR10 ATP-binding cassette (ABC) 
transporter 
3.03 3.47 
YNL116W DMA2 Protein involved in ubiquitination 3.01 3.39 
YLL052C AQY2 Water channel that mediates the 
transport of water across cell 
membranes, only expressed in 
proliferating cells, controlled by 
osmotic signals, may be involved in 
freeze tolerance 
3.01 2.45 
YNL311C YNL311
C 
F-box protein of unknown function 
predicted to be part of an SCF 
ubiquitin protease complex 
2.99 3.55 
YAL037W YAL037
W 
Putative protein of unknown function 2.96 3.46 
YAR020C PAU7 Member of the seripauperin 
multigene family, active during 
2.96 − 
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alcoholic fermentation, regulated by 
anaerobiosis, inhibited by oxygen 
YKR097W PCK1 Phosphoenolpyruvate carboxykinase 2.95 2.76 
YKL178C STE3 Receptor for a factor pheromone 2.95 − 
YHR044C DOG1 2-deoxyglucose-6-phosphate 
phosphatase,  
2.95 2.13 
YBR046C ZTA1 NADPH-dependent quinone 
reductase 
2.94 3.94 
YNR065C YNR065
C 
Protein of unknown function 2.93 − 
YNR057C BIO4 Dethiobiotin synthetase 2.92 4.31 
YMR201C RAD14 Protein that recognizes and binds 
damaged DNA during nucleotide 
excision repair 
2.90 3.28 
YPL258C THI21 Hydroxymethylpyrimidine phosphate 
kinase 
2.90 3.55 
YER184C YER184
C 
Putative zinc cluster protein 2.88 4.15 
YIR005W IST3 Component of the U2 snRNP, 
required for the first catalytic step of 
splicing and for spliceosomal 
assembly 
2.84 3.34 
YJR111C YJR111
C 
Putative protein of unknown function 2.83 3.51 
YBL006C LDB7 Component of the RSC chromatin 
remodeling complex 
2.83 3.07 
YHR122W YHR122
W 
Protein of unknown function required 
for establishment of sister chromatid 
cohesion 
2.83 3.14 
YJL219W HXT9 Putative hexose transporter that is 
nearly identical to Hxt11p, has 
similarity to major facilitator 
superfamily (MFS) transporters, 
expression of HXT9 is regulated by 
transcription factors Pdr1p and Pdr3p 
2.80 2.30 
YBR293W VBA2 Permease of basic amino acids in 
the vacuolar membrane 
2.80 2.99 
YOR242C SSP2 Sporulation specific protein that 
localizes to the spore wall 
2.80 2.26 
YDR523C SPS1 Putative protein serine/threonine 
kinase expressed at the end of 
meiosis and localized to the prospore 
membrane 
2.79 − 
YGL116W CDC20 Cell-cycle regulated activator of 
anaphase-promoting 
complex/cyclosome (APC/C) 
2.79 − 
YMR009
W 
ADI1 Acireductone dioxygenease involved 
in the methionine salvage pathway; 
ortholog of human MTCBP-1 
2.78 3.55 
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YOL159C-
A 
YOL159
C-A 
Putative protein of unknown function 2.76 2.70 
YJL043W YJL043
W 
Putative protein of unknown function 2.75 2.87 
YHL046C PAU13 Protein of unknown function 2.75 − 
YHR029C YHI9 Protein of unknown function 2.74 3.02 
YHR047C AAP1 Arginine/alanine aminopeptidase 2.73 3.19 
YER128W YER128
W 
Putative protein of unknown function 2.72 3.67 
YGL059W PKP2 Mitochondrial protein kinase that 
negatively regulates activity of the 
pyruvate dehydrogenase complex by 
phosphorylating the ser-133 residue 
of the Pda1p subunit 
2.71 − 
YKL220C FRE2 Ferric reductase and cupric 
reductase, reduces siderophore-
bound iron and oxidized copper prior 
to uptake by transporters 
2.71 − 
YLR213C CRR1 Putative glycoside hydrolase of the 
spore wall envelope 
2.70 2.62 
YMR096
W 
SNZ1 Protein involved in vitamin B6 
biosynthesis; member of a stationary 
phase-induced gene family 
2.70 4.64 
YAL068C PAU8 Protein of unknown function, member 
of the seripauperin multigene family 
encoded mainly in subtelomeric 
regions 
2.69 2.21 
YKL224C PAU16 Protein of unknown function, member 
of the seripauperin multigene family 
encoded mainly in subtelomeric 
regions 
2.65 − 
YBL108C-
A 
PAU9 Protein of unknown function, member 
of the seripauperin multigene family 
encoded mainly in subtelomeric 
regions 
2.65 − 
YNL240C NAR1 Component of the cytosolic iron-
sulfur (FeS) protein assembly 
machinery 
2.65 2.86 
YDR249C YDR249
C 
Putative protein of unknown function 2.65 3.19 
YHR214C
-E 
YHR214
C-E 
Putative protein of unknown function 2.65 − 
YGR286C BIO2 Biotin synthase 2.64 3.55 
YER040W GLN3 Transcriptional activator of genes 
regulated by nitrogen catabolite 
repression  
2.64 3.05 
YDR542W PAU10 Protein of unknown function 2.63 − 
YGR131
W 
YGR131
W 
Protein of unknown function 2.63 2.51 
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YHR185C PFS1 Sporulation protein required for 
prospore membrane formation at 
selected spindle poles, ensures 
functionality of all four spindle pole 
bodies during meiosis II 
2.63 − 
YGL224C SDT1 Pyrimidine nucleotidase 2.62 2.60 
YJL223C PAU1 Member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions, active during 
alcoholic fermentation, regulated by 
anaerobiosis, negatively regulated by 
oxygen, repressed by heme 
2.61 2.46 
YOR381
W 
FRE3 Ferric reductase 2.60 3.21 
YMR306
W 
FKS3 Protein involved in spore wall 
assembly, has similarity to 1,3-beta-
D-glucan synthase catalytic subunits 
Fks1p and Gsc2p 
2.60 2.79 
YOR190
W 
SPR1 Sporulation-specific exo-1,3-beta-
glucanase; contributes to ascospore 
thermoresistance 
2.60 − 
YBR240C THI2 Zinc finger protein of the Zn(II)2Cys6 
type, probable transcriptional 
activator of thiamine biosynthetic 
genes 
2.60 2.83 
YLR081W GAL2 Galactose permease, required for 
utilization of galactose 
2.60 − 
YCR020W
-B 
HTL1 Component of the RSC chromatin 
remodeling complex 
2.59 2.96 
YNR030W ALG12 Alpha-1,6-mannosyltransferase 
localized to the ER 
2.59 2.38 
YGR288
W 
MAL13 MAL-activator protein, part of 
complex locus MAL1 
2.59 − 
YDL177C YDL177
C 
Putative protein of unknown function 2.58 3.64 
YCR060W TAH1 HSP90 cofactor; interacts with 
Hsp82p, Pih1p, Rvb1 and Rvb2 
2.57 3.59 
YGL039W YGL039
W 
Oxidoreductase shown to reduce 
carbonyl compounds to chiral 
alcohols 
2.57 3.66 
YMR019
W 
STB4 Protein that binds Sin3p in a two-
hybrid assay 
2.56 2.94 
YJR079W YJR079
W 
Putative protein of unknown function; 
mutation results in impaired 
mitochondrial respiration 
2.55 − 
YIL176C PAU14 Protein of unknown function 2.55 2.44 
YBR068C BAP2 High-affinity leucine permease 2.53 2.73 
YER069W ARG5,6 Protein that is processed in the 
mitochondrion to yield 
2.53 2.28 
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acetylglutamate kinase and N-acetyl-
gamma-glutamyl-phosphate 
reductase 
YKL211C TRP3 Bifunctional enzyme exhibiting both 
indole-3-glycerol-phosphate 
synthase and anthranilate synthase 
2.52 2.77 
YOL165C AAD15 Putative aryl-alcohol dehydrogenase  2.52 2.77 
YLL060C GTT2 Glutathione S-transferase capable of 
homodimerization 
2.50 − 
YFR034C PHO4 Basic helix-loop-helix (bHLH) 
transcription factor of the myc-family; 
binds cooperatively with Pho2p to the 
PHO5 promoter 
2.49 3.33 
YBL102W SFT2 Non-essential tetra-spanning 
membrane protein found mostly in 
the late Golgi, can suppress some 
sed5 alleles; may be part of the 
transport machinery 
2.48 2.85 
YOL119C MCH4 Protein with similarity to mammalian 
monocarboxylate permeases 
2.48 3.28 
YGR197C SNG1 Protein involved in resistance to 
nitrosoguanidine (MNNG) and 6-
azauracil (6-AU) 
2.48 2.90 
YIL117C PRM5 Pheromone-regulated protein, 
predicted to have 1 transmembrane 
segment; induced during cell integrity 
signaling 
2.48 2.31 
YHR014W SPO13 Meiosis-specific protein, involved in 
maintaining sister chromatid 
cohesion during meiosis I as well as 
promoting proper attachment of 
kinetochores to the spindle during 
meiosis I and meiosis II 
2.47 − 
YDL241W YDL241
W 
Putative protein of unknown function 2.47 − 
YDL037C BSC1 Protein of unconfirmed function, 
similar to cell surface flocculin Muc1p 
2.46 − 
YIR035C YIR035
C 
Putative cytoplasmic protein of 
unknown function 
2.46 2.19 
YKR069W MET1 S-adenosyl-L-methionine 
uroporphyrinogen III transmethylase, 
involved in the biosynthesis of 
siroheme, a prosthetic group used by 
sulfite reductase; required for sulfate 
assimilation and methionine 
biosynthesis 
2.45 3.45 
YFL057C AAD16 Putative aryl-alcohol dehydrogenase  2.45 2.94 
YOL164W BDS1 Bacterially-derived sulfatase required 
for use of alkyl- and aryl-sulfates as 
2.45 2.45 
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sulfur sources 
YLR363C NMD4 Protein interacting with Nam7p, may 
be involved in the nonsense-
mediated mRNA decay pathway 
2.45 − 
YBR301W PAU24 Cell wall mannoprotein with similarity 
to Tir1p, Tir2p, Tir3p, and Tir4p; 
member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions 
2.44 − 
YOR303
W 
CPA1 Small subunit of carbamoyl 
phosphate synthetase 
2.43 − 
YPL272C YPL272
C 
Putative protein of unknown function 2.42 − 
YPL047W SGF11 Integral subunit of SAGA histone 
acetyltransferase complex 
2.41 2.81 
YNL331C AAD14 Putative aryl-alcohol dehydrogenase 
with similarity to P. chrysosporium 
aryl-alcohol dehydrogenase 
2.40 2.82 
YFL028C CAF16 Part of evolutionarily-conserved 
CCR4-NOT regulatory  
2.39 2.48 
YDL142C CRD1 Cardiolipin synthase; produces 
cardiolipin, which is a phospholipid of 
the mitochondrial inner membrane 
that is required for normal 
mitochondrial membrane potential 
and function 
2.39 2.36 
YMR062C ARG7 Mitochondrial ornithine 
acetyltransferase, catalyzes the fifth 
step in arginine biosynthesis 
2.39 2.36 
YBR076W ECM8 Non-essential protein of unknown 
function 
2.39 2.19 
YIL166C YIL166C Putative protein with similarity to the 
allantoate permease (Dal5p) 
subfamily of the major facilitator 
superfamily 
2.38 2.84 
YPR048W TAH18 Conserved NAPDH-dependent 
diflavin reductase, component of an 
early step in the cytosolic Fe-S 
protein assembly (CIA) machinery 
2.38 − 
YNR073C YNR073
C 
Putative mannitol dehydrogenase 2.38 − 
YFL011W HXT10 Putative hexose transporter, 
expressed at low levels and 
expression is repressed by glucose 
2.38 − 
YKL008C LAC1 Ceramide synthase component, 
involved in synthesis of ceramide 
from C26(acyl)-coenzyme A and 
dihydrosphingosine or 
phytosphingosine, functionally 
equivalent to Lag1p 
2.37 2.55 
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YBR256C RIB5 Riboflavin synthase 2.37 2.62 
YLL055W YCT1 High-affinity cysteine-specific 
transporter with similarity to the 
Dal5p family of transporters 
2.37 2.95 
YGR294
W 
PAU12 Protein of unknown function 2.36 − 
YGL154C LYS5 Phosphopantetheinyl transferase 
involved in lysine biosynthesis 
2.36 − 
YGL249W ZIP2 Meiosis-specific protein involved in 
normal synaptonemal complex 
formation and pairing between 
homologous chromosomes during 
meiosis 
2.36 − 
YFL020C PAU5 Member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions 
2.36 − 
YKL072W STB6 Protein that binds Sin3p in a two-
hybrid assay 
2.35 2.83 
YKL086W SRX1 Sulfiredoxin, contributes to oxidative 
stress resistance by reducing 
cysteine-sulfinic acid groups in the 
peroxiredoxin Tsa1p 
2.34 2.70 
YHL040C ARN1 Transporter, member of the ARN 
family of transporters that specifically 
recognize siderophore-iron chelates 
2.33 − 
YPL165C SET6 SET domain protein of unknown 
function 
2.33 2.60 
YGL180W ATG1 Protein ser/thr kinase required for 
vesicle formation in autophagy and 
the cytoplasm-to-vacuole targeting 
(Cvt) pathway 
2.33 2.49 
YGL117W YGL117
W 
Putative protein of unknown function 2.33 2.48 
YGR110
W 
CLD1 Mitochondrial cardiolipin-specific 
phospholipase 
2.33 2.21 
YOR114
W 
YOR114
W 
Putative protein of unknown function; 
null mutant is viable 
2.32 − 
YIR013C GAT4 Protein containing GATA family zinc 
finger motifs 
2.32 − 
YJR039W YJR039
W 
Putative protein of unknown function 2.32 2.43 
YMR187C YMR187
C 
Putative protein of unknown function 2.31 − 
YDR263C DIN7 Mitochondrial nuclease functioning in 
DNA repair and replication, 
modulates the stability of the 
mitochondrial  
2.31 2.07 
YPL135W ISU1 Conserved protein of the 
mitochondrial matrix 
2.31 2.79 
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YEL070W DSF1 Deletion suppressor of mpt5 
mutation 
2.31 − 
YIL120W QDR1 Multidrug transporter of the major 
facilitator superfamily, required for 
resistance to quinidine, 
ketoconazole, fluconazole, and 
barban 
2.31 2.17 
YJR095W SFC1 Mitochondrial succinate-fumarate 
transporter 
2.30 3.72 
YKL128C PMU1 Putative phosphomutase,  2.30 2.26 
YEL029C BUD16 Putative pyridoxal kinase 2.30 3.16 
YKL188C PXA2 Subunit of a heterodimeric 
peroxisomal ATP-binding cassette 
transporter complex (Pxa1p-Pxa2p) 
2.30 2.58 
YHR006W STP2 Transcription factor, activated by 
proteolytic processing in response to 
signals from the SPS sensor system 
for external amino acids 
2.30 2.37 
YER039C HVG1 Protein of unknown function, has 
homology to Vrg4p 
2.29 2.65 
YGR250C YGR250
C 
Putative RNA binding protein; 
localizes to stress granules induced 
by glucose deprivation; interacts with 
Rbg1p in a two-hybrid 
2.28 2.46 
YNL125C ESBP6 Protein with similarity to 
monocarboxylate permeases, 
appears not to be involved in 
transport of monocarboxylates such 
as lactate, pyruvate or acetate 
across the plasma membrane 
2.27 2.26 
YPR057W BRR1 snRNP protein component of 
spliceosomal snRNPs, required for 
pre-mRNA splicing and snRNP 
biogenesis 
2.27 2.50 
YNL335W DDI3 Protein of unknown function; 
expression is induced over 100-fold 
by DNA damage 
2.26 − 
YHL047C ARN2 Transporter, member of the ARN 
family of transporters that specifically 
recognize siderophore-iron chelates 
2.26 − 
YHR212W
-A 
YHR212
W-A 
Putative protein of unknown function 2.26 − 
YFL061W DDI2 Protein of unknown function; 
expression is induced over 100-fold 
by DNA damage; induction 
decreased in rad6 and rad18 
mutants 
2.25 − 
YLL038C ENT4 Protein of unknown function, 
contains an N-terminal epsin-like 
2.25 2.44 
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domain 
YLR031W YLR031
W 
Putative protein of unknown function 2.24 2.39 
YKL222C YKL222
C 
Protein of unknown function that may 
interact with ribosomes 
2.23 2.39 
YKL052C ASK1 Essential subunit of the Dam1 
complex (aka DASH complex), 
couples kinetochores to the force 
produced by MT depolymerization 
thereby aiding in chromosome 
segregation 
2.23 2.50 
YLR211C YLR211
C 
Putative protein of unknown function 2.23 − 
YGL248W PDE1 Low-affinity cyclic AMP 
phosphodiesterase, controls glucose 
and intracellular acidification-induced 
cAMP signaling, target of the cAMP-
protein kinase A (PKA) pathway 
2.22 2.38 
YLR461W PAU4 Member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions 
2.22 − 
YLR318W EST2 Reverse transcriptase subunit of the 
telomerase holoenzyme, essential for 
telomerase core catalytic activity, 
involved in other aspects of 
telomerase assembly and function 
2.21 − 
YOR389
W 
YOR389
W 
Putative protein of unknown function 2.21 − 
YER065C ICL1 Isocitrate lyase, catalyzes the 
formation of succinate and glyoxylate 
from isocitrate, a key reaction of the 
glyoxylate cycle 
2.21 − 
YKR102W FLO10 Lectin-like protein with similarity to 
Flo1p 
2.20 − 
YMR251
W 
GTO3 Omega class glutathione transferase; 
putative cytosolic localization 
2.20 − 
YOR337
W 
TEA1 Ty1 enhancer activator required for 
full levels of Ty enhancer-mediated 
transcription 
2.20 − 
YLR099W
-A 
YLR099
W-A 
Putative protein of unknown function 2.20 2.18 
YEL071W DLD3 D-lactate dehydrogenase 2.20 2.99 
YBR298C
-A 
YBR298
C-A 
Putative protein of unknown function 2.19 2.63 
YCL066W HMLAL
PHA1 
Silenced copy of ALPHA1 at HML, 
encoding a transcriptional coactivator 
involved in the regulation of mating-
type alpha-specific gene expression 
2.19 2.14 
YJR010W MET3 ATP sulfurylase 2.19 2.57 
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YLR037C PAU23 Cell wall mannoprotein with similarity 
to Tir1p, Tir2p, Tir3p, and Tir4p; 
member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions 
2.19 − 
YPR193C HPA2 Tetrameric histone acetyltransferase 
with similarity to Gcn5p, Hat1p, 
Elp3p, and Hpa3p 
2.18 2.84 
YFL040W YFL040
W 
Putative transporter 2.18 − 
YFR012W
-A 
YFR012
W-A 
Putative protein of unknown function; 
identified by homology 
2.17 − 
YML005W TRM12 S-adenosylmethionine-dependent 
methyltransferase of the seven beta-
strand family 
2.17 2.32 
YMR066
W 
SOV1 Mitochondrial protein of unknown 
function 
2.17 − 
YCR107W AAD3 Putative aryl-alcohol dehydrogenase 
with similarity to P. chrysosporium 
aryl-alcohol dehydrogenase 
2.17 − 
YIL015W BAR1 Aspartyl protease secreted into the 
periplasmic space of mating type a 
cells, helps cells find mating 
partners, cleaves and inactivates 
alpha factor allowing cells to recover 
from alpha-factor-induced cell cycle 
arrest 
2.17 2.01 
YLR228C ECM22 Sterol regulatory element binding 
protein, regulates transcription of 
sterol biosynthetic genes 
2.16 − 
YCR040W MATAL
PHA1 
Transcriptional co-activator involved 
in regulation of mating-type-specific 
gene expression 
2.16 2.20 
YOR245C DGA1 Diacylglycerol acyltransferase, 
catalyzes the terminal step of 
triacylglycerol (TAG) formation, 
acylates diacylglycerol using acyl-
CoA as an acyl donor, localized to 
lipid particles 
2.16 2.61 
YMR095C SNO1 Protein of unconfirmed function, 
involved in pyridoxine metabolism;  
2.16 3.92 
YNL046W YNL046
W 
Putative protein of unknown function; 
expression depends on Swi5p;  
2.16 2.17 
YGL261C PAU11 Putative protein of unknown function 
and member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions 
2.16 − 
YCR089W FIG2 Cell wall adhesin, expressed 
specifically during mating; may be 
involved in maintenance of cell wall 
2.15 − 
	  	  	  
73	  
	  
integrity during mating 
YGL251C HFM1 Meiosis specific DNA helicase 
involved in the conversion of double-
stranded breaks to later 
recombination intermediates and in 
crossover control 
2.15 − 
YBR131W CCZ1 Protein involved in vacuolar 
assembly, essential for autophagy 
and the cytoplasm-to-vacuole 
pathway 
2.15 2.40 
YMR175
W 
SIP18 Phospholipid-binding protein; 
expression is induced by osmotic 
stress 
2.14 2.34 
YJL088W ARG3 Ornithine carbamoyltransferase 
(carbamoylphosphate:L-ornithine 
carbamoyltransferase), catalyzes the 
sixth step in the biosynthesis of the 
arginine precursor ornithine 
2.14 2.51 
YGL146C RRT6 Putative protein of unknown function 2.14 − 
YBR085C
-A 
YBR085
C-A 
Putative protein of unknown function 2.14 2.30 
YDL067C COX9 Subunit VIIa of cytochrome c oxidase 2.14 − 
YDR530C APA2 Diadenosine 5',5''-P1,P4-
tetraphosphate phosphorylase II 
(AP4A phosphorylase), involved in 
catabolism of bis(5'-nucleosidyl) 
tetraphosphates; has similarity to 
Apa1p 
2.13 2.55 
YMR056C AAC1 Mitochondrial inner membrane 
ADP/ATP translocator, exchanges 
cytosolic ADP for mitochondrially 
synthesized ATP 
2.13 2.04 
YOL015W IRC10 Putative protein of unknown function 2.12 − 
YDR222W YDR222
W 
Protein of unknown function 2.12 − 
YOR009
W 
TIR4 Cell wall mannoprotein of the 
Srp1p/Tip1p family of serine-alanine-
rich proteins; expressed under 
anaerobic conditions and required for 
anaerobic growth 
2.12 − 
YPL187W MF(ALP
HA)1 
Mating pheromone alpha-factor, 
made by alpha cells 
2.11 − 
YHR161C YAP180
1 
Protein involved in clathrin cage 
assembly 
2.11 − 
YDR042C YDR042
C 
Putative protein of unknown function; 
expression is increased in ssu72-
ts69 mutant 
2.11 − 
YKR099W BAS1 Myb-related transcription factor 
involved in regulating basal and 
2.10 2.56 
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induced expression of genes of the 
purine and histidine biosynthesis 
pathways 
YOL001W PHO80 Cyclin, interacts with cyclin-
dependent kinase Pho85p 
2.10 2.14 
YHR162W YHR162
W 
Putative protein of unknown function 2.10 2.16 
YMR041C ARA2 NAD-dependent arabinose 
dehydrogenase 
2.10 2.28 
YPL278C YPL278
C 
Putative protein of unknown function 2.10 2.36 
YLR263W RED1 Protein component of the axial 
elements of the synaptonemal 
complex 
2.09 − 
YFR029W PTR3 Component of the SPS plasma 
membrane amino acid sensor 
system (Ssy1p-Ptr3p-Ssy5p), which 
senses external amino acid 
concentration and transmits 
intracellular signals that result in 
regulation of expression of amino 
acid permease genes 
2.09 2.27 
YMR106C YKU80 Subunit of the telomeric Ku complex 
(Yku70p-Yku80p), involved in 
telomere length maintenance, 
structure and telomere position effect 
2.08 2.57 
YBL060W YEL1 Guanine nucleotide exchange factor 
specific for Arf3p 
2.08 2.41 
YHR166C CDC23 Subunit of the Anaphase-Promoting 
Complex/Cyclosome (APC/C 
2.08 2.08 
YMR020
W 
FMS1 Polyamine oxidase, converts 
spermine to spermidine 
2.07 2.31 
YLL063C AYT1 Acetyltransferase; catalyzes 
trichothecene 3-O-acetylation 
2.07 2.51 
YPL277C YPL277
C 
Putative protein of unknown function; 
localized to the membranes 
2.07 2.19 
YJR156C THI11 Protein involved in synthesis of the 
thiamine precursor 
hydroxymethylpyrimidine (HMP) 
2.07 − 
YML097C VPS9 A guanine nucleotide exchange 
factor involved in vesicle-mediated 
vacuolar protein transport 
2.07 2.51 
YGR239C PEX21 Peroxin required for targeting of 
peroxisomal matrix proteins 
containing PTS2 
2.06 − 
YJR036C HUL4 Protein with similarity to hect domain 
E3 ubiquitin-protein ligases, not 
essential for viability 
2.06 2.14 
YBR294W SUL1 High affinity sulfate permease 2.06 − 
	  	  	  
75	  
	  
YCL055W KAR4 Transcription factor required for gene 
regulation in response to 
pheromones 
2.06 2.03 
YDR046C BAP3 Amino acid permease involved in the 
uptake of cysteine, leucine, 
isoleucine and valine 
2.06 2.47 
YDR459C PFA5 Palmitoyltransferase with 
autoacylation activity; likely functions 
in pathway(s) outside Ras 
2.05 2.29 
YJL045W YJL045
W 
Minor succinate dehydrogenase 
isozyme 
2.05 2.26 
YOR377
W 
ATF1 Alcohol acetyltransferase with 
potential roles in lipid and sterol 
metabolism 
2.05 2.31 
YOR306C MCH5 Plasma membrane riboflavin 
transporter  
2.05 − 
YDR481C PHO8 Repressible alkaline phosphatase  2.05 − 
YER130C YER130
C 
Protein of unknown function 2.04 2.43 
YKR071C DRE2 Conserved component of an early 
step in the cytosolic Fe-S protein 
assembly (CIA) machinery 
2.04 2.13 
YDR082W STN1 Telomere end-binding and capping 
protein, plays a key role with Pol12p 
in linking telomerase action with 
completion of lagging strand 
synthesis, and in a regulatory step 
required for telomere capping 
2.04 − 
YNL210W MER1 Protein with RNA-binding motifs 
required for meiosis-specific mRNA 
splicing; required for chromosome 
pairing and meiotic recombination 
2.04 2.88 
YLR214W FRE1 Ferric reductase and cupric 
reductase 
2.04 2.25 
YPR002W PDH1 Mitochondrial protein that 
participates in respiration 
2.03 − 
YIL020C HIS6 Phosphoribosyl-5-amino-1-
phosphoribosyl-4-
imidazolecarboxiamide isomerase, 
catalyzes the fourth step in histidine 
biosynthesis 
2.03 2.07 
YDR366C YDR366
C 
Putative protein of unknown function 2.02 − 
YNR076W PAU6 Member of the seripauperin 
multigene family encoded mainly in 
subtelomeric regions, active during 
alcoholic fermentation, regulated by 
anaerobiosis, negatively regulated by 
oxygen, repressed by heme 
2.02 − 
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YLL033W IRC19 Putative protein of unknown function 2.02 − 
YOL132W GAS4 1,3-beta-glucanosyltransferase 2.02 − 
YAR035W YAT1 Outer mitochondrial carnitine 
acetyltransferase 
2.01 2.12 
YIL024C YIL024C Putative protein of unknown function 2.01 − 
YCL069W VBA3 Permease of basic amino acids in 
the vacuolar membrane 
2.01 − 
YGL144C ROG1 Protein with putative serine active 
lipase domain 
2.01 − 
YDR531W CAB1 Pantothenate kinase (ATP:D-
pantothenate 4'-phosphotransferase 
2.00 2.32 
YPL241C CIN2 GTPase-activating protein (GAP) for 
Cin4p 
2.00 − 
YMR272C SCS7 Sphingolipid alpha-hydroxylase, 
functions in the alpha-hydroxylation 
of sphingolipid-associated very long 
chain fatty acids,  
2.00 2.36 
YEL066W HPA3 D-Amino acid N-acetyltransferase,  -2.00 -2.35 
YNL061W NOP2 Probable RNA m(5)C 
methyltransferase 
-2.01 -2.06 
YFL037W TUB2 Beta-tubulin; associates with alpha-
tubulin (Tub1p and Tub3p) to form 
tubulin dimer, which polymerizes to 
form microtubules 
-2.01 -2.48 
YDL137W ARF2 ADP-ribosylation factor, GTPase of 
the Ras superfamily involved in 
regulation of coated formation 
vesicles in intracellular trafficking 
within the Golgi 
-2.01 − 
YGR155
W 
CYS4 Cystathionine beta-synthase, 
catalyzes synthesis of cystathionine 
from serine and homocysteine, the 
first committed step in cysteine 
biosynthesis 
-2.02 − 
YPL154C PEP4 Vacuolar aspartyl protease 
(proteinase A), required for the 
posttranslational precursor 
maturation of vacuolar proteinases 
-2.02 − 
YEL039C CYC7 Cytochrome c isoform 2, expressed 
under hypoxic conditions 
-2.02 − 
YOL126C MDH2 Cytoplasmic malate dehydrogenase, 
one of three isozymes that catalyze 
interconversion of malate and 
oxaloacetate 
-2.02 − 
YIR038C GTT1 ER associated glutathione S-
transferase capable of 
homodimerization; expression 
induced during the diauxic shift and 
throughout stationary phase 
-2.04 − 
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YLR223C IFH1 Coactivator that regulates 
transcription of ribosomal protein 
(RP) genes;  
-2.06 − 
YDR516C EMI2 Non-essential protein of unknown 
function required for transcriptional 
induction of the early meiotic-specific 
transcription factor IME1 
-2.06 − 
YHR148W IMP3 Component of the SSU processome,  -2.06 − 
YDR496C PUF6 Pumilio-homology domain protein 
that binds the 3' UTR of ASH1 mRNA 
and represses its translation, 
resulting in proper asymmetric 
localization of ASH1 mRNA 
-2.06 − 
YDL022W GPD1 NAD-dependent glycerol-3-
phosphate dehydrogenase 
-2.07 -2.97 
YNL144C YNL144
C 
Putative protein of unknown function -2.07 − 
YOR239
W 
ABP140 Nonessential protein that binds actin 
filaments and localizes to actin 
patches and cables, has similarity to 
S-adenosylmethionine (AdoMet)-
dependent methyltransferases 
-2.07 -2.69 
YFL045C SEC53 Phosphomannomutase, involved in 
synthesis of GDP-mannose and 
dolichol-phosphate-mannose; 
required for folding and glycosylation 
of secretory proteins in the ER lumen 
-2.08 -2.94 
YHR088W RPF1 Nucleolar protein involved in the 
assembly and export of the large 
ribosomal subunit; constituent of 66S 
pre-ribosomal particles; contains a 
sigma(70)-like motif, which is thought 
to bind RNA 
-2.09 − 
YPL226W NEW1 ATP binding cassette protein that 
cosediments with polysomes and is 
required for biogenesis of the small 
ribosomal subunit 
-2.09 -2.34 
YMR309C NIP1 eIF3c subunit of the eukaryotic 
translation initiation factor 3 (eIF3), 
involved in the assembly of 
preinitiation complex and start codon 
selection 
-2.10 -2.21 
YDR155C CPR1 Cytoplasmic peptidyl-prolyl cis-trans 
isomerase (cyclophilin 
-2.10 − 
YML060W OGG1 Mitochondrial glycosylase/lyase that 
specifically excises 7,8-dihydro-8-
oxoguanine residues located 
opposite cytosine or thymine 
residues in DNA, repairs oxidative 
damage to mitochondrial DNA, 
-2.11 -2.05 
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contributes to UVA resistance 
YNL102W POL1 Catalytic subunit of the DNA 
polymerase I alpha-primase 
complex,  
-2.12 − 
YNR053C NOG2 Putative GTPase that associates with 
pre-60S ribosomal subunits in the 
nucleolus and is required for their 
nuclear export and maturation 
-2.13 − 
YPL256C CLN2 G1 cyclin involved in regulation of the 
cell cycle; activates Cdc28p kinase to 
promote the G1 to S phase transition 
-2.13 − 
YPR138C MEP3 Ammonium permease of high 
capacity and low affinity 
-2.14 − 
YLR401C DUS3 Dihydrouridine synthase, member of 
a widespread family of conserved 
proteins including Smm1p, Dus1p, 
and Dus4p; contains a consensus 
oleate response element (ORE) in its 
promoter region 
-2.15 − 
YJR074W MOG1 Conserved nuclear protein that 
interacts with GTP-Gsp1p, which is a 
Ran homolog of the Ras GTPase 
family, and stimulates nucleotide 
release, involved in nuclear protein 
import, nucleotide release is inhibited 
by Yrb1p 
-2.16 − 
YKL109W HAP4 Subunit of the heme-activated, 
glucose-repressed Hap2p/3p/4p/5p 
CCAAT-binding complex, a 
transcriptional activator and global 
regulator of respiratory gene 
expression 
-2.17 − 
YBR247C ENP1 Protein associated with U3 and U14 
snoRNAs, required for pre-rRNA 
processing and 40S ribosomal 
subunit synthesis 
-2.17 − 
YCL054W SPB1 AdoMet-dependent 
methyltransferase involved in rRNA 
processing and 60S ribosomal 
subunit maturation; methylates 
G2922 in the tRNA docking site of 
the large subunit rRNA and in the 
absence of snR52, U2921 
-2.19 -2.06 
YER158C YER158
C 
Protein of unknown function, has 
similarity to Afr1p; potentially 
phosphorylated by Cdc28p 
-2.19 -2.91 
YDR101C ARX1 Shuttling pre-60S factor; involved in 
the biogenesis of ribosomal large 
subunit biogenesis 
-2.20 -2.09 
YML008C ERG6 Delta(24)-sterol C-methyltransferase, -2.20 -2.23 
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converts zymosterol to fecosterol in 
the ergosterol biosynthetic pathway 
by methylating position C-24 
YKR077W MSA2 Putative transcriptional activator, that 
interacts with G1-specific 
transcription factor, MBF and G1-
specific promoters 
-2.21 − 
YCR034W FEN1 Fatty acid elongase, involved in 
sphingolipid biosynthesis; acts on 
fatty acids of up to 24 carbons in 
length; mutations have regulatory 
effects on 1,3-beta-glucan synthase, 
vacuolar ATPase, and the secretory 
pathway 
-2.21 -3.47 
YGL171W ROK1 ATP-dependent RNA helicase of the 
DEAD box family; required for 18S 
rRNA synthesis 
-2.21 − 
YFL052W YFL052
W 
Putative zinc cluster protein that 
contains a DNA binding domain 
-2.21 − 
YJL079C PRY1 Protein of unknown function -2.22 − 
YGR271C
-A 
EFG1 Essential protein required for 
maturation of 18S rRNA 
-2.22 − 
YBR078W ECM33 GPI-anchored protein of unknown 
function, has a possible role in apical 
bud growth; GPI-anchoring on the 
plasma membrane crucial to 
function; phosphorylated in 
mitochondria; similar to Sps2p and 
Pst1p 
-2.22 -2.85 
YLR056W ERG3 C-5 sterol desaturase, catalyzes the 
introduction of a C-5(6) double bond 
into episterol, a precursor in 
ergosterol biosynthesis; mutants are 
viable, but cannot grow on non-
fermentable carbon sources 
-2.23 − 
YIL136W OM45 Protein of unknown function, major 
constituent of the mitochondrial outer 
membrane; located on the outer 
(cytosolic) face of the outer 
membrane 
-2.24 − 
YBL030C PET9 Major ADP/ATP carrier of the 
mitochondrial inner membrane, 
exchanges cytosolic ADP for 
mitochondrially synthesized ATP 
-2.25 -2.74 
YGR079
W 
YGR079
W 
Putative protein of unknown function; 
YGR079W is not an essential gene 
-2.26 − 
YHR215W PHO12 One of three repressible acid 
phosphatases, a glycoprotein that is 
transported to the cell surface by the 
secretory pathway; nearly identical to 
-2.28 -2.49 
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Pho11p 
YEL011W GLC3 Glycogen branching enzyme, 
involved in glycogen accumulation 
-2.28 − 
YGR180C RNR4 Ribonucleotide-diphosphate 
reductase (RNR), small subunit; the 
RNR complex catalyzes the rate-
limiting step in dNTP synthesis and is 
regulated by DNA replication and 
DNA damage checkpoint pathways 
via localization of the small subunits 
-2.28 -2.60 
YNR016C ACC1 Acetyl-CoA carboxylase, biotin 
containing enzyme that catalyzes the 
carboxylation of acetyl-CoA to form 
malonyl-CoA 
-2.29 -2.88 
YPR112C MRD1 Essential conserved protein that is 
part of the 90S preribosome 
-2.29 − 
YNL058C YNL058
C 
Putative protein of unknown function; 
green fluorescent protein (GFP)-
fusion protein localizes to the 
vacuole 
-2.29 -2.26 
YKR081C RPF2 Essential protein involved in the 
processing of pre-rRNA and the 
assembly of the 60S ribosomal 
subunit; interacts with ribosomal 
protein L11 
-2.29 − 
YHR052W CIC1 Essential protein that interacts with 
proteasome components and has a 
potential role in proteasome 
substrate specificity 
-2.30 − 
YGR060
W 
ERG25 C-4 methyl sterol oxidase, catalyzes 
the first of three steps required to 
remove two C-4 methyl groups from 
an intermediate in ergosterol 
biosynthesis 
-2.30 -2.24 
YGR271C
-A 
EFG1 Essential protein required for 
maturation of 18S rRNA; null mutant 
is sensitive to hydroxyurea and is 
delayed in recovering from alpha-
factor arrest 
-2.30 − 
YOR101
W 
RAS1 GTPase involved in G-protein 
signaling in the adenylate cyclase 
activating pathway, plays a role in 
cell proliferation 
-2.35 -2.47 
YJR070C LIA1 Deoxyhypusine hydroxylase, a 
HEAT-repeat containing 
metalloenzyme that catalyzes 
hypusine formation 
-2.35 -2.86 
YPL093W NOG1 Putative GTPase that associates with 
free 60S ribosomal subunits in the 
nucleolus and is required for 60S 
-2.35 -2.14 
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ribosomal subunit biogenesis 
YJL026W RNR2 Ribonucleotide-diphosphate 
reductase (RNR), small subunit; the 
RNR complex catalyzes the rate-
limiting step in dNTP synthesis and is 
regulated by DNA replication and 
DNA damage checkpoint pathways 
via localization of the small subunits 
-2.35 -3.23 
YDR234W LYS4 Homoaconitase, catalyzes the 
conversion of homocitrate to 
homoisocitrate, which is a step in the 
lysine biosynthesis pathway 
-2.36 -2.28 
YER003C PMI40 Mannose-6-phosphate isomerase, 
catalyzes the interconversion of 
fructose-6-P and mannose-6-P; 
required for early steps in protein 
mannosylation 
-2.36 -3.87 
YJL173C RFA3 Subunit of heterotrimeric Replication 
Protein A (RPA), which is a highly 
conserved single-stranded DNA 
binding protein involved in DNA 
replication, repair, and recombination 
-2.37 -2.95 
YHR153C SPO16 Meiosis-specific protein involved in 
synaptonemal complex assembly; 
implicated in regulation of crossover 
formation 
-2.38 − 
YKR075C YKR075
C 
Protein of unknown function; similar 
to YOR062Cp and Reg1p 
-2.38 − 
YPL267W ACM1 Pseudosubstrate inhibitor of the 
anaphase-promoting 
complex/cyclosome (APC/C), that 
suppresses APC/C [Cdh1]-mediated 
proteolysis of mitotic cyclins; 
associates with Cdh1p, Bmh1p and 
Bmh2p; cell cycle regulated protein 
-2.39 − 
YMR145C NDE1 Mitochondrial external NADH 
dehydrogenase, a type II 
NAD(P)H:quinone oxidoreductase 
that catalyzes the oxidation of 
cytosolic NADH 
-2.39 -2.72 
YKL045W PRI2 Subunit of DNA primase, which is 
required for DNA synthesis and 
double-strand break repair 
-2.40 − 
YCL025C AGP1 Low-affinity amino acid permease 
with broad substrate range, involved 
in uptake of asparagine, glutamine, 
and other amino acids 
-2.41 -2.46 
YJR073C OPI3 Phospholipid methyltransferase, 
catalyzes the last two steps in 
phosphatidylcholine biosynthesis 
-2.42 − 
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YOR340C RPA43 RNA polymerase I subunit A43 -2.43 − 
YNL002C RLP7 Nucleolar protein with similarity to 
large ribosomal subunit L7 proteins 
-2.43 − 
YHR128W FUR1 Uracil phosphoribosyltransferase, 
synthesizes UMP from uracil; 
involved in the pyrimidine salvage 
pathway 
-2.43 -2.84 
YNL248C RPA49 RNA polymerase I subunit A49 -2.45 -2.35 
YPL186C UIP4 Protein that interacts with Ulp1p, a 
Ubl (ubiquitin-like protein)-specific 
protease for Smt3p protein 
conjugates 
-2.45 -2.63 
YNL274C GOR1 Glyoxylate reductase; null mutation 
results in increased biomass after 
diauxic shift 
-2.46 -2.32 
YMR196
W 
YMR196
W 
Putative protein of unknown function -2.48 − 
YLR134W PDC5 Minor isoform of pyruvate 
decarboxylase, key enzyme in 
alcoholic fermentation, 
decarboxylates pyruvate to 
acetaldehyde 
-2.51 -4.45 
YDR497C ITR1 Myo-inositol transporter with strong 
similarity to the minor myo-inositol 
transporter Itr2p, member of the 
sugar transporter superfamily 
-2.52 -3.86 
YNR014W YNR014
W 
Putative protein of unknown function; 
expression is cell-cycle regulated, 
Azf1p-dependent, and heat-inducible 
-2.52 − 
YER145C FTR1 High affinity iron permease involved 
in the transport of iron across the 
plasma membrane 
-2.55 − 
YDR097C MSH6 Protein required for mismatch repair 
in mitosis and meiosis, forms a 
complex with Msh2p to repair both 
single-base & insertion-deletion 
mispairs; potentially phosphorylated 
by Cdc28p 
-2.57 -2.01 
YMR058
W 
FET3 Ferro-O2-oxidoreductase required for 
high-affinity iron uptake and involved 
in mediating resistance to copper ion 
toxicity, belongs to class of integral 
membrane multicopper oxidases 
-2.60 − 
YBL039C URA7 Major CTP synthase isozyme (see 
also URA8), catalyzes the ATP-
dependent transfer of the amide 
nitrogen from glutamine to UTP, 
forming CTP, the final step in de 
novo biosynthesis of pyrimidines 
-2.69 -3.64 
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YDR453C TSA2 Stress inducible cytoplasmic 
thioredoxin peroxidase 
-2.70 -2.18 
YER001W MNN1 Alpha-1,3-mannosyltransferase, 
integral membrane glycoprotein of 
the Golgi complex, required for 
addition of alpha1,3-mannose 
linkages to N-linked and O-linked 
oligosaccharides, one of five S. 
cerevisiae proteins of the MNN1 
family 
-2.74 − 
YOL084W PHM7 Protein of unknown function, 
expression is regulated by phosphate 
levels 
-2.77 − 
YKL216W URA1 Dihydroorotate dehydrogenase, 
catalyzes the fourth enzymatic step 
in the de novo biosynthesis of 
pyrimidines, converting dihydroorotic 
acid into orotic acid 
-2.83 -4.34 
YGR159C NSR1 Nucleolar protein that binds nuclear 
localization sequences, required for 
pre-rRNA processing and ribosome 
biogenesis 
-2.84 − 
YGR121C MEP1 Ammonium permease; belongs to a 
ubiquitous family of cytoplasmic 
membrane proteins that transport 
only ammonium (NH4+); expression 
is under the nitrogen catabolite 
repression regulation 
-2.87 -2.69 
YGR248
W 
SOL4 6-phosphogluconolactonase with 
similarity to Sol3p 
-2.87 − 
YBR029C CDS1 Phosphatidate cytidylyltransferase 
(CDP-diglyceride synthetase 
-2.89 -4.85 
YIL094C LYS12 Homo-isocitrate dehydrogenase, an 
NAD-linked mitochondrial enzyme 
required for the fourth step in the 
biosynthesis of lysine 
-2.92 -2.90 
YCL024W KCC4 Protein kinase of the bud neck 
involved in the septin checkpoint,  
-2.93 − 
YHR183W GND1 6-phosphogluconate dehydrogenase  -2.93 -3.42 
YPR184W GDB1 Glycogen debranching enzyme 
containing glucanotranferase and 
alpha-1,6-amyloglucosidase 
activities, required for glycogen 
degradation; phosphorylated in 
mitochondria 
-2.94 − 
YJL200C ACO2 Putative mitochondrial aconitase 
isozyme 
-2.94 − 
YMR076C PDS5 Protein required for establishment 
and maintenance of sister chromatid 
condensation and cohesion 
-2.97 -2.54 
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YER091C MET6 Cobalamin-independent methionine 
synthase 
-3.08 − 
YMR250
W 
GAD1 Glutamate decarboxylase -3.12 -3.46 
YMR120C ADE17 Enzyme of 'de novo' purine 
biosynthesis containing both 5-
aminoimidazole-4-carboxamide 
ribonucleotide transformylase and 
inosine monophosphate 
cyclohydrolase activities, isozyme of 
Ade16p; ade16 ade17 mutants 
require adenine and histidine 
-3.14 − 
YOR074C CDC21 Thymidylate synthase -3.15 -3.29 
YOL109W ZEO1 Peripheral membrane protein of the 
plasma membrane that interacts with 
Mid2p 
-3.16 − 
YNL112W DBP2 Essential ATP-dependent RNA 
helicase of the DEAD-box protein 
family, involved in nonsense-
mediated mRNA decay and rRNA 
processing 
-3.24 − 
YDL003W MCD1 Essential subunit of the cohesin 
complex required for sister chromatid 
cohesion in mitosis and meiosis 
-3.29 − 
YFR015C GSY1 Glycogen synthase with similarity to 
Gsy2p, the more highly expressed 
yeast homolog 
-3.30 − 
YER043C SAH1 S-adenosyl-L-homocysteine 
hydrolase, catabolizes S-adenosyl-L-
homocysteine which is formed after 
donation of the activated methyl 
group of S-adenosyl-L-methionine 
(AdoMet) to an acceptor 
-3.37 -4.10 
YER026C CHO1 Phosphatidylserine synthase, 
functions in phospholipid 
biosynthesis; catalyzes the reaction 
CDP-diaclyglycerol + L-serine = CMP 
+ L-1-phosphatidylserine, 
transcriptionally repressed by myo-
inositol and choline 
-3.40 -5.43 
YDL204W RTN2 Protein of unknown function -3.54 − 
YPR037C ERV2 Flavin-linked sulfhydryl oxidase 
localized to the endoplasmic 
reticulum lumen, involved in disulfide 
bond formation within the ER 
-3.65 -4.55 
YLR183C TOS4 Forkhead Associated domain 
containing protein and putative 
transcription factor found associated 
with chromatin 
-3.76 -4.56 
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YBR208C DUR1,2 Urea amidolyase, contains both urea 
carboxylase and allophanate 
hydrolase activities, degrades urea to 
CO2 and NH3 
-3.79 − 
YOR315
W 
SFG1 Nuclear protein, putative transcription 
factor required for growth of 
superficial pseudohyphae (which do 
not invade the agar substrate) but 
not for invasive pseudohyphal 
growth; may act together with Phd1p 
-3.82 -5.06 
YMR105C PGM2 Phosphoglucomutase, catalyzes the 
conversion from glucose-1-
phosphate to glucose-6-phosphate 
-3.86 − 
YLR327C TMA10 Protein of unknown function that 
associates with ribosomes 
-3.90 − 
YLR180W SAM1 S-adenosylmethionine synthetase, 
catalyzes transfer of the adenosyl 
group of ATP to the sulfur atom of 
methionine 
-4.04 -2.26 
YDL227C HO Site-specific endonuclease required 
for gene conversion at the MAT locus 
(homothallic switching) through the 
generation of a ds DNA break 
-4.26 − 
YFR053C HXK1 Hexokinase isoenzyme 1, a cytosolic 
protein that catalyzes 
phosphorylation of glucose during 
glucose metabolism 
-4.35 − 
YBR291C CTP1 Mitochondrial inner membrane citrate 
transporter, member of the 
mitochondrial carrier family 
-4.42 -3.35 
YOR348C PUT4 Proline permease, required for high-
affinity transport of proline 
-4.47 − 
YML128C MSC1 Protein of unknown function; mutant 
is defective in directing meiotic 
recombination events to homologous 
chromatids 
-4.73 − 
YNL194C YNL194
C 
Integral membrane protein required 
for sporulation and plasma 
membrane sphingolipid content; has 
sequence similarity to SUR7 and 
FMP45; GFP-fusion protein is 
induced in response to the DNA-
damaging agent MMS 
-4.95 -6.45 
YOR375C GDH1 NADP(+)-dependent glutamate 
dehydrogenase, synthesizes 
glutamate from ammonia and alpha-
ketoglutarate; rate of alpha-
ketoglutarate utilization differs from 
Gdh3p; expression regulated by 
nitrogen and carbon sources 
-4.98 -7.99 
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YPR192W AQY1 Spore-specific water channel that 
mediates the transport of water 
across cell membranes, 
developmentally controlled; may play 
a role in spore maturation, probably 
by allowing water outflow, may be 
involved in freeze tolerance 
-5.07 -3.08 
YDR502C SAM2 S-adenosylmethionine synthetase -5.27 -14.85 
YNL065W AQR1 Plasma membrane multidrug 
transporter of the major facilitator 
superfamily, confers resistance to 
short-chain monocarboxylic acids 
and quinidine 
-5.53 -3.28 
YER070W RNR1 Major isoform of the large subunit of 
ribonucleotide-diphosphate 
reductase  
-5.60 -8.64 
YPR160W GPH1 Non-essential glycogen 
phosphorylase required for the 
mobilization of glycogen, activity is 
regulated by cyclic AMP-mediated 
phosphorylation,  
-6.10  
YBR092C PHO3 Constitutively expressed acid 
phosphatase similar to Pho5p 
-6.21 -6.52 
YNR050C LYS9 Saccharopine dehydrogenase 
(NADP+, L-glutamate-forming 
-6.39 -12.19 
YNL142W MEP2 Ammonium permease involved in 
regulation of pseudohyphal growth 
-6.62 -3.89 
YDR342C HXT7 High-affinity glucose transporter of 
the major facilitator superfamily, 
nearly identical to Hxt6p 
-8.35 − 
YKL096W CWP1 Cell wall mannoprotein that localizes 
specifically to birth scars of daughter 
cells, linked to a beta-1,3- and beta-
1,6-glucan heteropolymer through a 
phosphodiester bond; required for 
propionic acid resistance 
-8.71 -10.09 
YDR343C HXT6 High-affinity glucose transporter of 
the major facilitator superfamily, 
nearly identical to Hxt7p, expressed 
at high basal levels relative to other 
HXTs, repression of expression by 
high glucose requires SNF3 
-9.44 − 
YKR039W GAP1 General amino acid permease -11.78 -11.21 
YFL014W HSP12 Plasma membrane localized protein 
that protects membranes from 
desiccation 
-16.71 − 
YMR011
W 
HXT2 High-affinity glucose transporter of 
the major facilitator superfamily, 
expression is induced by low levels 
-22.27 -58.00 
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of glucose and repressed by high 
levels of glucose 
YLR012C YLR012
C 
Putative protein of unknown function − 10.42 
YGL138C YGL138
C 
Putative protein of unknown function − 10.37 
YGL183C MND1 Protein required for recombination 
and meiotic nuclear division 
− 6.18 
YER053C
-A 
YER053
C-A 
Putative protein of unknown function − 5.66 
YNR062C YNR062
C 
Putative membrane protein of 
unknown function 
− 5.12 
YJR149W YJR149
W 
Putative protein of unknown function − 4.93 
YCR101C YCR101
C 
Putative protein of unknown function − 4.89 
YOR298
W 
MUM3 Protein of unknown function involved 
in the organization of the outer spore 
wall layers 
− 4.29 
YJL072C PSF2 Subunit of the GINS complex (Sld5p, 
Psf1p, Psf2p, Psf3p), which is 
localized to DNA replication origins 
and implicated in assembly of the 
DNA replication machinery 
− 4.06 
YOL131W YOL131
W 
Putative protein of unknown function − 4.00 
YNR004W SWM2 Putative protein of unknown function − 3.89 
YCR005C CIT2 Citrate synthase, catalyzes the 
condensation of acetyl coenzyme A 
and oxaloacetate to form citrate, 
peroxisomal isozyme involved in 
glyoxylate cycle; expression is 
controlled by Rtg1p and Rtg2p 
transcription factors 
− 3.80 
YGR243
W 
FMP43 Putative protein of unknown function − 3.68 
YGR161C RTS3 Putative component of the protein 
phosphatase type 2A complex 
− 3.58 
YCR106W RDS1 Zinc cluster transcription factor 
involved in conferring resistance to 
cycloheximide 
− 3.48 
YIL029C YIL029C Putative protein of unknown function; 
deletion confers sensitivity to 4-(N-
(S-glutathionylacetyl)amino) 
phenylarsenoxide (GSAO) 
− 3.47 
YJL213W YJL213
W 
Protein of unknown function that may 
interact with ribosomes;  
− 3.46 
YLR266C PDR8 Transcription factor; targets include 
ATP-binding cassette (ABC) 
− 3.24 
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transporters, major facilitator 
superfamily transporters, and other 
genes involved in the pleiotropic drug 
resistance (PDR) phenomenon 
YGL096W TOS8 Homeodomain-containing protein 
and putative transcription factor 
found associated with chromatin 
− 3.13 
YGL170C SPO74 Component of the meiotic outer 
plaque of the spindle pole body, 
involved in modifying the meiotic 
outer plaque that is required prior to 
prospore membrane formation 
− 3.08 
YGL219C MDM34 Mitochondrial component of the 
ERMES complex that links the ER to 
mitochondria and may promote inter-
organellar calcium and phospholipid 
exchange as well as coordinating 
mitochondrial DNA replication and 
growth 
− 3.05 
YGR287C YGR287
C 
Major isomaltase (alpha-1,6-
glucosidase) required for isomaltose 
utilization; has specificity for 
isomaltose, palatinose, and methyl-
alpha-glucoside; member of the IMA 
isomaltase family 
− 2.97 
YHR184W SSP1 Protein involved in the control of 
meiotic nuclear division and 
coordination of meiosis with spore 
formation; transcription is induced 
midway through meiosis 
− 2.92 
YOR177C MPC54 Component of the meiotic outer 
plaque, a membrane-organizing 
center which is assembled on the 
cytoplasmic face of the spindle pole 
body during meiosis II and triggers 
the formation of the prospore 
membrane; potential Cdc28p 
substrate 
− 2.91 
YEL023C YEL023
C 
Putative protein of unknown function − 2.89 
YOR012
W 
YOR012
W 
Putative protein of unknown function − 2.88 
YOR213C SAS5 Subunit of the SAS complex (Sas2p, 
Sas4p, Sas5p), which  acetylates 
free histones and nucleosomes and 
regulates transcriptional silencing; 
stimulates Sas2p HAT activity 
− 2.87 
YMR034C YMR034
C 
Putative transporter, member of the 
SLC10 carrier family 
− 2.86 
YDL039C PRM7 Pheromone-regulated protein, − 2.86 
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predicted to have one 
transmembrane segment; promoter 
contains Gcn4p binding elements 
YPL026C SKS1 Putative serine/threonine protein 
kinase; involved in the adaptation to 
low concentrations of glucose 
independent of the SNF3 regulated 
pathway 
− 2.83 
YPL189W GUP2 Probable membrane protein with a 
possible role in proton symport of 
glycerol; member of the MBOAT 
family of putative membrane-bound 
O-acyltransferases 
− 2.83 
YMR035
W 
IMP2 Catalytic subunit of the mitochondrial 
inner membrane peptidase complex, 
required for maturation of 
mitochondrial proteins of the 
intermembrane space 
− 2.82 
YGL114W YGL114
W 
Putative protein of unknown function; 
predicted member of the oligopeptide 
transporter (OPT) family of 
membrane transporters 
− 2.82 
YER039C
-A 
YER039
C-A 
Putative protein of unknown function; 
YER039C-A is not an essential gene 
− 2.77 
YMR135C GID8 Protein of unknown function, involved 
in proteasome-dependent catabolite 
inactivation of fructose-1,6-
bisphosphatase 
− 2.74 
YJL058C BIT61 Subunit of TORC2 (Tor2p-Lst8p-
Avo1-Avo2-Tsc11p-Bit61p-Slm1p-
Slm2p), a membrane-associated 
complex that regulates cell cycle-
dependent actin cytoskeletal 
dynamics during polarized growth 
and cell wall integrity 
− 2.69 
YPL068C YPL068
C 
Protein of unknown function; green 
fluorescent protein (GFP)-fusion 
protein localizes to the nucleus and 
is induced in response to the DNA-
damaging agent MMS 
− 2.64 
YIL009C-
A 
EST3 Component of the telomerase 
holoenzyme, involved in telomere 
replication 
− 2.61 
YLR205C HMX1 ER localized heme oxygenase, 
involved in heme degradation during 
iron starvation and in the oxidative 
stress response 
− 2.60 
YGL162W SUT1 Transcription factor of the 
Zn[II]2Cys6 family involved in sterol 
uptake; involved in induction of 
− 2.60 
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hypoxic gene expression 
YAL064C-
A 
YAL064
C-A 
Putative protein of unknown function; 
YAL064C-A is not an essential gene 
− 2.60 
YDL039C PRM7 Pheromone-regulated protein, 
predicted to have one 
transmembrane segment; promoter 
contains Gcn4p binding elements 
− 2.59 
YNL314W DAL82 Positive regulator of allophanate 
inducible genes; binds a 
dodecanucleotide sequence 
upstream of all genes that are 
induced by allophanate; contains an 
UISALL DNA-binding, a 
transcriptional activation, and a 
coiled-coil domain 
− 2.53 
YNR074C AIF1 Mitochondrial cell death effector that 
translocates to the nucleus in 
response to apoptotic stimuli, 
homolog of mammalian Apoptosis-
Inducing Factor, putative reductase 
− 2.53 
YPL148C PPT2 Phosphopantetheine:protein 
transferase (PPTase), activates 
mitochondrial acyl carrier protein 
(Acp1p) by phosphopantetheinylation 
− 2.52 
YER073W ALD5 Mitochondrial aldehyde 
dehydrogenase, involved in 
regulation or biosynthesis of electron 
transport chain components and 
acetate formation 
− 2.50 
YFR025C HIS2 Histidinolphosphatase, catalyzes the 
eighth step in histidine biosynthesis; 
mutations cause histidine auxotrophy 
and sensitivity to Cu, Co, and Ni 
salts; transcription is regulated by 
general amino acid control 
− 2.49 
YPL024W RMI1 Subunit of the RecQ (Sgs1p) - Topo 
III (Top3p) complex; stimulates 
superhelical relaxing and ssDNA 
binding activities of Top3p 
− 2.48 
YNL042W BOP3 Protein of unknown function, 
potential Cdc28p substrate 
− 2.45 
YGL159W YGL159
W 
Putative protein of unknown function − 2.42 
YIL003W CFD1 Highly conserved, iron-sulfur cluster 
binding protein localized in the 
cytoplasm 
− 2.41 
YDL109C YDL109
C 
Putative lipase; involved in lipid 
metabolism 
− 2.41 
YLR030W YLR030
W 
Putative protein of unknown function − 2.38 
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YIL152W YIL152
W 
Putative protein of unknown function − 2.37 
YGR146C ECL1 Protein of unknown function, affects 
chronological lifespan 
− 2.35 
YFR035C YFR035
C 
Putative protein of unknown function, 
deletion mutant exhibits synthetic 
phenotype with alpha-synuclein 
− 2.34 
YOL133W HRT1 RING finger containing subunit of 
Skp1-Cullin-F-box ubiquitin protein 
ligases (SCF); required for Gic2p, 
Far1p, Sic1p and Cln2p degradation; 
may tether Cdc34p (a ubiquitin 
conjugating enzyme or E2) and 
Cdc53p (a cullin) subunits of SCF 
− 2.34 
YJR094C IME1 Master regulator of meiosis that is 
active only during meiotic events, 
activates transcription of early 
meiotic genes through interaction 
with Ume6p, degraded by the 26S 
proteasome following 
phosphorylation by Ime2p 
− 2.33 
YDL127W PCL2 Cyclin, interacts with cyclin-
dependent kinase Pho85p 
− 2.33 
YCL056C YCL056
C 
Protein of unknown function − 2.32 
YOL025W LAG2 Protein that negatively regulates the 
SCF E3-ubiquitin ligase by 
interacting with and preventing 
neddyation of the cullin subunit, 
Cdc53p; longevity determinant that is 
preferentially expressed in young 
cells; similar to mammalian Cand1 
− 2.30 
YLR326W YLR326
W 
Putative protein of unknown function, 
predicted to be palmitoylated 
− 2.30 
YFR008W FAR7 Protein involved in recovery from cell 
cycle arrest in response to 
pheromone, in a Far1p-independent 
pathway 
− 2.30 
YDR408C ADE8 Phosphoribosyl-glycinamide 
transformylase, catalyzes a step in 
the 'de novo' purine nucleotide 
biosynthetic pathway 
− 2.28 
YOR179C SYC1 Subunit of the APT subcomplex of 
cleavage and polyadenylation factor, 
may have a role in 3' end formation 
of both polyadenylated and non-
polyadenylated RNAs 
− 2.27 
YCR007C YCR007
C 
Putative integral membrane protein, 
member of DUP240 gene family; 
YCR007C is not an essential gene 
− 2.27 
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YLR452C SST2 GTPase-activating protein for Gpa1p, 
regulates desensitization to alpha 
factor pheromone 
− 2.27 
YOR201C MRM1 Ribose methyltransferase that 
modifies a functionally critical, 
conserved nucleotide in 
mitochondrial 21S rRNA 
− 2.26 
YJR021C REC107 Protein involved in early stages of 
meiotic recombination; involved in 
coordination between the initiation of 
recombination and the first division of 
meiosis; part of a complex (Rec107p-
Mei4p-Rec114p) required for ds 
break formation 
− 2.25 
YPR083W MDM36 Mitochondrial protein required for 
normal mitochondrial morphology 
and inheritance; proposed 
involvement in the formation of 
Dnm1p and Num1p-containing 
cortical anchor complexes that 
promote mitochondrial fission 
− 2.24 
YJR127C RSF2 Zinc-finger protein involved in 
transcriptional control of both nuclear 
and mitochondrial genes, many of 
which specify products required for 
glycerol-based growth, respiration, 
and other functions 
− 2.23 
YJL163C YJL163
C 
Putative protein of unknown function − 2.23 
YPL252C YAH1 Ferredoxin of the mitochondrial 
matrix required for formation of 
cellular iron-sulfur proteins; involved 
in heme A biosynthesis 
− 2.23 
YMR059
W 
SEN15 Subunit of the tRNA splicing 
endonuclease, which is composed of 
Sen2p, Sen15p, Sen34p, and 
Sen54p 
− 2.23 
YBR107C IML3 Protein with a role in kinetochore 
function, localizes to the outer 
kinetochore in a Ctf19p-dependent 
manner, interacts with Chl4p and 
Ctf19p 
− 2.23 
YMR065
W 
KAR5 Protein required for nuclear 
membrane fusion during karyogamy, 
localizes to the membrane with a 
soluble portion in the endoplasmic 
reticulum lumen, may form a 
complex with Jem1p and Kar2p; 
expression of the gene is regulated 
by pheromone 
− 2.21 
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YJL100W LSB6 Type II phosphatidylinositol 4-kinase 
that binds Las17p, which is a 
homolog of human Wiskott-Aldrich 
Syndrome protein involved in actin 
patch assembly and actin 
polymerization 
− 2.21 
YPL214C THI6 Bifunctional enzyme with thiamine-
phosphate pyrophosphorylase and 4-
methyl-5-beta-hydroxyethylthiazole 
kinase activities, required for 
thiamine biosynthesis 
− 2.20 
YOR211C MGM1 Chr XV from 741569-738924, 
reverse complement, Verified ORF, 
""Mitochondrial GTPase, present in 
complex with Ugo1p and Fzo1p 
− 2.20 
YIL114C POR2 Putative mitochondrial porin (voltage-
dependent anion channel), related to 
Por1p but not required for 
mitochondrial membrane 
permeability or mitochondrial osmotic 
stability 
− 2.19 
YDR259C YAP6 Putative basic leucine zipper (bZIP) 
transcription factor; overexpression 
increases sodium and lithium 
tolerance 
− 2.19 
YHL027W RIM101 Transcriptional repressor involved in 
response to pH and in cell wall 
construction; required for alkaline 
pH-stimulated haploid invasive 
growth and sporulation; activated by 
proteolytic processing 
− 2.17 
YOR019
W 
YOR019
W 
Protein of unknown function that may 
interact with ribosomes, based on co-
purification experiments 
− 2.17 
YLR193C UPS1 Mitochondrial intermembrane space 
protein that regulates mitochondrial 
cardiolipin levels, null has defects in 
Mgm1p processing, integrity of 
mitochondrial inner membrane 
complexes, and mitochondrial 
morphology; ortholog of human 
PRELI 
− 2.17 
YFR005C SAD1 Conserved zinc-finger domain 
protein involved in pre-mRNA 
splicing, required for assembly of U4 
snRNA into the U4/U6 particle 
− 2.17 
YJR097W JJJ3 Protein of unknown function, 
contains a J-domain, which is a 
region with homology to the E. coli 
DnaJ protein 
− 2.16 
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YFL050C ALR2 Probable Mg(2+) transporter; 
overexpression confers increased 
tolerance to Al(3+) and Ga(3+) ions; 
plays a role in regulating Ty1 
transposition 
− 2.16 
YHR199C AIM46 Putative protein of unknown function; 
the authentic, non-tagged protein is 
detected in highly purified 
mitochondria in high-throughput 
studies; null mutant displays elevated 
frequency of mitochondrial genome 
loss 
− 2.15 
YFR036W CDC26 Subunit of the Anaphase-Promoting 
Complex/Cyclosome (APC/C), which 
is a ubiquitin-protein ligase required 
for degradation of anaphase 
inhibitors, including mitotic cyclins, 
during the metaphase/anaphase 
transition 
− 2.14 
YBR063C YBR063
C 
Putative protein of unknown function; 
YBR063C is not an essential gene 
− 2.14 
YML002W YML002
W 
Putative protein of unknown function; 
expression induced by heat and by 
calcium shortage 
− 2.13 
YOR028C CIN5 Basic leucine zipper (bZIP) 
transcription factor of the yAP-1 
family, mediates pleiotropic drug 
resistance and salt tolerance 
− 2.13 
YKR106W YKR106
W 
Protein of unconfirmed function; 
displays a topology characteristic of 
the Major Facilitators Superfamily of 
membrane proteins; coding 
sequence 98% identical to that of 
YCL073C 
− 2.13 
YJR136C TTI2 Putative protein of unknown function − 2.12 
YGR230
W 
BNS1 Protein with some similarity to 
Spo12p; overexpression bypasses 
need for Spo12p, but not required for 
meiosis 
− 2.11 
YPR071W YPR071
W 
Putative membrane protein; 
YPR071W is not an essential gene 
− 2.11 
YBR004C GPI18 Functional ortholog of human PIG-V, 
which is a mannosyltransferase that 
transfers the second mannose in 
glycosylphosphatidylinositol 
biosynthesis; the authentic, non-
tagged protein was localized to 
mitochondria 
− 2.11 
YAL015C NTG1 DNA N-glycosylase and 
apurinic/apyrimidinic (AP) lyase 
− 2.10 
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involved in base excision repair; acts 
in both nucleus and mitochondrion; 
creates a double-strand break at 
mtDNA origins that stimulates 
replication in response to oxidative 
stress 
YKR019C IRS4 EH domain-containing protein 
involved in regulating 
phosphatidylinositol 4,5-
bisphosphate levels and autophagy 
− 2.10 
YOR383C FIT3 Mannoprotein that is incorporated 
into the cell wall via a 
glycosylphosphatidylinositol (GPI) 
anchor, involved in the retention of 
siderophore-iron in the cell wall 
− 2.10 
YNR029C YNR029
C 
Putative protein of unknown function, 
deletion confers reduced fitness in 
saline 
− 2.10 
YOR079C ATX2 Golgi membrane protein involved in 
manganese homeostasis; 
overproduction suppresses the sod1 
(copper, zinc superoxide dismutase) 
null mutation 
− 2.10 
YIL104C SHQ1 Chaperone protein required for the 
assembly of box H/ACA snoRNPs 
and thus for pre-rRNA processing, 
forms a complex with Naf1p and 
interacts with H/ACA snoRNP 
components Nhp2p and Cbf5p; 
homology with known Hsp90p 
cochaperones 
− 2.10 
YFL051C YFL051
C 
Putative protein of unknown function; 
YFL051C is not an essential gene 
− 2.10 
YOR183
W 
FYV12 Protein of unknown function, required 
for survival upon exposure to K1 
killer toxin 
− 2.09 
YGR029
W 
ERV1 Flavin-linked sulfhydryl oxidase of 
the mitochondrial intermembrane 
space (IMS), oxidizes Mia40p as part 
of a disulfide relay system that 
promotes IMS retention of imported 
proteins; ortholog of human 
hepatopoietin (ALR) 
− 2.09 
YDR093W DNF2 Aminophospholipid translocase 
(flippase) that localizes primarily to 
the plasma membrane; contributes to 
endocytosis, protein transport and 
cell polarity; type 4 P-type ATPase 
− 2.09 
YFL027C GYP8 GTPase-activating protein for yeast 
Rab family members; Ypt1p is the 
− 2.08 
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preferred in vitro substrate but also 
acts on Sec4p, Ypt31p and Ypt32p; 
involved in the regulation of ER to 
Golgi vesicle transport 
YOL163W YOL163
W 
Putative protein of unknown function; 
member of the Dal5p subfamily of 
the major facilitator family 
− 2.07 
YLR125W YLR125
W 
Putative protein of unknown function − 2.06 
YAR028W YAR028
W 
Putative integral membrane protein, 
member of DUP240 gene family;  
− 2.06 
YOR268C YOR268
C 
Putative protein of unknown function − 2.06 
YPR061C JID1 Probable Hsp40p co-chaperone, has 
a DnaJ-like domain and appears to 
be involved in ER-associated 
degradation of misfolded proteins 
containing a tightly folded 
cytoplasmic domain 
− 2.05 
YGL025C PGD1 Subunit of the RNA polymerase II 
mediator complex 
− 2.05 
YDL236W PHO13 Alkaline phosphatase specific for p-
nitrophenyl phosphate 
− 2.05 
YOR107
W 
RGS2 Negative regulator of glucose-
induced cAMP signaling 
− 2.04 
YMR303C ADH2 Glucose-repressible alcohol 
dehydrogenase II, catalyzes the 
conversion of ethanol to 
acetaldehyde 
− 2.04 
YCR073C SSK22 MAP kinase kinase kinase of the 
HOG1 mitogen-activated signaling 
pathway 
− 2.04 
YIL099W SGA1 Intracellular sporulation-specific 
glucoamylase involved in glycogen 
degradation; induced during 
starvation of a/a diploids late in 
sporulation, but dispensable for 
sporulation 
− 2.04 
YGL179C TOS3 Protein kinase, related to and 
functionally redundant with Elm1p 
and Sak1p for the phosphorylation 
and activation of Snf1p 
− 2.03 
YDR073W SNF11 Subunit of the SWI/SNF chromatin 
remodeling complex involved in 
transcriptional regulation 
− 2.03 
YDR191W HST4 Member of the Sir2 family of NAD(+)-
dependent protein deacetylases; 
involved along with Hst3p in silencing 
at telomeres,  
− 2.03 
YPR058W YMC1 Mitochondrial protein, putative inner − 2.03 
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membrane transporter with a role in 
oleate metabolism and glutamate 
biosynthesis 
YNL227C JJJ1 Co-chaperone that stimulates the 
ATPase activity of Ssa1p, required 
for a late step of ribosome 
biogenesis; associated with the 
cytosolic large ribosomal subunit 
− 2.02 
YBR278W DPB3 Third-largest subunit of DNA 
polymerase II (DNA polymerase 
epsilon), required to maintain fidelity 
of chromosomal replication and also 
for inheritance of telomeric silencing 
− 2.01 
YMR023C MSS1 Mitochondrial protein, forms a 
heterodimer complex with Mto1p that 
performs the 5-
carboxymethylaminomethyl 
modification of the wobble uridine 
base in mitochondrial tRNAs 
− 2.01 
YMR176
W 
ECM5 Non-essential protein of unknown 
function, contains ATP/GTP-binding 
site motif A; null mutant exhibits 
cellular volume up to four times 
greater than wild-type, also large 
drooping buds with elongated necks 
− 2.00 
YGR074
W 
SMD1 Core Sm protein Sm D1; part of 
heteroheptameric complex (with 
Smb1p, Smd2p, Smd3p, Sme1p, 
Smx3p, and Smx2p) that is part of 
the spliceosomal U1, U2, U4, and U5 
snRNPs; homolog of human Sm D1 
− 2.00 
YPR013C YPR013
C 
Putative zinc finger protein; 
YPR013C is not an essential gene 
− 2.00 
YML085C TUB1 Alpha-tubulin; associates with beta-
tubulin (Tub2p) to form tubulin dimer, 
which polymerizes to form 
microtubules 
− -2.01 
YOL030W GAS5 1,3-beta-glucanosyltransferase − -2.01 
YKL027W YKL027
W 
Protein of unknown function, 
localized to the mitochondrial outer 
membrane 
− -2.02 
YHR123W EPT1 sn-1,2-diacylglycerol ethanolamine- 
and cholinephosphotranferase 
− -2.02 
YJL177W RPL17B Protein component of the large (60S) 
ribosomal subunit, nearly identical to 
Rpl17Ap and has similarity to E. coli 
L22 and rat L17 ribosomal proteins 
− -2.02 
YNL280C ERG24 C-14 sterol reductase, acts in 
ergosterol biosynthesis 
− -2.02 
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YER031C YPT31 Rab family GTPase, very similar to 
Ypt32p 
− -2.02 
YML093W UTP14 Subunit of U3-containing Small 
Subunit (SSU) processome complex 
involved in production of 18S rRNA 
and assembly of small ribosomal 
subunit 
− -2.02 
YDR391C YDR391
C 
Putative protein of unknown function − -2.03 
YLR172C DPH5 Methyltransferase required for 
synthesis of diphthamide 
− -2.03 
YBR189W RPS9B Protein component of the small (40S) 
ribosomal subunit 
− -2.03 
YNL151C RPC31 RNA polymerase III subunit C31 − -2.03 
YKR059W TIF1 Translation initiation factor eIF4A, 
identical to Tif2p; DEA(D/H)-box 
RNA helicase that couples ATPase 
activity to RNA binding and 
unwinding 
− -2.04 
YBR137W YBR137
W 
Protein of unknown function; 
localized to the cytoplasm 
− -2.04 
YOR168
W 
GLN4 Glutamine tRNA synthetase, 
monomeric class I tRNA synthetase  
− -2.04 
YHL033C RPL8A Ribosomal protein L4 of the large 
(60S) ribosomal subunit, nearly 
identical to Rpl8Bp and has similarity 
to rat L7a ribosomal protein; mutation 
results in decreased amounts of free 
60S subunits 
− -2.04 
YBR025C OLA1 P-loop ATPase with similarity to 
human OLA1 and bacterial YchF; 
identified as specifically interacting 
with the proteasome 
− -2.04 
YGL200C EMP24 Integral membrane component of 
endoplasmic reticulum-derived 
COPII-coated vesicles, which 
function in ER to Golgi transport 
− -2.05 
YMR307
W 
GAS1 Beta-1,3-glucanosyltransferase, 
required for cell wall assembly and 
also has a role in transcriptional 
silencing; localizes to the cell surface 
via a glycosylphosphatidylinositol 
(GPI) anchor 
− -2.05 
YEL040W UTR2 Chitin transglycosylase that functions 
in the transfer of chitin to beta(1-6) 
and beta(1-3) glucans in the cell wall 
− -2.05 
YLR150W STM1 Protein required for optimal 
translation under nutrient stress; 
perturbs association of Yef3p with 
ribosomes; involved in TOR signaling 
− -2.05 
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YEL031W SPF1 P-type ATPase, ion transporter of the 
ER membrane involved in ER 
function and Ca2+ homeostasis 
− -2.05 
YJL138C TIF2 Translation initiation factor eIF4A, 
identical to Tif1p; DEA(D/H)-box 
RNA helicase that couples ATPase 
activity to RNA binding and 
unwinding 
− -2.05 
YDL145C COP1 Alpha subunit of COPI vesicle 
coatomer complex, which surrounds 
transport vesicles in the early 
secretory pathway 
− -2.05 
YEL054C RPL12A Protein component of the large (60S) 
ribosomal subunit, nearly identical to 
Rpl12Bp; rpl12a rpl12b double 
mutant exhibits slow growth and slow 
translation; has similarity to E. coli 
L11 and rat L12 ribosomal proteins 
− -2.06 
YJR103W URA8 Minor CTP synthase isozyme (see 
also URA7), catalyzes the ATP-
dependent transfer of the amide 
nitrogen from glutamine to UTP, 
forming CTP, the final step in de 
novo biosynthesis of pyrimidines 
− -2.07 
YJL050W MTR4 ATP-dependent 3'-5' RNA helicase of 
the Dead-box family, involved in 
nuclear RNA processing and 
degradation both as a component of 
the TRAMP complex and in TRAMP 
independent processes 
− -2.07 
YAL003W EFB1 Translation elongation factor 1 beta; 
stimulates nucleotide exchange to 
regenerate EF-1 alpha-GTP for the 
next elongation cycle 
− -2.07 
YDR002W YRB1 Ran GTPase binding protein; 
involved in nuclear protein import 
and RNA export, ubiquitin-mediated 
protein degradation during the cell 
cycle 
− -2.07 
YFR014C CMK1 Calmodulin-dependent protein 
kinase; may play a role in stress 
response, many CA++/calmodulan 
dependent phosphorylation 
substrates demonstrated in vitro, 
amino acid sequence similar to 
Cmk2p and mammalian Cam Kinase 
II 
− -2.09 
YGR214
W 
RPS0A Protein component of the small (40S) 
ribosomal subunit, nearly identical to 
Rps0Bp; required for maturation of 
− -2.09 
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18S rRNA along with Rps0Bp 
YHR113W YHR113
W 
Cytoplasmic aspartyl 
aminopeptidase; cleaves unblocked 
N-terminal acidic amino acid 
residues from peptide substrates 
− -2.10 
YPL247C YPL247
C 
Putative protein of unknown function; 
green fluorescent protein (GFP)-
fusion protein localizes to the 
cytoplasm and nucleus 
− -2.10 
YLR249W YEF3 Gamma subunit of translational 
elongation factor eEF1B, stimulates 
the binding of aminoacyl-tRNA (AA-
tRNA) to ribosomes by releasing 
eEF1A (Tef1p/Tef2p) from the 
ribosomal complex; contains two 
ABC cassettes; binds and hydrolyzes 
ATP 
− -2.10 
YOR198C BFR1 Component of mRNP complexes 
associated with polyribosomes; 
implicated in secretion and nuclear 
segregation; multicopy suppressor of 
BFA (Brefeldin A) sensitivity 
− -2.12 
YGR123C PPT1 Protein serine/threonine 
phosphatase with similarity to human 
phosphatase PP5; present in both 
the nucleus and cytoplasm 
− -2.12 
YJL080C SCP160 Essential RNA-binding G protein 
effector of mating response pathway, 
mainly associated with nuclear 
envelope and ER, interacts in 
mRNA-dependent manner with 
translating ribosomes via multiple KH 
domains, similar to vertebrate vigilins 
− -2.12 
YMR260C TIF11 Translation initiation factor eIF1A, 
essential protein that forms a 
complex with Sui1p (eIF1) and the 
40S ribosomal subunit and scans for 
the start codon; C-terminus 
associates with Fun12p (eIF5B 
− -2.12 
YJR115W YJR115
W 
Putative protein of unknown function − -2.13 
YJR133W XPT1 Xanthine-guanine phosphoribosyl 
transferase, required for xanthine 
utilization and for optimal utilization 
of guanine 
− -2.13 
YER110C KAP123 Karyopherin beta, mediates nuclear 
import of ribosomal proteins prior to 
assembly into ribosomes and import 
of histones H3 and H4 
− -2.13 
YLR133W CKI1 Choline kinase, catalyzing the first − -2.14 
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step in phosphatidylcholine synthesis 
via the CDP-choline (Kennedy 
pathway 
YOR230
W 
WTM1 Transcriptional modulator involved in 
regulation of meiosis, silencing, and 
expression of RNR genes; required 
for nuclear localization of the 
ribonucleotide reductase small 
subunit Rnr2p and Rnr4p; contains 
WD repeats 
− -2.15 
YLR153C ACS2 Acetyl-coA synthetase isoform which, 
along with Acs1p, is the nuclear 
source of acetyl-coA for histone 
acetylation 
− -2.15 
YBL042C FUI1 High affinity uridine permease, 
localizes to the plasma membrane; 
also mediates low but significant 
transport of the cytotoxic nucleoside 
analog 5-fluorouridine; not involved 
in uracil transport 
− -2.16 
YER131W RPS26B Protein component of the small (40S) 
ribosomal subunit; nearly identical to 
Rps26Ap and has similarity to rat 
S26 ribosomal protein 
− -2.17 
YAR071W PHO11 One of three repressible acid 
phosphatases, a glycoprotein that is 
transported to the cell surface by the 
secretory pathway; induced by 
phosphate starvation and 
coordinately regulated by PHO4 and 
PHO2 
− -2.17 
YPL211W NIP7 Nucleolar protein required for 60S 
ribosome subunit biogenesis, 
constituent of 66S pre-ribosomal 
particles; physically interacts with 
Nop8p and the exosome subunit 
Rrp43p 
− -2.17 
YOR293
W 
RPS10A Protein component of the small (40S) 
ribosomal subunit; nearly identical to 
Rps10Bp and has similarity to rat 
ribosomal protein S10 
− -2.18 
YFL022C FRS2 Alpha subunit of cytoplasmic 
phenylalanyl-tRNA synthetase 
− -2.18 
YLR347C KAP95 Karyopherin beta, forms a complex 
with Srp1p/Kap60p 
− -2.19 
YIR036C IRC24 Putative benzil reductase;(GFP)-
fusion protein localizes to the 
cytoplasm and is induced by the 
DNA-damaging agent MMS 
− -2.19 
YKL093W MBR1 Protein involved in mitochondrial − -2.19 
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functions and stress response; 
overexpression suppresses growth 
defects of hap2, hap3, and hap4 
mutants 
YKL073W LHS1 Molecular chaperone of the 
endoplasmic reticulum lumen, 
involved in polypeptide translocation 
and folding 
− -2.19 
YOR099
W 
KTR1 Alpha-1,2-mannosyltransferase 
involved in O- and N-linked protein 
glycosylation; type II membrane 
protein 
− -2.19 
YHR049W FSH1 Putative serine hydrolase that 
localizes to both the nucleus and 
cytoplasm; sequence is similar to S. 
cerevisiae Fsh2p and Fsh3p and the 
human candidate tumor suppressor 
OVCA2 
− -2.19 
YDL084W SUB2 Component of the TREX complex 
required for nuclear mRNA export; 
member of the DEAD-box RNA 
helicase superfamily and is involved 
in early and late steps of 
spliceosome assembly 
− -2.19 
YFR041C ERJ5 Type I membrane protein with a J 
domain is required to preserve the 
folding capacity of the endoplasmic 
reticulum 
− -2.20 
YAL040C CLN3 G1 cyclin involved in cell cycle 
progression; activates Cdc28p 
kinase to promote the G1 to S phase 
transition; plays a role in regulating 
transcription of the other G1 cyclins, 
CLN1 and CLN2 
− -2.20 
YOL107W YOL107
W 
Putative protein of unknown function; 
green fluorescent protein (GFP)-
fusion protein localizes to the 
cytoplasm and colocalizes in a 
punctate pattern with the early 
golgi/COPI vesicles 
− -2.20 
YCR084C TUP1 General repressor of transcription, 
forms complex with Cyc8p, involved 
in the establishment of repressive 
chromatin structure through 
interactions with histones H3 and H4, 
appears to enhance expression of 
some genes 
− -2.20 
YNL110C NOP15 Constituent of 66S pre-ribosomal 
particles, involved in 60S ribosomal 
subunit biogenesis 
− -2.21 
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YHL034C SBP1 Putative RNA binding protein − -2.21 
YDL148C NOP14 Nucleolar protein, forms a complex 
with Noc4p that mediates maturation 
and nuclear export of 40S ribosomal 
subunits 
− -2.23 
YOR310C NOP58 Protein involved in pre-rRNA 
processing, 18S rRNA synthesis, and 
snoRNA synthesis; component of the 
small subunit processome complex, 
which is required for processing of 
pre-18S rRNA 
− -2.24 
YPL106C SSE1 ATPase that is a component of the 
heat shock protein Hsp90 chaperone 
complex; binds unfolded proteins; 
member of the heat shock protein 70 
(HSP70) family; localized to the 
cytoplasm 
− -2.24 
YBR106W PHO88 Probable membrane protein, 
involved in phosphate transport 
− -2.25 
YNL300W TOS6 Glycosylphosphatidylinositol-
dependent cell wall protein, 
expression is periodic and decreases 
in respone to ergosterol perturbation 
or upon entry into stationary phase 
− -2.25 
YPL111W CAR1 Arginase, responsible for arginine 
degradation, expression responds to 
both induction by arginine and 
nitrogen catabolite repression 
− -2.25 
YMR315
W 
YMR315
W 
Protein with NADP(H) 
oxidoreductase activity 
− -2.26 
YOL012C HTZ1 Histone variant H2AZ − -2.26 
YEL042W GDA1 Guanosine diphosphatase located in 
the Golgi 
− -2.27 
YGL077C HNM1 Choline/ethanolamine transporter − -2.27 
YJL012C VTC4 Vacuolar membrane polyphosphate 
polymerase 
− -2.28 
YML056C IMD4 Inosine monophosphate 
dehydrogenase 
− -2.30 
YNL209W SSB2 Cytoplasmic ATPase that is a 
ribosome-associated molecular 
chaperone,  
− -2.30 
YCL036W GFD2 Protein of unknown function, 
identified as a high-copy suppressor 
of a dbp5 mutation 
− -2.30 
YMR199
W 
CLN1 G1 cyclin involved in regulation of the 
cell cycle 
− -2.30 
YBR286W APE3 Vacuolar aminopeptidase Y, 
processed to mature form by Prb1p 
− -2.30 
YKL081W TEF4 Gamma subunit of translational − -2.30 
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elongation factor eEF1B 
YKR001C VPS1 Dynamin-like GTPase required for 
vacuolar sorting 
− -2.35 
YNL016W PUB1 Poly (A)+ RNA-binding protein − -2.36 
YOR176
W 
HEM15 Ferrochelatase − -2.37 
YER145C FTR1 High affinity iron permease involved 
in the transport of iron across the 
plasma membrane 
− -2.38 
YDL229W SSB1 Cytoplasmic ATPase that is a 
ribosome-associated molecular 
chaperone,  
− -2.38 
YMR003
W 
AIM34 Protein of unknown function − -2.40 
YKL069W YKL069
W 
Methionine-R-sulfoxide reductase − -2.41 
YER023W PRO3 Delta 1-pyrroline-5-carboxylate 
reductase, catalyzes the last step in 
proline biosynthesis 
− -2.42 
YJL012C VTC4 Vacuolar membrane polyphosphate 
polymerase 
− -2.43 
YLR432W IMD3 Inosine monophosphate 
dehydrogenase 
− -2.45 
YDL014W NOP1 Nucleolar protein − -2.47 
YNL169C PSD1 Phosphatidylserine decarboxylase of 
the mitochondrial inner membrane 
− -2.47 
YMR186
W 
HSC82 Cytoplasmic chaperone of the Hsp90 
family 
− -2.50 
YAL007C ERP2 Protein that forms a heterotrimeric 
complex with Erp1p, Emp24p, and 
Erv25p 
− -2.52 
YMR049C ERB1 Constituent of 66S pre-ribosomal 
particles 
− -2.53 
YJL091C GWT1 Protein involved in the inositol 
acylation of glucosaminyl 
phosphatidylinositol (GlcN-PI) to form 
glucosaminyl(acyl)phosphatidylinosit
ol (GlcN(acyl)PI) 
− -2.57 
YAL005C SSA1 ATPase involved in protein folding 
and nuclear localization signal (NLS)-
directed nuclear transport 
− -2.58 
YPL163C SVS1 Cell wall and vacuolar protein − -2.58 
YHL028W WSC4 ER membrane protein involved in the 
translocation of soluble secretory 
proteins and insertion of membrane 
proteins into the ER membrane 
− -2.61 
YHR096C HXT5 Hexose transporter with moderate 
affinity for glucose 
− -2.64 
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YDL095W PMT1 Protein O-mannosyltransferase − -2.66 
YNL289W PCL1 Cyclin, interacts with cyclin-
dependent kinase Pho85p 
− -2.67 
YKL182W FAS1 Beta subunit of fatty acid synthetase − -2.70 
YMR215
W 
GAS3 Putative 1,3-beta-
glucanosyltransferase 
− -2.74 
YNL246W VPS75 NAP family histone chaperone − -2.75 
YGR244C LSC2 Beta subunit of succinyl-CoA ligase − -2.78 
YPR069C SPE3 Spermidine synthase − -2.79 
YGL120C PRP43 RNA helicase in the DEAH-box 
family 
− -2.85 
YPR183W DPM1 Dolichol phosphate mannose (Dol-P-
Man) synthase of the ER membrane 
− -2.94 
YMR290C HAS1 ATP-dependent RNA helicase − -2.95 
YNL135C FPR1 Peptidyl-prolyl cis-trans isomerase 
(PPIase 
− -2.96 
YGL255W ZRT1 High-affinity zinc transporter of the 
plasma membrane 
− -2.96 
YJL034W KAR2 ATPase involved in protein import 
into the ER 
− -3.03 
YAL023C PMT2 Protein O-mannosyltransferase − -3.04 
YDR399W HPT1 Dimeric hypoxanthine-guanine 
phosphoribosyltransferase 
− -3.27 
YNL195C YNL195
C 
Putative protein of unknown function − -3.32 
YJL073W JEM1 DnaJ-like chaperone required for 
nuclear membrane fusion during 
mating 
− -3.37 
YPL127C HHO1 Histone H1, a linker histone required 
for nucleosome packaging at 
restricted sites 
− -3.46 
YKL165C MCD4 Protein involved in 
glycosylphosphatidylinositol (GPI) 
anchor synthesis 
− -3.46 
YDL079C MRK1 Glycogen synthase kinase 3 (GSK-3) 
homolog 
− -3.80 
YNL044W YIP3 Protein localized to COPII vesicles − -3.82 
YHR216W IMD2 Inosine monophosphate 
dehydrogenase,  
− -4.01 
YDR034W
-B 
YDR034
W-B 
Predicted tail-anchored plasma 
membrane protein containing a 
conserved CYSTM module 
− -4.20 
YGR157
W 
CHO2 Phosphatidylethanolamine 
methyltransferase (PEMT 
− -4.32 
YNL141W AAH1 Adenine deaminase (adenine 
aminohydrolase), converts adenine 
to hypoxanthine; involved in purine 
salvage 
− -4.43 
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YBR088C POL30 Proliferating cell nuclear antigen 
(PCNA 
− -4.98 
YDL227C HO Site-specific endonuclease required 
for gene conversion at the MAT locus 
(homothallic switching) through the 
generation of a ds DNA break 
− -5.27 
YJL153C INO1 Inositol-3-phosphate synthase − -21.48 
YMR011
W 
HXT2 High-affinity glucose transporter of 
the major facilitator superfamily,  
− -58.00 
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Table 2.2. Genes showing more than 2 fold change in response to chronic VPA 
treatment. (Gene descriptions are from Saccharomyces Genome Database). 
 
Systemic 
name 
Gene 
name 
Description Fold change 
VPA+/VPA- 
   Inositol+ Inositol- 
YCR034W FEN1 Fatty acid elongase, involved in sphingolipid 
biosynthesis; acts on fatty acids of up to 24 
carbons in length 
2.46 2.86 
YLR372W SUR4 Elongase, involved in fatty acid and sphingolipid 
biosynthesis 
2.77 2.47 
YNR056C BIO5 Putative transmembrane protein involved in the 
biotin biosynthesis pathway 
− -8.92 
YCL025C AGP1 Low-affinity amino acid permease with broad 
substrate range, involved in uptake of 
asparagine, glutamine, and other amino acids 
− -3.77 
YKR039W GAP1 General amino acid permease; localization to 
the plasma membrane is regulated by nitrogen 
source 
− -2.85 
YBR068C BAP2 High-affinity leucine permease, functions as a 
branched-chain amino acid permease involved 
in the uptake of leucine, isoleucine and valine 
− -6.22 
YPL265W DIP5 Dicarboxylic amino acid permease, mediates 
high-affinity and high-capacity transport of L-
glutamate and L-aspartate 
-2.22 -2.36 
YDL210W UGA4 Permease that serves as a gamma-
aminobutyrate (GABA) transport protein 
involved in the utilization of GABA as a nitrogen 
source 
− -2.26 
YEL063C CAN1 Plasma membrane arginine permease − -2.31 
YPL274W SAM3 High-affinity S-adenosylmethionine permease, 
required for utilization of S-adenosylmethionine 
as a sulfur source 
− -13.79 
YDR518W EUG1 Protein disulfide isomerase of the endoplasmic 
reticulum lumen, function overlaps with that of 
Pdi1p 
− 2.39 
YJL073W JEM1 DnaJ-like chaperone required for nuclear 
membrane fusion during mating, localizes to the 
ER membrane 
− 5.81 
YKL073W LHS1 Molecular chaperone of the endoplasmic 
reticulum lumen, involved in polypeptide 
translocation and folding; nucleotide exchange 
factor for the ER lumenal Hsp70 chaperone 
Kar2p; regulated by the unfolded protein 
response pathway 
− 3.50 
YCL043C PDI1 Protein disulfide isomerase, multifunctional 
protein resident in the endoplasmic reticulum 
lumen 
− 2.83 
YPL187W MF(ALPH Mating pheromone alpha-factor, made by alpha 11.29 − 
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A)1 cells 
YOR153W PDR5 Plasma membrane ATP-binding cassette (ABC) 
transporter, multidrug transporter actively 
regulated by Pdr1p 
10.09 12.10 
YLR307W CDA1 Chitin deacetylase, together with Cda2p 
involved in the biosynthesis ascospore wall 
component, chitosan 
8.54 8.31 
YJL116C NCA3 Protein that functions with Nca2p to regulate 
mitochondrial expression of subunits 6 (Atp6p) 
and 8 (Atp8p ) of the Fo-F1 ATP synthase 
7.43 − 
YKL121W DGR2 Protein of unknown function 5.55 2.68 
YKL178C STE3 Receptor for a factor pheromone, couples to 
MAP kinase cascade to mediate pheromone 
response 
5.53 − 
YBR040W FIG1 Integral membrane protein required for efficient 
mating 
5.37 − 
YOL101C IZH4 Membrane protein involved in zinc ion 
homeostasis, member of the four-protein IZH 
family, expression induced by fatty acids and 
altered zinc levels 
5.35 5.88 
YEL057C YEL057C Protein of unknown function involved in 
telomere maintenance 
5.30 − 
YNL289W PCL1 Cyclin, interacts with cyclin-dependent kinase 
Pho85p 
5.25 − 
YJR078W BNA2 Putative tryptophan 2,3-dioxygenase or 
indoleamine 2,3-dioxygenase, required for de 
novo biosynthesis of NAD from tryptophan via 
kynurenine 
5.13 − 
YGR225W AMA1 Activator of meiotic anaphase promoting 
complex (APC/C 
5.03 2.59 
YOR315W SFG1 Nuclear protein, putative transcription factor 
required for growth of superficial pseudohyphae 
(which do not invade the agar substrate) but not 
for invasive pseudohyphal growth 
4.94 − 
YDR317W HIM1 Protein of unknown function involved in DNA 
repair 
4.78 − 
YML027W YOX1 Homeodomain-containing transcriptional 
repressor, binds to Mcm1p and to early cell 
cycle boxes (ECBs) in the promoters of cell 
cycle-regulated genes expressed in M/G1 
phase; expression is cell cycle-regulated 
4.59 − 
YGL055W OLE1 Delta(9) fatty acid desaturase, required for 
monounsaturated fatty acid synthesis and for 
normal distribution of mitochondria 
4.59 − 
YER060W FCY21 Putative purine-cytosine permease, very similar 
to Fcy2p but cannot substitute for its function 
4.56 − 
YPR119W CLB2 B-type cyclin involved in cell cycle progression 
proteasome 
4.54 − 
YOL014W YOL014W Putative protein of unknown function 4.43 11.01 
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YHL028W WSC4 ER membrane protein involved in the 
translocation of soluble secretory proteins and 
insertion of membrane proteins into the ER 
membrane 
4.22 − 
YLR183C TOS4 Forkhead Associated domain containing protein 
and putative transcription factor found 
associated with chromatin 
4.22 5.96 
YBR021W FUR4 Uracil permease, localized to the plasma 
membrane 
4.20 − 
YDL101C DUN1 Cell-cycle checkpoint serine-threonine kinase 
required for DNA damage-induced transcription 
of certain target genes, phosphorylation of 
Rad55p and Sml1p, and transient G2/M arrest 
after DNA damage 
4.19 − 
YCL048W SPS22 Protein of unknown function, redundant with 
Sps2p for the organization of the beta-glucan 
layer of the spore wall 
4.12 2.53 
YMR215W GAS3 Putative 1,3-beta-glucanosyltransferase, has 
similarity to Gas1p 
4.07  
YKL216W URA1 Dihydroorotate dehydrogenase, catalyzes the 
fourth enzymatic step in the de novo 
biosynthesis of pyrimidines, converting 
dihydroorotic acid into orotic acid 
3.93 4.66 
YKR090W PXL1 LIM domain-containing protein that localizes to 
sites of polarized growth, required for selection 
and/or maintenance of polarized growth sites, 
may modulate signaling by the GTPases 
Cdc42p and Rho1p 
3.88  
YPL081W RPS9A Protein component of the small (40S) ribosomal 
subunit 
3.88 3.15 
YJL158C CIS3 Mannose-containing glycoprotein constituent of 
the cell wall 
3.85 3.06 
YMR199W CLN1 G1 cyclin involved in regulation of the cell cycle; 
activates Cdc28p kinase to promote the G1 to S 
phase transition 
3.80 − 
YPL256C CLN2 G1 cyclin involved in regulation of the cell cycle; 
activates Cdc28p kinase to promote the G1 to S 
phase transition 
3.80 − 
YHL024W RIM4 Putative RNA-binding protein required for the 
expression of early and middle sporulation 
genes 
3.75 − 
YMR076C PDS5 Protein required for establishment and 
maintenance of sister chromatid condensation 
and cohesion, colocalizes with cohesin on 
chromosomes, may function as a protein-protein 
interaction scaffold 
3.75 − 
YHR184W SSP1 Protein involved in the control of meiotic nuclear 
division and coordination of meiosis with spore 
formation 
3.66 − 
YLR012C YLR012C Putative protein of unknown function 3.64 − 
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YHR172W SPC97 Component of the microtubule-nucleating Tub4p 
(gamma-tubulin) complex 
3.56 − 
YJL037W IRC18 Putative protein of unknown function; 
expression induced in respiratory-deficient cells 
and in carbon-limited chemostat cultures 
3.55 − 
YLR103C CDC45 DNA replication initiation factor 3.50 − 
YHR154W RTT107 Protein implicated in Mms22-dependent DNA 
repair during S phase, DNA damage induces 
phosphorylation by Mec1p at one or more 
SQ/TQ motifs 
3.49 − 
YHR153C SPO16 Meiosis-specific protein involved in 
synaptonemal complex assembly 
3.49 5.79 
YDR451C YHP1 One of two homeobox transcriptional repressors 
(see also Yox1p), that bind to Mcm1p and to 
early cell cycle box (ECB) elements of cell cycle 
regulated genes, thereby restricting ECB-
mediated transcription to the M/G1 interval 
3.37 − 
YJL194W CDC6 Essential ATP-binding protein required for DNA 
replication, component of the pre-replicative 
complex (pre-RC) which requires ORC to 
associate with chromatin and is in turn required 
for Mcm2-7p DNA association 
3.36 − 
YBR088C POL30 Proliferating cell nuclear antigen (PCNA), 
functions as the sliding clamp for DNA 
polymerase delta 
3.36 5.26 
YJR053W BFA1 Component of the GTPase-activating Bfa1p-
Bub2p complex involved in multiple cell cycle 
checkpoint pathways that control exit from 
mitosis 
3.34 2.67 
YJR092W BUD4 Protein involved in bud-site selection and 
required for axial budding pattern 
3.33 − 
YDR146C SWI5 Transcription factor that activates transcription 
of genes expressed at the M/G1 phase 
boundary and in G1 phase 
3.33 − 
YDR042C YDR042C Putative protein of unknown function; 
expression is increased in ssu72-ts69 mutant 
3.33 − 
YPL231W FAS2 Alpha subunit of fatty acid synthetase, which 
catalyzes the synthesis of long-chain saturated 
fatty acids 
3.31 2.66 
YMR101C SRT1 Cis-prenyltransferase involved in synthesis of 
long-chain dolichols (19-22 isoprene units; as 
opposed to Rer2p which synthesizes shorter-
chain dolichols 
3.30 − 
YNR030W ALG12 Alpha-1,6-mannosyltransferase localized to the 
ER 
3.30 − 
YMR305C SCW10 Cell wall protein with similarity to glucanases; 
may play a role in conjugation during mating 
based on mutant phenotype and its regulation 
by Ste12p 
3.30 − 
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YOL151W GRE2 3-methylbutanal reductase and NADPH-
dependent methylglyoxal reductase (D-
lactaldehyde dehydrogenase) 
3.26 − 
YNL301C RPL18B Protein component of the large (60S) ribosomal 
subunit, identical to Rpl18Ap and has similarity 
to rat L18 ribosomal protein 
3.19 2.86 
YNR073C YNR073C Putative mannitol dehydrogenase 3.17 − 
YMR144W YMR14W Putative protein of unknown function; localized 
to the nucleus 
3.11 − 
YDL003W MCD1 Essential subunit of the cohesin complex 
required for sister chromatid cohesion in mitosis 
and meiosis 
3.10 3.70 
YCL026C-
B 
HBN1 Putative protein of unknown function; similar to 
bacterial nitroreductases 
3.05 2.68 
YMR032W HOF1 Bud neck-localized, SH3 domain-containing 
protein required for cytokinesis 
3.03 − 
YER187W YER18W Putative protein of unknown function 2.98 − 
YJL092W SRS2 DNA helicase and DNA-dependent ATPase 
involved in DNA repair, needed for proper timing 
of commitment to meiotic recombination and 
transition from Meiosis I to II 
2.93 − 
YBR078W ECM33 GPI-anchored protein of unknown function, has 
a possible role in apical bud growth 
2.91 − 
YLR054C OSW2 Protein of unknown function proposed to be 
involved in the assembly of the spore wall 
2.89 2.17 
YMR303C ADH2 Glucose-repressible alcohol dehydrogenase II, 
catalyzes the conversion of ethanol to 
acetaldehyde 
2.89 − 
YDL114W YDL114W Putative protein of unknown function with 
similarity to acyl-carrier-protein reductases 
2.82 − 
YGR286C BIO2 Biotin synthase, catalyzes the conversion of 
dethiobiotin to biotin, which is the last step of 
the biotin biosynthesis pathway 
2.79 − 
YOL132W GAS4 1,3-beta-glucanosyltransferase, involved with 
Gas2p in spore wall assembly 
2.77 − 
YAL061W BDH2 Putative medium-chain alcohol dehydrogenase 
with similarity to BDH1 
2.76 − 
YDR528W HLR1 Protein involved in regulation of cell wall 
composition and integrity and response to 
osmotic stress 
2.75 − 
YIL123W SIM1 Protein of the SUN family (Sim1p, Uth1p, 
Nca3p, Sun4p) that may participate in DNA 
replication, promoter contains SCB regulation 
box at -300 bp indicating that expression may 
be cell cycle-regulated 
2.74 − 
YJL080C SCP160 Essential RNA-binding G protein effector of 
mating response pathway, mainly associated 
with nuclear envelope and ER 
2.72 − 
YBL031W SHE1 Mitotic spindle protein that interacts with 2.71 2.20 
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components of the Dam1 (DASH) complex, its 
effector Sli15p, and microtubule-associated 
protein Bim1p 
YBR092C PHO3 Constitutively expressed acid phosphatase 
similar to Pho5p 
2.71 − 
YJL102W MEF2 Mitochondrial elongation factor involved in 
translational elongation 
2.70 3.61 
YAR007C RFA1 Subunit of heterotrimeric Replication Protein A 
(RPA), which is a highly conserved single-
stranded DNA binding protein involved in DNA 
replication, repair, and recombination 
2.68 2.97 
YLR131C ACE2 Transcription factor that activates expression of 
early G1-specific genes, localizes to daughter 
cell nuclei after cytokinesis and delays G1 
progression in daughters, localization is 
regulated by phosphorylation 
2.66 2.33 
YER095W RAD51 Strand exchange protein, forms a helical 
filament with DNA that searches for homology 
2.66 − 
YOR049C RSB1 Suppressor of sphingoid long chain base (LCB) 
sensitivity of an LCB-lyase mutation 
2.65 − 
YDR503C LPP1 Lipid phosphate phosphatase, catalyzes 
Mg(2+)-independent dephosphorylation of 
phosphatidic acid (PA), lysophosphatidic acid, 
and diacylglycerol pyrophosphate 
2.62 − 
YBR184W YBR18W Putative protein of unknown function 2.62 − 
YPL248C GAL4 DNA-binding transcription factor required for the 
activation of the GAL genes in response to 
galactose 
2.58 − 
YER043C SAH1 S-adenosyl-L-homocysteine hydrolase, 
catabolizes S-adenosyl-L-homocysteine which 
is formed after donation of the activated methyl 
group of S-adenosyl-L-methionine (AdoMet) to 
an acceptor 
2.57 2.62 
YDR497C ITR1 Myo-inositol transporter with strong similarity to 
the minor myo-inositol transporter Itr2p, member 
of the sugar transporter superfamily 
2.57 − 
YER032W FIR1 Protein involved in 3' mRNA processing, 
interacts with Ref2p 
2.56 2.28 
YPL127C HHO1 Histone H1, a linker histone required for 
nucleosome packaging at restricted sites 
2.55 − 
YER085C YER085C Putative protein of unknown function 2.54 − 
YCR088W ABP1 Actin-binding protein of the cortical actin 
cytoskeleton, important for activation of the 
Arp2/3 complex that plays a key role actin in 
cytoskeleton organization 
2.54 − 
YNR019W ARE2 Acyl-CoA:sterol acyltransferase, isozyme of 
Are1p 
2.52 2.74 
YLR045C STU2 Microtubule-associated protein (MAP) of the 
XMAP215/Dis1 family 
2.51 − 
	  	  	  
113	  
	  
YBR069C TAT1 Amino acid transport protein for valine, leucine, 
isoleucine, and tyrosine, low-affinity tryptophan 
and histidine transporter 
2.51 − 
YEL070W DSF1 Deletion suppressor of mpt5 mutation 2.50 − 
YDR501W PLM2 Forkhead Associated domain containing protein 
and putative transcription factor found 
associated with chromatin 
2.50 − 
YNL333W SNZ2 Member of a stationary phase-induced gene 
family 
2.50 2.15 
YIR033W MGA2 ER membrane protein involved in regulation of 
OLE1 transcription, acts with homolog Spt23p 
2.48 2.54 
YMR116C ASC1 G-protein beta subunit and guanine nucleotide 
dissociation inhibitor for Gpa2p 
2.48 2.55 
YER070W RNR1 Major isoform of the large subunit of 
ribonucleotide-diphosphate reductase 
2.47 7.99 
YAR018C KIN3 Nonessential protein kinase with unknown 
cellular role 
2.46 − 
YDR507C GIN4 Protein kinase involved in bud growth and 
assembly of the septin ring, proposed to have 
kinase-dependent and kinase-independent 
activities 
2.46 − 
YBR071W YBR07W Putative protein of unknown function 2.46 − 
YEL040W UTR2 Chitin transglycosylase that functions in the 
transfer of chitin to beta(1-6) and beta(1-3) 
glucans in the cell wall 
2.46 − 
YFL037W TUB2 Beta-tubulin; associates with alpha-tubulin 
(Tub1p and Tub3p) to form tubulin dimer, which 
polymerizes to form microtubules 
2.46 2.34 
YML085C TUB1 Alpha-tubulin 2.45 2.30 
YBL063W KIP1 Kinesin-related motor protein required for mitotic 
spindle assembly, chromosome segregation, 
and 2 micron plasmid partitioning 
2.44 − 
YPL163C SVS1 Cell wall and vacuolar protein, required for wild-
type resistance to vanadate 
2.43 − 
YOR025W HST3 Member of the Sir2 family of NAD(+)-dependent 
protein deacetylases 
2.43 − 
YNL135C FPR1 Peptidyl-prolyl cis-trans isomerase (PPIase), 
binds to the drugs FK506 and rapamycin 
2.43 2.31 
YJR118C ILM1 Protein of unknown function 2.41 2.05 
YML028W TSA1 Thioredoxin peroxidase, acts as both a 
ribosome-associated and free cytoplasmic 
antioxidant 
2.41 3.43 
YJL045W YJL045W Minor succinate dehydrogenase isozyme; 
homologous to Sdh1p, the major isozyme 
reponsible for the oxidation of succinate and 
transfer of electrons to ubiquinone 
2.40 − 
YKL107W YKL107W Putative protein of unknown function 2.38 2.30 
YLR413W YLR413W Putative protein of unknown function 2.38 4.85 
	  	  	  
114	  
	  
YDR113C PDS1 Securin, inhibits anaphase by binding separin 
Esp1p 
2.36 − 
YNL067W RPL9B Protein component of the large (60S) ribosomal 
subunit, nearly identical to Rpl9Ap and has 
similarity to E. coli L6 and rat L9 ribosomal 
proteins 
2.35 − 
YPL255W BBP1 Protein required for the spindle pole body (SPB) 
duplication, localized at the central plaque 
periphery 
2.35 2.17 
YGL242C YGL242C Putative protein of unknown function; deletion 
mutant is viable 
2.35 4.01 
YJR047C ANB1 Translation elongation factor eIF-5A, previously 
thought to function in translation initiation 
2.33 − 
YAL024C LTE1 Protein similar to GDP/GTP exchange factors 
but without detectable GEF activity 
2.32 − 
YBR160W CDC28 Catalytic subunit of the main cell cycle cyclin-
dependent kinase (CDK 
2.31 2.15 
YMR179W SPT21 Protein with a role in transcriptional silencing; 
required for normal transcription at several loci 
including HTA2-HTB2 and HHF2-HHT2, but not 
required at the other histone loci 
2.30 − 
YKL165C MCD4 Protein involved in glycosylphosphatidylinositol 
(GPI) anchor synthesis 
2.30 6.19 
YLL002W RTT109 Histone acetyltransferase critical for cell survival 
in the presence of DNA damage during S 
phase; acetylates H3-K56 and H3-K9 
2.30 − 
YJL091C GWT1 Protein involved in the inositol acylation of 
glucosaminyl phosphatidylinositol (GlcN-PI) to 
form glucosaminyl(acyl)phosphatidylinositol 
(GlcN(acyl)PI), an intermediate in the 
biosynthesis of glycosylphosphatidylinositol 
(GPI) anchors 
2.30 3.32 
YML058W SML1 Ribonucleotide reductase inhibitor involved in 
regulating dNTP production 
2.29 2.11 
YKR042W UTH1 Mitochondrial outer membrane and cell wall 
localized SUN family member involved in cell 
wall biogenesis and required for mitochondrial 
autophagy 
2.29 − 
YBL035C POL12 B subunit of DNA polymerase alpha-primase 
complex, required for initiation of DNA 
replication during mitotic and premeiotic DNA 
synthesis 
2.29 − 
YMR001C CDC5 Polo-like kinase with multiple functions in 
mitosis and cytokinesis through substrate 
phosphorylation, also functions in adaptation to 
DNA damage during meiosis 
2.27 − 
YLR273C PIG1 Putative targeting subunit for the type-1 protein 
phosphatase Glc7p that tethers it to the Gsy2p 
glycogen synthase 
2.27 − 
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YHR061C GIC1 Protein of unknown function involved in initiation 
of budding and cellular polarization, interacts 
with Cdc42p via the Cdc42/Rac-interactive 
binding (CRIB) domain 
2.26 − 
YGR260W TNA1 High affinity nicotinic acid plasma membrane 
permease, responsible for uptake of low levels 
of nicotinic acid 
2.26 − 
YGR014W MSB2 Mucin family member involved in the Cdc42p- 
and MAP kinase-dependent filamentous growth 
signaling pathway 
2.24 − 
YJL219W HXT9 Putative hexose transporter that is nearly 
identical to Hxt11p, has similarity to major 
facilitator superfamily (MFS) transporters, 
expression of HXT9 is regulated by transcription 
factors Pdr1p and Pdr3p 
2.24 − 
YOR071C NRT1 High-affinity nicotinamide riboside transporter; 
also transports thiamine with low affinity; shares 
sequence similarity with Thi7p and Thi72p 
2.21 − 
YAR008W SEN34 Subunit of the tRNA splicing endonuclease, 
which is composed of Sen2p, Sen15p, Sen34p, 
and Sen54p 
2.21 2.59 
YGR254W ENO1 Enolase I, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis 
2.20 2.67 
YDR368W YPR1 NADPH-dependent aldo-keto reductase, 
reduces multiple substrates including 2-
methylbutyraldehyde and D,L-glyceraldehyde, 
expression is induced by osmotic and oxidative 
stress; functionally redundant with other aldo-
keto reductases 
2.20 2.25 
YGL038C OCH1 Mannosyltransferase of the cis-Golgi apparatus, 
initiates the polymannose outer chain elongation 
of N-linked oligosaccharides of glycoproteins 
2.19 − 
YOL120C RPL18A Protein component of the large (60S) ribosomal 
subunit, identical to Rpl18Bp and has similarity 
to rat L18 ribosomal protein 
2.19 − 
YNL012W SPO1 Meiosis-specific prospore protein; required for 
meiotic spindle pole body duplication and 
separation 
2.19 − 
YLR231C BNA5 Kynureninase, required for the de novo 
biosynthesis of NAD from tryptophan via 
kynurenine; expression regulated by Hst1p 
2.19 2.41 
YGR049W SCM4 Potential regulatory effector of CDC4 function, 
suppresses a temperature-sensitive allele of 
CDC4, tripartite protein structure in which a 
charged region separates two uncharged 
domains, not essential for mitosis or meiosis 
2.19 − 
YPR175W DPB2 Second largest subunit of DNA polymerase II 
(DNA polymerase epsilon), required for normal 
2.18 − 
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yeast chromosomal replication 
YHR043C DOG2 2-deoxyglucose-6-phosphate phosphatase, 
member of a family of low molecular weight 
phosphatases, similar to Dog1p, induced by 
oxidative and osmotic stress, confers 2-
deoxyglucose resistance when overexpressed 
2.18 3.70 
YGR037C ACB1 Acyl-CoA-binding protein, transports newly 
synthesized acyl-CoA esters from fatty acid 
synthetase (Fas1p-Fas2p) to acyl-CoA-
consuming processes 
2.16 2.74 
YER154W OXA1 Mitochondrial inner membrane insertase, 
mediates the insertion of both mitochondrial- 
and nuclear-encoded proteins from the matrix 
into the inner membrane, interacts with 
mitochondrial ribosomes 
2.16 − 
YJL115W ASF1 Nucleosome assembly factor, involved in 
chromatin assembly and disassembly, anti-
silencing protein that causes derepression of 
silent loci when overexpressed 
2.15 − 
YDL164C CDC9 DNA ligase found in the nucleus and 
mitochondria, an essential enzyme that joins 
Okazaki fragments during DNA replication 
2.15 − 
YPL158C AIM44 Protein of unknown function; GFP-fusion protein 
localizes to the bud neck 
2.14 − 
YGL226C-
A 
OST5 Zeta subunit of the oligosaccharyltransferase 
complex of the ER lumen, which catalyzes 
asparagine-linked glycosylation of newly 
synthesized proteins 
2.14 2.22 
YBR243C ALG7 UDP-N-acetyl-glucosamine-1-P transferase, 
transfers Glc-Nac-P from UDP-GlcNac to Dol-P 
in the ER in the first step of the dolichol pathway 
of protein asparagine-linked glycosylation 
2.14 − 
YMR198W CIK1 Kinesin-associated protein required for both 
karyogamy and mitotic spindle organization, 
interacts stably and specifically with Kar3p and 
may function to target this kinesin to a specific 
cellular role 
2.14 − 
YDR309C GIC2 Redundant rho-like GTPase Cdc42p effector; 
homolog of Gic1p; involved in initiation of 
budding and cellular polarization 
2.14 − 
YLR187W SKG3 Protein of unknown function; green fluorescent 
protein (GFP)-fusion protein localizes to the cell 
periphery, cytoplasm, bud, and bud neck 
2.14 − 
YKR010C TOF2 Protein required for rDNA silencing and mitotic 
rDNA condensation 
2.13 − 
YDR009W GAL3 Transcriptional regulator involved in activation of 
the GAL genes in response to galactose 
2.12 − 
YPL227C ALG5 UDP-glucose:dolichyl-phosphate 
glucosyltransferase, involved in asparagine-
linked glycosylation in the endoplasmic 
2.11 − 
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reticulum 
YGR156W PTI1 Essential protein that is a component of CPF 
(cleavage and polyadenylation factor 
2.11 − 
YML078W CPR3 Mitochondrial peptidyl-prolyl cis-trans isomerase 
(cyclophilin), catalyzes the cis-trans 
isomerization of peptide bonds N-terminal to 
proline residues 
2.11 − 
YNL246W VPS75 NAP family histone chaperone; binds to 
histones and Rtt109p, stimulating histone 
acetyltransferase activity 
2.10 − 
YLR084C RAX2 N-glycosylated protein involved in the 
maintenance of bud site selection during bipolar 
budding; localization requires Rax1p 
2.10 − 
YLR209C PNP1 Purine nucleoside phosphorylase, specifically 
metabolizes inosine and guanosine 
nucleosides; involved in the nicotinamide 
riboside salvage pathway 
2.09 − 
YOL143C RIB4 Lumazine synthase (6,7-dimethyl-8-
ribityllumazine synthase, also known as DMRL 
synthase 
2.07 3.24 
YJL181W YJL181W Putative protein of unknown function; 
expression is cell-cycle regulated as shown by 
microarray analysis 
2.07 − 
YLR134W PDC5 Minor isoform of pyruvate decarboxylase, key 
enzyme in alcoholic fermentation, 
decarboxylates pyruvate to acetaldehyde, 
regulation is glucose- and ethanol-dependent, 
repressed by thiamine, involved in amino acid 
catabolism 
2.07 3.16 
YGR292W MAL12 Maltase (alpha-D-glucosidase), inducible protein 
involved in maltose catabolism 
2.07 − 
YAL062W GDH3 NADP(+)-dependent glutamate dehydrogenase, 
synthesizes glutamate from ammonia and 
alpha-ketoglutarate 
2.06 2.11 
YFL045C SEC53 Phosphomannomutase, involved in synthesis of 
GDP-mannose and dolichol-phosphate-
mannose 
2.06 − 
YDR261C EXG2 Exo-1,3-beta-glucanase, involved in cell wall 
beta-glucan assembly 
2.04 − 
YKL113C RAD27 5' to 3' exonuclease, 5' flap endonuclease, 
required for Okazaki fragment processing and 
maturation as well as for long-patch base-
excision repair 
2.04 − 
YLR293C GSP1 Ran GTPase, GTP binding protein (mammalian 
Ranp homolog) involved in the maintenance of 
nuclear organization, RNA processing and 
transport 
2.04 2.36 
YNL072W RNH201 Ribonuclease H2 catalytic subunit, removes 
RNA primers during Okazaki fragment synthesis 
and errant ribonucleotides misincorporated 
2.03 2.49 
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during DNA replication 
YHR149C SKG6 Integral membrane protein that localizes 
primarily to growing sites such as the bud tip or 
the cell periphery; potential Cdc28p substrate 
2.03 − 
YPL208W RKM1 SET-domain lysine-N-methyltransferase, 
catalyzes the formation of dimethyllysine 
residues on the large ribsomal subunit protein 
L23a (RPL23A and RPL23B) 
2.03 − 
YGL251C HFM1 Meiosis specific DNA helicase involved in the 
conversion of double-stranded breaks to later 
recombination intermediates and in crossover 
control 
2.03 − 
YDL145C COP1 Alpha subunit of COPI vesicle coatomer 
complex, which surrounds transport vesicles in 
the early secretory pathway 
2.02 2.15 
YGR221C TOS2 Protein involved in localization of Cdc24p to the 
site of bud growth 
2.02 2.09 
YML009C MRPL39 Mitochondrial ribosomal protein of the large 
subunit 
2.01 − 
YJR048W CYC1 Cytochrome c, isoform 1 2.00 3.06 
YLR272C YCS4 Subunit of the condensin complex 2.00 − 
YDR361C BCP1 Essential protein involved in nuclear export of 
Mss4p, which is a lipid kinase that generates 
phosphatidylinositol 4,5-biphosphate and plays 
a role in actin cytoskeleton organization and 
vesicular transport 
-2.01 − 
YML099C ARG81 Zinc-finger transcription factor of the Zn(2)-
Cys(6) binuclear cluster domain type, involved 
in the regulation of arginine-responsive genes; 
acts with Arg80p and Arg82p 
-2.01 − 
YGR030C POP6 Subunit of both RNase MRP, which cleaves pre-
rRNA, and nuclear RNase P, which cleaves 
tRNA precursors to generate mature 5' ends 
-2.01 − 
YLL056C YLL056C Putative protein of unknown function, 
transcription is activated by paralogous 
transcription factors Yrm1p and Yrr1p and 
genes involved in pleiotropic drug resistance 
(PDR 
-2.02 − 
YPR086W SUA7 Transcription factor TFIIB, a general 
transcription factor required for transcription 
initiation and start site selection by RNA 
polymerase II 
-2.02 -2.18 
YDL169C UGX2 Protein of unknown function, transcript 
accumulates in response to any combination of 
stress conditions 
-2.02 − 
YBR293W VBA2 Permease of basic amino acids in the vacuolar 
membrane 
-2.03 -2.58 
YDR465C RMT2 Arginine N5 methyltransferase; methylates 
ribosomal protein Rpl12 (L12) on Arg67 
-2.04 − 
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YNL314W DAL82 Positive regulator of allophanate inducible 
genes 
-2.04 − 
YDL025C YDL025C Putative protein kinase, potentially 
phosphorylated by Cdc28p 
-2.04 − 
YPR157W YPR157
W 
Putative protein of unknown function -2.05 − 
YPL199C YPL199C Putative protein of unknown function, predicted 
to be palmitoylated 
-2.06 -2.56 
YDR244W PEX5 Peroxisomal membrane signal receptor for the 
C-terminal tripeptide signal sequence (PTS1) of 
peroxisomal matrix proteins, required for 
peroxisomal matrix protein import 
-2.07 − 
YNL004W HRB1  Poly(A+) RNA-binding protein, involved in the 
export of mRNAs from the nucleus to the 
cytoplasm; similar to Gbp2p and Npl3p 
-2.07 -2.15 
YBR297W MAL33 MAL-activator protein, part of complex locus 
MAL3; nonfunctional in genomic reference 
strain S288C 
-2.07 − 
YHR066W SSF1 Constituent of 66S pre-ribosomal particles, 
required for ribosomal large subunit maturation 
-2.07 -4.63 
YMR265C YMR265C Putative protein of unknown function -2.08 -2.35 
YDL121C YDL121C Putative protein of unknown function -2.08 -2.47 
YPR112C MRD1 Essential conserved protein that is part of the 
90S preribosome 
-2.08 − 
YNL119W NCS2 Protein required for thiolation of the uridine at 
the wobble position of Lys(UUU) and Glu(UUC) 
tRNAs 
-2.11 − 
YOR213C SAS5 Subunit of the SAS complex (Sas2p, Sas4p, 
Sas5p), which  acetylates free histones and 
nucleosomes and regulates transcriptional 
silencing; stimulates Sas2p HAT activity 
-2.11 − 
YER015W FAA2 Medium chain fatty acyl-CoA synthetase, 
activates imported fatty acids; accepts a wide 
range of fatty acid chain lengths with a 
preference for medium chains, C9:0-C13:0; 
localized to the peroxisome 
-2.11 -2.09 
YOR179C SYC1 Subunit of the APT subcomplex of cleavage and 
polyadenylation factor, may have a role in 3' 
end formation of both polyadenylated and non-
polyadenylated RNAs 
-2.11 − 
YLR161W YLR161W Putative protein of unknown function -2.11 − 
YPR048W TAH18 Conserved NAPDH-dependent diflavin 
reductase, component of an early step in the 
cytosolic Fe-S protein assembly (CIA) 
machinery 
-2.11 − 
YDR312W SSF2 Protein required for ribosomal large subunit 
maturation, functionally redundant with Ssf1p 
-2.11 − 
YHR166C CDC23 Subunit of the Anaphase-Promoting 
Complex/Cyclosome (APC/C), which is a 
-2.13 -2.12 
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ubiquitin-protein ligase required for degradation 
of anaphase inhibitors, including mitotic cyclins, 
during the metaphase/anaphase transition 
YOL136C PFK27 6-phosphofructo-2-kinase, catalyzes synthesis 
of fructose-2,6-bisphosphate 
-2.14 − 
YOR101W RAS1 GTPase involved in G-protein signaling in the 
adenylate cyclase activating pathway, plays a 
role in cell proliferation 
-2.14 − 
YDL223C HBT1 Substrate of the Hub1p ubiquitin-like protein that 
localizes to the shmoo tip (mating projection) 
-2.14 − 
YNL113W RPC19 RNA polymerase subunit AC19, common to 
RNA polymerases I and III 
-2.14 − 
YKL099C UTP11 Subunit of U3-containing Small Subunit (SSU) 
processome complex involved in production of 
18S rRNA and assembly of small ribosomal 
subunit 
-2.15 − 
YGL153W PEX14 Peroxisomal membrane peroxin that is a central 
component of the peroxisomal protein import 
machinery 
-2.15 − 
YJL212C OPT1 Proton-coupled oligopeptide transporter of the 
plasma membrane 
-2.16 -3.25 
YLR407W YLR407W Putative protein of unknown function -2.18 − 
YLR159W YLR159W Putative protein of unknown function -2.18 − 
YKR058W GLG1 Self-glucosylating initiator of glycogen 
synthesis, also glucosylates n-dodecyl-beta-D-
maltoside 
-2.18 − 
YJL112W MDV1 Peripheral protein of the cytosolic face of the 
mitochondrial outer membrane, required for 
mitochondrial fission 
-2.19 − 
YCR100C YCR100C Putative protein of unknown function -2.19 -2.34 
YLL051C FRE6 Putative ferric reductase with similarity to Fre2p; 
expression induced by low iron levels 
-2.19 − 
YGR202C PCT1 Cholinephosphate cytidylyltransferase, also 
known as CTP:phosphocholine 
cytidylyltransferase, rate-determining enzyme of 
the CDP-choline pathway for 
phosphatidylcholine synthesis 
-2.20 − 
YDR030C RAD28 Protein involved in DNA repair, related to the 
human CSA protein that is involved in 
transcription-coupled repair nucleotide excision 
repair 
-2.20 − 
YGR081C SLX9 Protein required for pre-rRNA processing; 
associated with the 90S pre-ribosome and 43S 
small ribosomal subunit precursor 
-2.20 -2.57 
YIL113W SDP1 Stress-inducible dual-specificity MAP kinase 
phosphatase, negatively regulates Slt2p MAP 
kinase by direct dephosphorylation, diffuse 
localization under normal conditions shifts to 
punctate localization after heat shock 
-2.20 − 
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YPL202C AFT2 Iron-regulated transcriptional activator -2.21 − 
YER037W PHM8 Protein of unknown function, expression is 
induced by low phosphate levels and by 
inactivation of Pho85p 
-2.22 − 
YBL033C RIB1 GTP cyclohydrolase II -2.22 -2.34 
YGR129W SYF2 Member of the NineTeen Complex (NTC) that 
contains Prp19p and stabilizes U6 snRNA in 
catalytic forms of the spliceosome containing 
U2, U5, and U6 snRNAs 
-2.22 − 
YOR056C NOB1 Essential nuclear protein involved in 
proteasome maturation and synthesis of 40S 
ribosomal subunits 
-2.23 − 
YOR262W YOR26W Protein of unknown function required for 
establishment of sister chromatid cohesion; 
contains an ATP/GTP binding site motif 
-2.23 − 
YPL212C PUS1 tRNA:pseudouridine synthase, introduces 
pseudouridines at positions 26-28, 34-36, 65, 
and 67 of tRNA 
-2.24 − 
YMR185W YMR18W Putative protein of unknown function -2.25 − 
YER184C YER184C Putative zinc cluster protein -2.25 -3.03 
YIR031C DAL7 Malate synthase, role in allantoin degradation 
unknown 
-2.26 − 
YJL072C PSF2 Subunit of the GINS complex (Sld5p, Psf1p, 
Psf2p, Psf3p), which is localized to DNA 
replication origins and implicated in assembly of 
the DNA replication machinery 
-2.26 -3.81 
YKL106W AAT1 Mitochondrial aspartate aminotransferase, 
catalyzes the conversion of oxaloacetate to 
aspartate in aspartate and asparagine 
biosynthesis 
-2.26 − 
YBR141C YBR141C Putative S-adenosylmethionine-dependent 
methyltransferase 
-2.26 − 
YNL221C POP1 Subunit of both RNase MRP, which cleaves pre-
rRNA, and nuclear RNase P, which cleaves 
tRNA precursors to generate mature 5' ends 
-2.29 -2.07 
YOR004W UTP23 Essential nucleolar protein that is a component 
of the SSU (small subunit) processome involved 
in 40S ribosomal subunit biogenesis 
-2.30 -2.09 
YHR150W PEX28 Peroxisomal integral membrane peroxin, 
involved in the regulation of peroxisomal size, 
number and distribution 
-2.30 − 
YKR024C DBP7 Putative ATP-dependent RNA helicase of the 
DEAD-box family involved in ribosomal 
biogenesis 
-2.31 − 
YLR284C ECI1 Peroxisomal delta3,delta2-enoyl-CoA 
isomerase, hexameric protein that converts 3-
hexenoyl-CoA to trans-2-hexenoyl-CoA, 
essential for the beta-oxidation of unsaturated 
fatty acids, oleate-induced 
-2.32 − 
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YDR421W ARO80 Zinc finger transcriptional activator of the 
Zn2Cys6 family 
-2.32 − 
YER137C YER137C Putative protein of unknown function -2.35 − 
YOR338W YOR33W Putative protein of unknown function -2.35 − 
YCR107W AAD3 Putative aryl-alcohol dehydrogenase with 
similarity to P. chrysosporium aryl-alcohol 
dehydrogenase 
-2.35 − 
YMR201C RAD14 Protein that recognizes and binds damaged 
DNA during nucleotide excision repair 
-2.37 − 
YBL054W TOD6 PAC motif binding protein involved in rRNA and 
ribosome biogenesis 
-2.37 − 
YBR257W POP4 Subunit of both RNase MRP, which cleaves pre-
rRNA, and nuclear RNase P, which cleaves 
tRNA precursors to generate mature 5' ends 
-2.38 -2.59 
YBR105C VID24 Peripheral membrane protein located at Vid 
(vacuole import and degradation) vesicles 
-2.39 -3.67 
YKL072W STB6 Protein that binds Sin3p in a two-hybrid assay -2.39 -2.55 
YGR121C MEP1 Ammonium permease; belongs to a ubiquitous 
family of cytoplasmic membrane proteins that 
transport only ammonium (NH4 
-2.39 -2.92 
YNL014W HEF3 Translational elongation factor EF-3; paralog of 
YEF3 and member of the ABC superfamily 
-2.40 − 
YPL230W USV1 Putative transcription factor containing a C2H2 
zinc finger 
-2.40 − 
YLR312C YLR312C Putative protein of unknown function -2.40 -2.10 
YLR023C IZH3 Membrane protein involved in zinc ion 
homeostasis, member of the four-protein IZH 
family, expression induced by zinc deficiency 
-2.42 − 
YMR009W ADI1 Acireductone dioxygenease involved in the 
methionine salvage pathway 
-2.42 − 
YMR145C NDE1 Mitochondrial external NADH dehydrogenase, a 
type II NAD(P)H:quinone oxidoreductase that 
catalyzes the oxidation of cytosolic NADH 
-2.43 − 
YHR046C INM1 Inositol monophosphatase, involved in 
biosynthesis of inositol and in phosphoinositide 
second messenger signaling 
-2.44 -2.11 
YEL029C BUD16 Putative pyridoxal kinase, a key enzyme 
involved in pyridoxal 5'-phosphate synthesis, 
the active form of vitamin B6 
-2.44 − 
YFL030W AGX1 Alanine:glyoxylate aminotransferase (AGT), 
catalyzes the synthesis of glycine from 
glyoxylate, which is one of three pathways for 
glycine biosynthesis in yeast 
-2.49 -2.27 
YKL023W YKL023W Putative protein of unknown function, predicted 
by computational methods to be involved in 
mRNA degradation 
-2.50 -3.03 
YOR192C THI72 Transporter of thiamine or related compound; 
shares sequence similarity with Thi7p 
-2.52 -3.27 
	  	  	  
123	  
	  
YLR387C REH1 Cytoplasmic 60S subunit biogenesis factor, 
associates with pre-60S particles 
-2.52 − 
YLL061W MMP1 High-affinity S-methylmethionine permease, 
required for utilization of S-methylmethionine as 
a sulfur source; has similarity to S-
adenosylmethionine permease Sam3p 
-2.53 − 
YBL069W AST1 Peripheral membrane protein that interacts with 
the plasma membrane ATPase Pma1p and has 
a role in its targeting to the plasma membrane, 
possibly by influencing its incorporation into lipid 
rafts 
-2.54 − 
YPL017C IRC15 Microtubule associated protein -2.56 -2.27 
YNL234W YNL234W Protein of unknown function with similarity to 
globins; has a functional heme-binding domain 
-2.57 − 
YOL165C AAD15 Putative aryl-alcohol dehydrogenase with 
similarity to P. chrysosporium aryl-alcohol 
dehydrogenase; mutational analysis has not yet 
revealed a physiological role 
-2.60 -2.72 
YGR159C NSR1 Nucleolar protein that binds nuclear localization 
sequences, required for pre-rRNA processing 
and ribosome biogenesis 
-2.61 − 
YDR120C TRM1 tRNA methyltransferase; two forms of the 
protein are made by alternative translation starts 
-2.65 − 
YKL143W LTV1 Component of the GSE complex, which is 
required for proper sorting of amino acid 
permease Gap1p 
-2.68 − 
YLR460C YLR460C Member of the quinone oxidoreductase family, 
up-regulated in response to the fungicide 
mancozeb 
-2.71 − 
YPR111W DBF20 Ser/Thr kinase involved in late nuclear division, 
one of the mitotic exit network (MEN) proteins 
-2.73 -3.36 
YHR088W RPF1 Nucleolar protein involved in the assembly and 
export of the large ribosomal subunit 
-2.76 -2.13 
YLL053C YLL053C Putative protein; in the Sigma 1278B strain 
background YLL053C is contiguous with AQY2 
which encodes an aquaporin 
-2.79 -2.85 
YDR342C HXT7 High-affinity glucose transporter of the major 
facilitator superfamily, nearly identical to Hxt6p, 
expressed at high basal levels relative to other 
HXTs, expression repressed by high glucose 
levels 
-2.80 − 
YFL061W DDI2 Protein of unknown function; expression is 
induced over 100-fold by DNA damage 
-2.87 -5.18 
YLR297W YLR297W Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the vacuole 
-2.88 − 
YLL052C AQY2 Water channel that mediates the transport of 
water across cell membranes, only expressed in 
proliferating cells, controlled by osmotic signals, 
-2.89 -3.13 
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may be involved in freeze tolerance 
YOR363C PIP2 Autoregulatory oleate-specific transcriptional 
activator of peroxisome proliferation, contains 
Zn(2)-Cys(6) cluster domain, forms heterodimer 
with Oaf1p, binds oleate response elements 
(OREs), activates beta-oxidation genes 
-2.90 − 
YMR189W GCV2 P subunit of the mitochondrial glycine 
decarboxylase complex, required for the 
catabolism of glycine to 5,10-methylene-THF 
-2.90 -5.24 
YKR099W BAS1 Myb-related transcription factor involved in 
regulating basal and induced expression of 
genes of the purine and histidine biosynthesis 
pathways 
-2.91 -4.06 
YIL019W FAF1 Protein required for pre-rRNA processing and 
40S ribosomal subunit assembly 
-2.94 − 
YHR033W YHR03W Putative protein of unknown function -2.95 − 
YGR239C PEX21 Peroxin required for targeting of peroxisomal 
matrix proteins containing PTS2 
-3.02 -4.21 
YDR343C HXT6 High-affinity glucose transporter of the major 
facilitator superfamily, nearly identical to Hxt7p, 
expressed at high basal levels relative to other 
HXTs, repression of expression by high glucose 
requires SNF3 
-3.02 − 
YLR152C YLR152C Putative protein of unknown function -3.03 -4.74 
YIL003W CFD1 Highly conserved, iron-sulfur cluster binding 
protein localized in the cytoplasm 
-3.03 -3.22 
YDR533C HSP31 Possible chaperone and cysteine protease with 
similarity to E. coli Hsp31 
-3.03 -2.24 
YER176W ECM32 DNA dependent ATPase/DNA helicase 
belonging to the Dna2p- and Nam7p-like family 
of helicases that is involved in modulating 
translation termination 
-3.05 − 
YDL170W UGA3 Transcriptional activator necessary for gamma-
aminobutyrate (GABA)-dependent induction of 
GABA genes (such as UGA1, UGA2, UGA4 
-3.18 -5.69 
YOL158C ENB1 Endosomal ferric enterobactin transporter, 
expressed under conditions of iron deprivation 
-3.21 -3.60 
YDR019C GCV1 T subunit of the mitochondrial glycine 
decarboxylase complex, required for the 
catabolism of glycine to 5,10-methylene-THF 
-3.24 -4.41 
YNL162W YNL162W Putative protein of unknown function -3.25 − 
YNL279W PRM1 Pheromone-regulated multispanning membrane 
protein involved in membrane fusion during 
mating 
-3.29 − 
YKL155C RSM22 Mitochondrial ribosomal protein of the small 
subunit 
-3.63 − 
YER145C FTR1 High affinity iron permease involved in the 
transport of iron across the plasma membrane 
-3.64 -5.70 
YNL142W MEP2 Ammonium permease involved in regulation of -3.66 − 
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pseudohyphal growth 
YMR107W SPG4 Protein required for survival at high temperature 
during stationary phase 
-4.07 − 
YOR306C MCH5 Plasma membrane riboflavin transporter -4.11 − 
YML123C PHO84 High-affinity inorganic phosphate (Pi) 
transporter and low-affinity manganese 
transporter 
-4.19 − 
YNL112W DBP2 Essential ATP-dependent RNA helicase of the 
DEAD-box protein family, involved in nonsense-
mediated mRNA decay and rRNA processing 
-4.19 − 
YNR069C BSC5 Protein of unknown function, ORF exhibits 
genomic organization compatible with a 
translational readthrough-dependent mode of 
expression 
-4.47 − 
YJL213W YJL213W Protein of unknown function that may interact 
with ribosomes; periodically expressed during 
the yeast metabolic cycle 
-4.50 -13.17 
YPL092W SSU1 Plasma membrane sulfite pump involved in 
sulfite metabolism and required for efficient 
sulfite efflux 
-4.79 -6.75 
YGR230W BNS1 Protein with some similarity to Spo12p -4.87 -3.61 
YIR032C DAL3 Ureidoglycolate hydrolase, converts 
ureidoglycolate to glyoxylate and urea in the 
third step of allantoin degradation 
-5.20 -4.19 
YPR192W AQY1 Spore-specific water channel that mediates the 
transport of water across cell membranes, 
developmentally controlled 
-5.28 − 
YHR048W YHK8 Presumed antiporter of the DHA1 family of 
multidrug resistance transporters 
-5.55 -6.38 
YLL055W YCT1 High-affinity cysteine-specific transporter with 
similarity to the Dal5p family of transporters; 
green fluorescent protein (GFP)-fusion protein 
localizes to the endoplasmic reticulum 
-5.99 − 
YIL165C YIL165C Putative protein of unknown function -6.03 -7.59 
YIL164C NIT1 Nitrilase, member of the nitrilase branch of the 
nitrilase superfamily 
-6.31 -7.94 
YOR186W YOR18W Putative protein of unknown function; proper 
regulation of expression during heat stress is 
sphingolipid-dependent 
-6.37 -6.03 
YMR058W FET3 Ferro-O2-oxidoreductase required for high-
affinity iron uptake and involved in mediating 
resistance to copper ion toxicity, belongs to 
class of integral membrane multicopper 
oxidases 
-6.64 -11.97 
YFR055W IRC7 Putative cystathionine beta-lyase; involved in 
copper ion homeostasis and sulfur metabolism 
-6.82 -11.69 
YDR242W AMD2 Putative amidase -7.12 -8.88 
YBL043W ECM13 Non-essential protein of unknown function; 
induced by treatment with 8-methoxypsoralen 
-7.22 -9.22 
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and UVA irradiation 
YHL016C DUR3 Plasma membrane transporter for both urea and 
polyamines, expression is highly sensitive to 
nitrogen catabolite repression and induced by 
allophanate, the last intermediate of the 
allantoin degradative pathway 
-7.66 -8.79 
YPL095C EEB1 Acyl-coenzymeA:ethanol O-acyltransferase 
responsible for the major part of medium-chain 
fatty acid ethyl ester biosynthesis during 
fermentation 
-8.32 -3.60 
YCL064C CHA1 Catabolic L-serine (L-threonine) deaminase, 
catalyzes the degradation of both L-serine and 
L-threonine 
-9.36 -12.61 
YHR096C HXT5 Hexose transporter with moderate affinity for 
glucose, induced in the presence of non-
fermentable carbon sources, induced by a 
decrease in growth rate 
-9.51 -8.23 
YHR137W ARO9 Aromatic aminotransferase II, catalyzes the first 
step of tryptophan, phenylalanine, and tyrosine 
catabolism 
-16.37 -10.86 
YKR034W DAL80 Negative regulator of genes in multiple nitrogen 
degradation pathways; expression is regulated 
by nitrogen levels and by Gln3p 
-22.06 − 
YJL153C INO1 Inositol-3-phosphate synthase, involved in 
synthesis of inositol phosphates and inositol-
containing phospholipids 
− 32.84 
YER003C PMI40 Mannose-6-phosphate isomerase, catalyzes the 
interconversion of fructose-6-P and mannose-6-
P 
− 8.04 
YGR109C CLB6 B-type cyclin involved in DNA replication during 
S phase; activates Cdc28p to promote initiation 
of DNA synthesis 
− 6.29 
YKL165C MCD4 Protein involved in glycosylphosphatidylinositol 
(GPI) anchor synthesis 
− 6.19 
YGR256W GND2 6-phosphogluconate dehydrogenase 
(decarboxylating), catalyzes an NADPH 
regenerating reaction in the pentose phosphate 
pathway 
− 6.06 
YOR387C YOR387C Putative protein of unknown function − 5.85 
YBR088C POL30 Proliferating cell nuclear antigen (PCNA), 
functions as the sliding clamp for DNA 
polymerase delta 
− 5.26 
YML058W-
A 
HUG1 Protein involved in the Mec1p-mediated 
checkpoint pathway that responds to DNA 
damage or replication arrest, transcription is 
induced by DNA damage 
− 5.03 
YGR213C RTA1 Protein involved in 7-aminocholesterol 
resistance 
− 4.73 
YNR016C ACC1 Acetyl-CoA carboxylase, biotin containing − 4.40 
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enzyme that catalyzes the carboxylation of 
acetyl-CoA to form malonyl-CoA 
YLR099C ICT1 Lysophosphatidic acid acyltransferase, 
responsible for enhanced phospholipid 
synthesis during organic solvent stress 
− 4.32 
YGL253W HXK2 Hexokinase isoenzyme 2 that catalyzes 
phosphorylation of glucose in the cytosol 
− 4.18 
YGR234W YHB1 Nitric oxide oxidoreductase, flavohemoglobin 
involved in nitric oxide detoxification 
− 3.97 
YAL023C PMT2 Protein O-mannosyltransferase, transfers 
mannose residues from dolichyl phosphate-D-
mannose to protein Ser/Thr residues 
− 3.84 
YML070W DAK1 Dihydroxyacetone kinase, required for 
detoxification of dihydroxyacetone (DHA 
− 3.75 
YOR388C FDH1 NAD(+)-dependent formate dehydrogenase, 
may protect cells from exogenous formate 
− 3.45 
YML028W TSA1 Thioredoxin peroxidase, acts as both a 
ribosome-associated and free cytoplasmic 
antioxidant 
− 3.43 
YKL182W FAS1 Beta subunit of fatty acid synthetase, which 
catalyzes the synthesis of long-chain saturated 
fatty acids 
− 3.41 
YJL167W ERG20 Farnesyl pyrophosphate synthetase, has both 
dimethylallyltranstransferase and 
geranyltranstransferase activities 
− 3.41 
YOL143C RIB4 Lumazine synthase (6,7-dimethyl-8-
ribityllumazine synthase, also known as DMRL 
synthase 
− 3.24 
YHR174W ENO2 Enolase II, a phosphopyruvate hydratase that 
catalyzes the conversion of 2-phosphoglycerate 
to phosphoenolpyruvate during glycolysis and 
the reverse reaction during gluconeogenesis 
− 3.20 
YLR134W PDC5 Minor isoform of pyruvate decarboxylase, key 
enzyme in alcoholic fermentation, 
decarboxylates pyruvate to acetaldehyde 
− 3.16 
YOR321W PMT3 Protein O-mannosyltransferase, transfers 
mannose residues from dolichyl phosphate-D-
mannose to protein serine/threonine residues 
− 3.15 
YHR183W GND1 6-phosphogluconate dehydrogenase 
(decarboxylating), catalyzes an NADPH 
regenerating reaction in the pentose phosphate 
pathway 
− 3.13 
YLR354C TAL1 Transaldolase, enzyme in the non-oxidative 
pentose phosphate pathway 
− 3.10 
YOR198C BFR1 Component of mRNP complexes associated 
with polyribosomes 
− 3.03 
YOR393W ERR1 Protein of unknown function − 3.02 
YFL011W HXT10 Putative hexose transporter, expressed at low 
levels and expression is repressed by glucose 
− 3.00 
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YPL281C ERR2 Protein of unknown function − 3.00 
YMR323W ERR3 Protein of unknown function − 2.98 
YOR288C MPD1 Member of the protein disulfide isomerase (PDI) 
family 
− 2.96 
YLR259C HSP60 Tetradecameric mitochondrial chaperonin 
required for ATP-dependent folding of precursor 
polypeptides and complex assembly 
− 2.81 
YMR214W SCJ1 One of several homologs of bacterial chaperone 
DnaJ, located in the ER lumen where it 
cooperates with Kar2p to mediate maturation of 
proteins 
− 2.76 
YPL240C HSP82 Hsp90 chaperone required for pheromone 
signaling and negative regulation of Hsf1p 
− 2.76 
YOR176W HEM15 Ferrochelatase, a mitochondrial inner 
membrane protein, catalyzes the insertion of 
ferrous iron into protoporphyrin IX 
− 2.75 
YNR019W ARE2 Acyl-CoA:sterol acyltransferase, isozyme of 
Are1p 
− 2.74 
YGR037C ACB1 Acyl-CoA-binding protein, transports newly 
synthesized acyl-CoA esters from fatty acid 
synthetase (Fas1p-Fas2p) to acyl-CoA-
consuming processes 
− 2.74 
YJR030C YJR030C Putative protein of unknown function; 
expression repressed in carbon limited vs 
carbon replete chemostat cultures 
− 2.72 
YLR304C ACO1 Aconitase, required for the tricarboxylic acid 
(TCA) cycle and also independently required for 
mitochondrial genome maintenance 
− 2.72 
YOL031C SIL1 Nucleotide exchange factor for the endoplasmic 
reticulum (ER) lumenal Hsp70 chaperone 
Kar2p, required for protein translocation into the 
ER; homolog of Yarrowia lipolytica SLS1 
− 2.69 
YKL121W DGR2 Protein of unknown function − 2.68 
YBR011C IPP1 Cytoplasmic inorganic pyrophosphatase 
(PPase), homodimer that catalyzes the rapid 
exchange of oxygens from Pi with water 
− 2.67 
YBR029C CDS1 Phosphatidate cytidylyltransferase (CDP-
diglyceride synthetase 
− 2.62 
YPL058C PDR12 Plasma membrane ATP-binding cassette (ABC) 
transporter, weak-acid-inducible multidrug 
transporter required for weak organic acid 
resistance 
− 2.60 
YNL102W POL1 Catalytic subunit of the DNA polymerase I 
alpha-primase complex, required for the 
initiation of DNA replication during mitotic DNA 
synthesis and premeiotic DNA synthesis 
− 2.60 
YLR234W TOP3 DNA Topoisomerase III, conserved protein that 
functions in a complex with Sgs1p and Rmi1p to 
relax single-stranded negatively-supercoiled 
− 2.56 
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DNA preferentially 
YHR104W GRE3 Aldose reductase involved in methylglyoxal, d-
xylose, arabinose, and galactose metabolism; 
stress induced (osmotic, ionic, oxidative, heat 
shock, starvation and heavy metals) 
− 2.53 
YGL256W ADH4 Alcohol dehydrogenase isoenzyme type IV, 
dimeric enzyme demonstrated to be zinc-
dependent despite sequence similarity to iron-
activated alcohol dehydrogenases 
− 2.51 
YOR073W SGO1 Component of the spindle checkpoint, involved 
in sensing lack of tension on mitotic 
chromosomes 
− 2.51 
YDR148C KGD2 Dihydrolipoyl transsuccinylase, component of 
the mitochondrial alpha-ketoglutarate 
dehydrogenase complex, which catalyzes the 
oxidative decarboxylation of alpha-ketoglutarate 
to succinyl-CoA in the TCA cycle 
− 2.49 
YKL103C LAP4 Vacuolar aminopeptidase yscI − 2.48 
YOR247W SRL1 Mannoprotein that exhibits a tight association 
with the cell wall, required for cell wall stability in 
the absence of GPI-anchored mannoproteins; 
has a high serine-threonine content 
− 2.47 
YOR385W YOR385
W 
Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm 
− 2.43 
YOR254C SEC63 Essential subunit of Sec63 complex (Sec63p, 
Sec62p, Sec66p and Sec72p 
− 2.42 
YDR050C TPI1 Triose phosphate isomerase, abundant 
glycolytic enzyme 
− 2.41 
YCL050C APA1 Diadenosine 5',5''-P1,P4-tetraphosphate 
phosphorylase I (AP4A phosphorylase), 
involved in catabolism of bis(5'-nucleosidyl) 
tetraphosphates 
− 2.40 
YDL103C QRI1 UDP-N-acetylglucosamine pyrophosphorylase, 
catalyzes the formation of UDP-N-
acetylglucosamine (UDP-GlcNAc) 
− 2.38 
YDL022W GPD1 NAD-dependent glycerol-3-phosphate 
dehydrogenase, key enzyme of glycerol 
synthesis, essential for growth under osmotic 
stress 
− 2.38 
YBL032W HEK2 RNA binding protein involved in the asymmetric 
localization of ASH1 mRNA 
− 2.38 
YER103W SSA4 Heat shock protein that is highly induced upon 
stress 
− 2.38 
YBR072W HSP26 Small heat shock protein (sHSP) with 
chaperone activity 
− 2.37 
YJR143C PMT4 Protein O-mannosyltransferase, transfers 
mannose residues from dolichyl phosphate-D-
mannose to protein serine/threonine residues 
− 2.37 
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YGR285C ZUO1 Ribosome-associated chaperone, functions in 
ribosome biogenesis and, in partnership with 
Ssz1p and SSb1/2, as a chaperone for nascent 
polypeptide chains 
− 2.36 
YGL137W SEC27 Essential beta'-coat protein of the COPI 
coatomer, involved in ER-to-Golgi and Golgi-to-
ER transport; contains WD40 domains that 
mediate cargo selective interactions 
− 2.34 
YBL002W HTB2 Histone H2B, core histone protein required for 
chromatin assembly and chromosome function 
− 2.34 
YLR131C ACE2 Transcription factor that activates expression of 
early G1-specific genes, localizes to daughter 
cell nuclei after cytokinesis and delays G1 
progression in daughters, localization is 
regulated by phosphorylation 
− 2.33 
YGR240C PFK1 Alpha subunit of heterooctameric 
phosphofructokinase involved in glycolysis,  
− 2.33 
YKL152C GPM1 Tetrameric phosphoglycerate mutase, mediates 
the conversion of 3-phosphoglycerate to 2-
phosphoglycerate during glycolysis and the 
reverse reaction during gluconeogenesis 
− 2.29 
YLR132C YLR132C Essential protein of unknown function − 2.28 
YNL082W PMS1 ATP-binding protein required for mismatch 
repair in mitosis and meiosis 
− 2.28 
YIL041W GVP36 BAR domain-containing protein that localizes to 
both early and late Golgi vesicles 
− 2.27 
YHR064C SSZ1 Hsp70 protein that interacts with Zuo1p (a DnaJ 
homolog) to form a ribosome-associated 
complex that binds the ribosome via the Zuo1p 
subunit 
− 2.26 
YDR508C GNP1 High-affinity glutamine permease, also 
transports Leu, Ser, Thr, Cys, Met and Asn 
− 2.26 
YFL059W SNZ3 Member of a stationary phase-induced gene 
family 
− 2.25 
YHL018W YHL018W Putative protein of unknown function − 2.24 
YOR083W WHI5 Repressor of G1 transcription that binds to SCB 
binding factor (SBF) at SCB target promoters in 
early G1; phosphorylation of Whi5p by the CDK, 
Cln3p/Cdc28p relieves repression and promoter 
binding by Whi5; periodically expressed in G1 
− 2.20 
YLR133W CKI1 Choline kinase, catalyzing the first step in 
phosphatidylcholine synthesis via the CDP-
choline (Kennedy pathway) 
− 2.19 
YNL071W LAT1 Dihydrolipoamide acetyltransferase component 
(E2) of pyruvate dehydrogenase complex, which 
catalyzes the oxidative decarboxylation of 
pyruvate to acetyl-CoA 
− 2.19 
YDL004W ATP16 Delta subunit of the central stalk of 
mitochondrial F1F0 ATP synthase, which is a 
− 2.18 
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large, evolutionarily conserved enzyme complex 
required for ATP synthesis 
YPR183W DPM1 Dolichol phosphate mannose (Dol-P-Man) 
synthase of the ER membrane, catalyzes the 
formation of Dol-P-Man from Dol-P and GDP-
Man 
− 2.17 
YFL053W DAK2 Dihydroxyacetone kinase, required for 
detoxification of dihydroxyacetone (DHA 
− 2.16 
YOR388C FDH1 NAD(+)-dependent formate dehydrogenase, 
may protect cells from exogenous formate 
− 2.16 
YDL192W ARF1 ADP-ribosylation factor, GTPase of the Ras 
superfamily involved in regulation of coated 
vesicle formation in intracellular trafficking within 
the Golgi 
− 2.14 
YGL175C SAE2 Endonuclease that processes hairpin DNA 
structures with the MRX complex 
− 2.14 
YBR053C YBR053C Putative protein of unknown function − 2.13 
YDL140C RPO21 RNA polymerase II largest subunit B220, part of 
central core 
− 2.12 
YDL219W DTD1 D-Tyr-tRNA(Tyr) deacylase, functions in protein 
translation, may affect nonsense suppression 
via alteration of the protein synthesis machinery 
− 2.12 
YDR226W ADK1 Adenylate kinase, required for purine 
metabolism 
− 2.11 
YHR068W DYS1 Deoxyhypusine synthase, catalyzes formation of 
deoxyhypusine, the first step in hypusine 
biosynthesis 
− 2.10 
YMR205C PFK2 Beta subunit of heterooctameric 
phosphofructokinase involved in glycolysis, 
indispensable for anaerobic growth, activated by 
fructose-2,6-bisphosphate and AMP, mutation 
inhibits glucose induction of cell cycle-related 
genes 
− 2.09 
YDR432W NPL3 RNA-binding protein that promotes elongation, 
regulates termination, and carries poly(A) 
mRNA from nucleus to cytoplasm; required for 
pre-mRNA splicing 
− 2.08 
YNL233W BNI4 Targeting subunit for Glc7p protein 
phosphatase, localized to the bud neck, 
required for localization of chitin synthase III to 
the bud neck via interaction with the chitin 
synthase III regulatory subunit Skt5p 
− 2.07 
YMR027W YMR027
W 
Putative protein of unknown function − 2.06 
YDR111C ALT2 Putative alanine transaminase (glutamic pyruvic 
transaminase) 
− 2.06 
YFL038C YPT1 Rab family GTPase, involved in the ER-to-Golgi 
step of the secretory pathway) 
− 2.05 
YNR035C ARC35 Subunit of the ARP2/3 complex, which is − 2.04 
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required for the motility and integrity of cortical 
actin patches 
YGL105W ARC1 Protein that binds tRNA and methionyl- and 
glutamyl-tRNA synthetases (Mes1p and 
Gus1p), delivering tRNA to them, stimulating 
catalysis, and ensuring their localization to the 
cytoplasm 
− 2.04 
YNL010W YNL010W Putative protein of unknown function with 
similarity to phosphoserine phosphatases; 
green fluorescent protein (GFP)-fusion protein 
localizes to the cytoplasm and nucleus 
− 2.04 
YPL032C SVL3 Protein of unknown function, mutant phenotype 
suggests a potential role in vacuolar function 
− 2.02 
YDR510W SMT3 Ubiquitin-like protein of the SUMO family, 
conjugated to lysine residues of target proteins 
− 2.01 
YDL185W TFP1 Subunit A of the eight-subunit V1 peripheral 
membrane domain of the vacuolar H+-ATPase 
− 2.01 
YHL031C GOS1 v-SNARE protein involved in Golgi transport, 
homolog of the mammalian protein GOS-
28/GS28 
− 2.01 
YML054C CYB2 Cytochrome b2 (L-lactate cytochrome-c 
oxidoreductase), component of the 
mitochondrial intermembrane space, required 
for lactate utilization 
− 2.00 
YGR279C SCW4 Cell wall protein with similarity to glucanases; 
scw4 scw10 double mutants exhibit defects in 
mating 
− 2.00 
YOL164W BDS1 Bacterially-derived sulfatase required for use of 
alkyl- and aryl-sulfates as sulfur sources 
− -2.00 
YGR074W SMD1 Core Sm protein Sm D1 − -2.00 
YMR126C DLT1 Protein of unknown function, mutant sensitive to 
6-azauracil (6AU) and mycophenolic acid (MPA) 
− -2.00 
YLR266C PDR8 Transcription factor; targets include ATP-binding 
cassette (ABC) transporters, major facilitator 
superfamily transporters, and other genes 
involved in the pleiotropic drug resistance (PDR) 
phenomenon 
− -2.01 
YKR009C FOX2 Multifunctional enzyme of the peroxisomal fatty 
acid beta-oxidation pathway 
− -2.01 
YIL046W MET30 F-box protein containing five copies of the 
WD40 motif, controls cell cycle function, sulfur 
metabolism, and methionine biosynthesis as 
part of the ubiquitin ligase complex 
− -2.03 
YGR166W KRE11 Subunit of TRAPPII, a multimeric guanine 
nucleotide-exchange factor for Ypt1p 
− -2.04 
YBR212W NGR1 RNA binding protein that negatively regulates 
growth rate; interacts with the 3' UTR of the 
mitochondrial porin (POR1) mRNA and 
enhances its degradation 
− -2.05 
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YDL231C BRE4 Zinc finger protein containing five 
transmembrane domains 
− -2.05 
YFR046C CNN1 Kinetochore protein of unknown function; 
associated with the essential kinetochore 
proteins Nnf1p and Spc24p 
− -2.06 
YMR132C JLP2 Protein of unknown function, contains sequence 
that closely resembles a J domain (typified by 
the E. coli DnaJ protein) 
− -2.06 
YNL221C POP1 Subunit of both RNase MRP, which cleaves pre-
rRNA, and nuclear RNase P, which cleaves 
tRNA precursors to generate mature 5' ends 
− -2.07 
YDL215C GDH2 NAD(+)-dependent glutamate dehydrogenase, 
degrades glutamate to ammonia and alpha-
ketoglutarate 
− -2.08 
YER015W FAA2 Medium chain fatty acyl-CoA synthetase, 
activates imported fatty acids 
− -2.09 
YOR004W UTP23 Essential nucleolar protein that is a component 
of the SSU (small subunit) processome involved 
in 40S ribosomal subunit biogenesis 
− -2.09 
YFR025C HIS2 Histidinolphosphatase, catalyzes the eighth step 
in histidine biosynthesis 
− -2.10 
YLL048C YBT1 Transporter of the ATP-binding cassette (ABC) 
family involved in bile acid transport 
− -2.10 
YER092W IES5 Protein that associates with the INO80 
chromatin remodeling complex under low-salt 
conditions 
− -2.11 
YNR074C AIF1 Mitochondrial cell death effector that 
translocates to the nucleus in response to 
apoptotic stimuli, homolog of mammalian 
Apoptosis-Inducing Factor, putative reductase 
− -2.11 
YJR050W ISY1 Member of NineTeen Complex (NTC) that 
contains Prp19p and stabilizes U6 snRNA in 
catalytic forms of spliceosome containing U2, 
U5, and U6 snRNAs, interacts with Prp16p to 
modulate splicing fidelity 
− -2.11 
YIR013C GAT4 Protein containing GATA family zinc finger 
motifs 
− -2.12 
YLR193C UPS1 Mitochondrial intermembrane space protein that 
regulates mitochondrial cardiolipin levels, null 
has defects in Mgm1p processing, integrity of 
mitochondrial inner membrane complexes, and 
mitochondrial morphology 
− -2.12 
YGR280C PXR1 Essential protein involved in rRNA and snoRNA 
maturation; competes with TLC1 RNA for 
binding to Est2p, suggesting a role in negative 
regulation of telomerase 
− -2.15 
YPR200C ARR2 Arsenate reductase required for arsenate 
resistance 
− -2.16 
YDR249C YDR249C Putative protein of unknown function − -2.16 
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YOL044W PEX15 Phosphorylated tail-anchored type II integral 
peroxisomal membrane protein required for 
peroxisome biogenesis, cells lacking Pex15p 
mislocalize peroxisomal matrix proteins to 
cytosol 
− -2.19 
YBL049W MOH1 Protein of unknown function, has homology to 
kinase Snf7p 
− -2.20 
YOR184W SER1 3-phosphoserine aminotransferase, catalyzes 
the formation of phosphoserine from 3-
phosphohydroxypyruvate, required for serine 
and glycine biosynthesis 
− -2.20 
YOL047C YOL047C Protein of unknown function − -2.21 
YER040W GLN3 Transcriptional activator of genes regulated by 
nitrogen catabolite repression (NCR), 
localization and activity regulated by quality of 
nitrogen source 
− -2.21 
YPR168W NUT2 Subunit of the RNA polymerase II mediator 
complex 
− -2.21 
YLR130C ZRT2 Low-affinity zinc transporter of the plasma 
membrane 
− -2.21 
YKL220C FRE2 Ferric reductase and cupric reductase, reduces 
siderophore-bound iron and oxidized copper 
prior to uptake by transporters 
− -2.22 
YLR004C THI73 Putative plasma membrane permease proposed 
to be involved in carboxylic acid uptake and 
repressed by thiamine 
− -2.22 
YOL084W PHM7 Protein of unknown function, expression is 
regulated by phosphate levels 
− -2.23 
YNL046W YNL046W Putative protein of unknown function − -2.25 
YDR257C RKM4 Ribosomal lysine methyltransferase specific for 
monomethylation of Rpl42ap and Rpl42bp 
(lysine 55) 
− -2.29 
YNL116W DMA2 Protein involved in ubiquitination; plays a role in 
regulating spindle position and orientation 
− -2.30 
YEL065W SIT1 Ferrioxamine B transporter, member of the ARN 
family of transporters that specifically recognize 
siderophore-iron chelates 
− -2.35 
YBR043C QDR3 Multidrug transporter of the major facilitator 
superfamily, required for resistance to quinidine, 
barban, cisplatin, and bleomycin 
− -2.37 
YNL129W NRK1 Nicotinamide riboside kinase, catalyzes the 
phosphorylation of nicotinamide riboside and 
nicotinic acid riboside in salvage pathways for 
NAD+ biosynthesis 
− -2.37 
YBL029W YBL029W Non-essential protein of unknown function − -2.38 
YPR128C ANT1 Peroxisomal adenine nucleotide transporter − -2.41 
YBR166C TYR1 Prephenate dehydrogenase involved in tyrosine 
biosynthesis, expression is dependent on 
phenylalanine levels 
− -2.41 
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YLL027W ISA1 Mitochondrial matrix protein involved in 
biogenesis of the iron-sulfur (Fe/S) cluster of 
Fe/S proteins, isa1 deletion causes loss of 
mitochondrial DNA and respiratory deficiency  
− -2.43 
YGL146C RRT6 Putative protein of unknown function − -2.45 
YIL117C PRM5 Pheromone-regulated protein, predicted to have 
1 transmembrane segment 
− -2.46 
YBL103C RTG3 Basic helix-loop-helix-leucine zipper (bHLH/Zip) 
transcription factor that forms a complex with 
another bHLH/Zip protein, Rtg1p, to activate the 
retrograde (RTG) and TOR pathways 
− -2.46 
YDR090C YDR090C Putative protein of unknown function − -2.46 
YMR187C YMR187C Putative protein of unknown function − -2.46 
YGR029W ERV1 Flavin-linked sulfhydryl oxidase of the 
mitochondrial intermembrane space (IMS), 
oxidizes Mia40p as part of a disulfide relay 
system that promotes IMS retention of imported 
proteins 
− -2.47 
YDL121C YDL121C Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the endoplasmic reticulum 
− -2.47 
YCR089W FIG2 Cell wall adhesin, expressed specifically during 
mating 
− -2.48 
YER039C HVG1 Protein of unknown function, has homology to 
Vrg4p 
− -2.52 
YNL125C ESBP6 Protein with similarity to monocarboxylate 
permeases, appears not to be involved in 
transport of monocarboxylates such as lactate, 
pyruvate or acetate across the plasma 
membrane 
− -2.53 
YAL044C GCV3 H subunit of the mitochondrial glycine 
decarboxylase complex, required for the 
catabolism of glycine to 5,10-methylene-THF 
− -2.53 
YBL095W YBL095W Putative protein of unknown function − -2.54 
YHR160C PEX18 Peroxin required for targeting of peroxisomal 
matrix proteins containing PTS2 
− -2.54 
YBR115C LYS2 Alpha aminoadipate reductase, catalyzes the 
reduction of alpha-aminoadipate to alpha-
aminoadipate 6-semialdehyde, which is the fifth 
step in biosynthesis of lysine 
− -2.55 
YGL205W POX1 Fatty-acyl coenzyme A oxidase, involved in the 
fatty acid beta-oxidation pathway 
− -2.56 
YGL114W YGL114W Putative protein of unknown function − -2.62 
YFL021W GAT1 Transcriptional activator of genes involved in 
nitrogen catabolite repression 
− -2.64 
YCR023C YCR023C Vacuolar membrane protein of unknown 
function 
− -2.64 
YML097C VPS9 A guanine nucleotide exchange factor involved 
in vesicle-mediated vacuolar protein transport; 
− -2.66 
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specifically stimulates the intrinsic guanine 
nucleotide exchange activity of Vps21p/Rab5 
YOR221C MCT1 Predicted malonyl-CoA:ACP transferase, 
putative component of a type-II mitochondrial 
fatty acid synthase that produces intermediates 
for phospholipid remodeling 
− -2.68 
YKL033W-
A 
YKL033W
-A 
Putative protein of unknown function − -2.75 
YLL057C JLP1 Fe(II)-dependent sulfonate/alpha-ketoglutarate 
dioxygenase, involved in sulfonate catabolism 
for use as a sulfur source; contains sequence 
that resembles a J domain (typified by the E. 
coli DnaJ protein); induced by sulphur starvation 
− -2.76 
YMR019W STB4 Protein that binds Sin3p in a two-hybrid assay − -2.78 
YBR248C HIS7 Imidazole glycerol phosphate synthase 
(glutamine amidotransferase:cyclase), catalyzes 
the fifth and sixth steps of histidine biosynthesis 
and also produces 5-aminoimidazole-4-
carboxamide ribotide (AICAR), a purine 
precursor 
− -2.82 
YNR065C YNR065C Protein of unknown function − -2.84 
YOR339C UBC11 Ubiquitin-conjugating enzyme most similar in 
sequence to Xenopus ubiquitin-conjugating 
enzyme E2-C, but not a true functional homolog 
of this E2; unlike E2-C 
− -2.86 
YOR008C-
A 
YOR008C
-A 
Putative protein of unknown function, includes a 
potential transmembrane domain 
− -2.87 
YDR384C ATO3 Plasma membrane protein, regulation pattern 
suggests a possible role in export of ammonia 
from the cell 
− -2.89 
YBR249C ARO4 3-deoxy-D-arabino-heptulosonate-7-phosphate 
(DAHP) synthase, catalyzes the first step in 
aromatic amino acid biosynthesis and is 
feedback-inhibited by tyrosine or high 
concentrations of phenylalanine  
− -2.91 
YGR121C MEP1 Ammonium permease; belongs to a ubiquitous 
family of cytoplasmic membrane proteins that 
transport only ammonium (NH4+) 
− -2.92 
YPL052W OAZ1 Regulator of ornithine decarboxylase (Spe1p), 
antizyme that binds to Spe1p to regulate 
ubiquitin-independent degradation 
− -2.95 
YBL071W-
A 
KTI11 Zn-ribbon protein that co-purifies with Dph1 and 
Dph2 in a complex required for synthesis of 
diphthamide on translation factor eEF2 and with 
Elongator subunits Iki3p, Elp2p, and Elp3p 
involved in modification of wobble nucleosides 
in tRNAs 
− -2.96 
YER055C HIS1 ATP phosphoribosyltransferase, a hexameric 
enzyme, catalyzes the first step in histidine 
− -2.97 
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biosynthesis; mutations cause histidine 
auxotrophy and sensitivity to Cu, Co, and Ni 
salts 
YIR034C LYS1 Saccharopine dehydrogenase (NAD+, L-lysine-
forming), catalyzes the conversion of 
saccharopine to L-lysine, which is the final step 
in the lysine biosynthesis pathway 
− -2.98 
YER184C YER184C Putative zinc cluster protein − -3.03 
YDR487C RIB3 3,4-dihydroxy-2-butanone-4-phosphate 
synthase (DHBP synthase), required for 
riboflavin biosynthesis from ribulose-5-
phosphate 
− -3.03 
YDR076W RAD55 Protein that stimulates strand exchange by 
stabilizing the binding of Rad51p to single-
stranded DNA 
− -3.05 
YNL311C YNL311C F-box protein of unknown function predicted to 
be part of an SCF ubiquitin protease complex; 
involved in regulating protein levels of sulfur 
metabolism enzymes 
− -3.11 
YPL135W ISU1 Conserved protein of the mitochondrial matrix, 
performs a scaffolding function during assembly 
of iron-sulfur clusters, interacts physically and 
functionally with yeast frataxin (Yfh1p 
− -3.13 
YGR197C SNG1 Protein involved in resistance to 
nitrosoguanidine (MNNG) and 6-azauracil (6-
AU) 
− -3.13 
YLR090W XDJ1 Putative chaperone, homolog of E. coli DnaJ, 
closely related to Ydj1p 
− -3.14 
YGL154C LYS5 Phosphopantetheinyl transferase involved in 
lysine biosynthesis 
− -3.23 
YLR348C DIC1 Mitochondrial dicarboxylate carrier, integral 
membrane protein, catalyzes a dicarboxylate-
phosphate exchange across the inner 
mitochondrial membrane 
− -3.25 
YOR192C THI72 Transporter of thiamine or related compound − -3.27 
YJR010W MET3 ATP sulfurylase, catalyzes the primary step of 
intracellular sulfate activation, essential for 
assimilatory reduction of sulfate to sulfide, 
involved in methionine metabolism 
− -3.33 
YGR154C GTO1 Omega-class glutathione transferase − -3.34 
YHR208W BAT1 Mitochondrial branched-chain amino acid 
aminotransferase, homolog of murine ECA39 
− -3.37 
YER039C YER039C Putative protein of unknown function − -3.37 
YGL186C TPN1 Plasma membrane pyridoxine (vitamin B6) 
transporter; member of the purine-cytosine 
permease subfamily within the major facilitator 
superfamily 
− -3.38 
YHR122W YHR12W Protein of unknown function required for 
establishment of sister chromatid cohesion 
− -3.41 
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YKL211C TRP3 Bifunctional enzyme exhibiting both indole-3-
glycerol-phosphate synthase and anthranilate 
synthase activities 
− -3.43 
YPR078C YPR078C Putative protein of unknown function − -3.45 
YDL054C MCH1 Protein with similarity to mammalian 
monocarboxylate permeases, which are 
involved in transport of monocarboxylic acids 
across the plasma membrane 
− -3.51 
YLR042C YLR042C Protein of unknown function; localizes to the 
cytoplasm 
− -3.58 
YOR161C PNS1 Protein of unknown function − -3.59 
YJR155W AAD10 Putative aryl-alcohol dehydrogenase with 
similarity to P. chrysosporium aryl-alcohol 
dehydrogenase 
− -3.59 
YPL188W POS5 Mitochondrial NADH kinase, phosphorylates 
NADH; also phosphorylates NAD(+) with lower 
specificity 
− -3.60 
YGL059W PKP2 Mitochondrial protein kinase that negatively 
regulates activity of the pyruvate 
dehydrogenase complex by phosphorylating the 
ser-133 residue of the Pda1p subunit 
− -3.63 
YBR105C VID24 Peripheral membrane protein located at Vid 
(vacuole import and degradation) vesicles 
− -3.67 
YKR071C DRE2 Conserved component of an early step in the 
cytosolic Fe-S protein assembly (CIA) 
machinery 
− -3.70 
YBR104W YMC2 Mitochondrial protein, putative inner membrane 
transporter with a role in oleate metabolism and 
glutamate biosynthesis 
− -3.74 
YJL072C PSF2 Subunit of the GINS complex (Sld5p, Psf1p, 
Psf2p, Psf3p), which is localized to DNA 
replication origins and implicated in assembly of 
the DNA replication machinery 
− -3.81 
YDR158W HOM2 Aspartic beta semi-aldehyde dehydrogenase, 
catalyzes the second step in the common 
pathway for methionine and threonine 
biosynthesis 
− -3.82 
YPL273W SAM4 S-adenosylmethionine-homocysteine 
methyltransferase, functions along with Mht1p in 
the conversion of S-adenosylmethionine 
(AdoMet) to methionine to control the 
methionine/AdoMet ratio 
− -3.83 
YPL033C SRL4 Protein of unknown function − -3.84 
YCL030C HIS4 Multifunctional enzyme containing 
phosphoribosyl-ATP pyrophosphatase, 
phosphoribosyl-AMP cyclohydrolase, and 
histidinol dehydrogenase activities 
− -3.85 
YNL036W NCE103 Carbonic anhydrase; poorly transcribed under 
aerobic conditions and at an undetectable level 
− -3.86 
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under anaerobic conditions 
YBR045C GIP1 Meiosis-specific regulatory subunit of the Glc7p 
protein phosphatase, regulates spore wall 
formation and septin organization 
− -3.88 
YER056C FCY2 Purine-cytosine permease, mediates purine 
(adenine, guanine, and hypoxanthine) and 
cytosine accumulation 
− -4.04 
YMR321C YMR321C Putative protein of unknown function − -4.07 
YHR018C ARG4 Argininosuccinate lyase, catalyzes the final step 
in the arginine biosynthesis pathway 
− -4.10 
YPR058W YMC1 Mitochondrial protein, putative inner membrane 
transporter with a role in oleate metabolism and 
glutamate biosynthesis 
− -4.10 
YOL141W PPM2 AdoMet-dependent tRNA methyltransferase 
also involved in methoxycarbonylation 
− -4.15 
YKL218C SRY1 3-hydroxyaspartate dehydratase, deaminates L-
threo-3-hydroxyaspartate to form oxaloacetate 
and ammonia 
− -4.31 
YOL091W SPO21 Component of the meiotic outer plaque of the 
spindle pole body, involved in modifying the 
meiotic outer plaque that is required prior to 
prospore membrane formation 
− -4.32 
YDR253C MET32 Zinc-finger DNA-binding protein, involved in 
transcriptional regulation of the methionine 
biosynthetic genes, similar to Met31p 
− -4.35 
YPL252C YAH1 Ferredoxin of the mitochondrial matrix required 
for formation of cellular iron-sulfur proteins 
− -4.39 
YIL056W VHR1 Transcriptional activator, required for the vitamin 
H-responsive element (VHRE) mediated 
induction of VHT1 (Vitamin H transporter) and 
BIO5 (biotin biosynthesis intermediate 
transporter) in response to low biotin 
concentrations 
− -4.41 
YOR303W CPA1 Small subunit of carbamoyl phosphate 
synthetase, which catalyzes a step in the 
synthesis of citrulline, an arginine precursor 
− -4.45 
YDR354W TRP4 Anthranilate phosphoribosyl transferase of the 
tryptophan biosynthetic pathway, catalyzes the 
phosphoribosylation of anthranilate 
− -4.58 
YOR130C ORT1 Ornithine transporter of the mitochondrial inner 
membrane, exports ornithine from mitochondria 
as part of arginine biosynthesis 
− -4.59 
YER060W-
A 
FCY22 Putative purine-cytosine permease, very similar 
to Fcy2p but cannot substitute for its function 
− -4.59 
YNR057C BIO4 Dethiobiotin synthetase, catalyzes the third step 
in the biotin biosynthesis pathway 
− -4.68 
YGL224C SDT1 Pyrimidine nucleotidase; overexpression 
suppresses the 6-AU sensitivity of transcription 
elongation factor S-II, as well as resistance to 
− -4.89 
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other pyrimidine derivatives 
YNL095C YNL095C Putative protein of unknown function predicted 
to contain a transmembrane domain 
− -4.94 
YMR062C ARG7 Mitochondrial ornithine acetyltransferase, 
catalyzes the fifth step in arginine biosynthesis 
− -4.99 
YJL198W PHO90 Low-affinity phosphate transporter; deletion of 
pho84, pho87, pho89, pho90, and pho91 
causes synthetic lethality 
− -5.08 
YOR302W YOR302
W 
CPA1 uORF, Arginine attenuator peptide, 
regulates translation of the CPA1 mRNA 
− -5.18 
YOL058W ARG1 Arginosuccinate synthetase, catalyzes the 
formation of L-argininosuccinate from citrulline 
and L-aspartate in the arginine biosynthesis  
− -5.19 
YBR256C RIB5 Riboflavin synthase; catalyzes the last step of 
the riboflavin biosynthesis pathway 
− -5.28 
YDL198C GGC1 Mitochondrial GTP/GDP transporter, essential 
for mitochondrial genome maintenance 
− -5.29 
YOR032C HMS1 Basic helix-loop-helix (bHLH) protein with 
similarity to myc-family transcription factors 
− -5.29 
YIR017C MET28 Basic leucine zipper (bZIP) transcriptional 
activator in the Cbf1p-Met4p-Met28p complex, 
participates in the regulation of sulfur 
metabolism 
− -5.33 
YLR089C ALT1 Alanine transaminase (glutamic pyruvic 
transaminase) 
− -5.33 
YJR111C YJR111C Putative protein of unknown function; green 
fluorescent protein (GFP)-fusion protein 
localizes to the mitochondria 
− -5.38 
YJR154W YJR154W Putative protein of unknown function − -5.49 
YJR137C MET5 Sulfite reductase beta subunit, involved in 
amino acid biosynthesis, transcription repressed 
by methionine 
− -5.66 
YNL104C LEU4 Alpha-isopropylmalate synthase (2-
isopropylmalate synthase 
− -5.87 
YER174C GRX4 Hydroperoxide and superoxide-radical 
responsive glutathione-dependent 
oxidoreductase; monothiol glutaredoxin 
subfamily member along with Grx3p and Grx5p 
− -5.88 
YPR167C MET16 3'-phosphoadenylsulfate reductase, reduces 3'-
phosphoadenylyl sulfate to adenosine-3',5'-
bisphosphate and free sulfite using reduced 
thioredoxin as cosubstrate, involved in sulfate 
assimilation and methionine metabolism 
− -5.95 
YJR109C CPA2 Large subunit of carbamoyl phosphate 
synthetase, which catalyzes a step in the 
synthesis of citrulline, an arginine precursor 
− -6.23 
YER024W YAT2 Carnitine acetyltransferase; has similarity to 
Yat1p, which is a carnitine acetyltransferase 
associated with the mitochondrial outer 
− -6.25 
	  	  	  
141	  
	  
membrane 
YNR068C YNR068C Putative protein of unknown function − -6.35 
YKR069W MET1 S-adenosyl-L-methionine uroporphyrinogen III 
transmethylase, involved in the biosynthesis of 
siroheme, a prosthetic group used by sulfite 
reductase 
− -6.40 
YER069W ARG5,6 Protein that is processed in the mitochondrion to 
yield acetylglutamate kinase and N-acetyl-
gamma-glutamyl-phosphate reductase, which 
catalyze the 2nd and 3rd steps in arginine 
biosynthesis 
− -6.44 
YKL029C MAE1 Mitochondrial malic enzyme, catalyzes the 
oxidative decarboxylation of malate to pyruvate, 
which is a key intermediate in sugar metabolism 
and a precursor for synthesis of several amino 
acids 
− -6.47 
YML116W ATR1 Multidrug efflux pump of the major facilitator 
superfamily, required for resistance to 
aminotriazole and 4-nitroquinoline-N-oxide 
− -6.51 
YGR065C VHT1 High-affinity plasma membrane H+-biotin 
(vitamin H) symporter 
− -6.60 
YJR130C STR2 Cystathionine gamma-synthase, converts 
cysteine into cystathionine 
− -6.63 
YLR092W SUL2 High affinity sulfate permease; sulfate uptake is 
mediated by specific sulfate transporters Sul1p 
and Sul2p, which control the concentration of 
endogenous activated sulfate intermediates 
− -6.83 
YMR108W ILV2 Acetolactate synthase, catalyses the first 
common step in isoleucine and valine 
biosynthesis and is the target of several classes 
of inhibitors, localizes to the mitochondria 
− -6.90 
YOL140W ARG8 Acetylornithine aminotransferase, catalyzes the 
fourth step in the biosynthesis of the arginine 
precursor ornithine 
− -7.11 
YPL264C YPL264C Putative membrane protein of unknown function − -7.16 
YOL119C MCH4 Protein with similarity to mammalian 
monocarboxylate permeases, which are 
involved in transport of monocarboxylic acids 
across the plasma membrane 
− -7.39 
YPR027C YPR027C Putative protein of unknown function − -7.46 
YGR224W AZR1 Plasma membrane transporter of the major 
facilitator superfamily, involved in resistance to 
azole drugs such as ketoconazole and 
fluconazole 
− -7.62 
YFR030W MET10 Subunit alpha of assimilatory sulfite reductase, 
which converts sulfite into sulfide 
− -7.71 
YHR071W PCL5 Cyclin, interacts with and phosphorylated by 
Pho85p cyclin-dependent kinase (Cdk), induced 
by Gcn4p at level of transcription, specifically 
− -7.71 
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required for Gcn4p degradation, may be sensor 
of cellular protein biosynthetic capacity 
YNR058W BIO3 7,8-diamino-pelargonic acid aminotransferase 
(DAPA), catalyzes the second step in the biotin 
biosynthesis pathway 
− -8.23 
YBR296C PHO89 Na+/Pi cotransporter, active in early growth 
phase 
− -9.20 
YHR029C YHI9 Protein of unknown function; null mutant is 
defective in unfolded protein response 
− -9.30 
YER175C TMT1 Trans-aconitate methyltransferase, cytosolic 
enzyme that catalyzes the methyl esterification 
of 3-isopropylmalate, an intermediate of the 
leucine biosynthetic pathway, and trans-
aconitate, which inhibits the citric acid cycle 
− -9.72 
YGL117W YGL117W Putative protein of unknown function − -9.72 
YGL184C STR3 Cystathionine beta-lyase, converts cystathionine 
into homocysteine 
− -9.83 
YBR148W YSW1 Protein required for normal prospore membrane 
formation 
− -10.31 
YBR047W FMP23 Putative protein of unknown function − -12.46 
YJL088W ARG3 Ornithine carbamoyltransferase 
(carbamoylphosphate:L-ornithine 
carbamoyltransferase), catalyzes the sixth step 
in the biosynthesis of the arginine precursor 
ornithine 
− -14.12 
YMR096W SNZ1 Protein involved in vitamin B6 biosynthesis − -17.82 
YPL250C ICY2 Protein of unknown function − -18.06 
YDR380W ARO10 Phenylpyruvate decarboxylase, catalyzes 
decarboxylation of phenylpyruvate to 
phenylacetaldehyde, which is the first specific 
step in the Ehrlich pathway 
− -25.87 
YMR095C SNO1 Protein of unconfirmed function, involved in 
pyridoxine metabolism 
− -33.55 
YBR294W SUL1 High affinity sulfate permease − -39.15 
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CHAPTER 3 VALPROIC ACID INDUCES THE UNFOLDED PROTEIN RESPONSE BY 
INCREASING CERAMIDE LEVELS 
 
INTRODUCTION 
 Bipolar disorder (BD), one of the most severe forms of mood disorder, is 
characterized by recurrent episodes of depression and mania (Belmaker, 2004; 
Goodwin and Jamison, 2007). BD is ranked as the sixth leading cause of disability 
worldwide. It affects about 1-2% of the total world population (Belmaker, 2004; Goodwin 
and Jamison, 2007, Cheng et al., 2005) and leads to suicide in 15% of cases (Bostwick 
and Pankratz, 2000). Valproic acid (VPA), a branched short-chain fatty acid, is one of 
the most widely used drugs for the treatment of BD. However, it is effective in only 40-
60% of cases and results in serious side effects, including hepatotoxicity and 
teratogenicity (Henry et al., 2003). Although many hypotheses have been postulated to 
explain its efficacy, the therapeutic mechanism of the drug is not understood, nor is the 
underlying cause of the disease (Gould et al., 2004; Williams et al., 2002; Yu and 
Greenberg, 2016). This knowledge gap hampers the development of more effective 
drugs to treat BD. 
 The inositol depletion hypothesis has had a major impact on research in BD. 
Berridge proposed that lithium, widely used to treat BD, inhibits inositol 
monophosphatase (IMPase), causing inositol depletion and subsequently decreasing 
inositol 1,4,5-triphosphate mediated signaling (Berridge, 1989; Hallcher and Sherman 
1980).  Previous studies show that VPA, similar to lithium, causes a decrease in 
intracellular inositol in yeast and mammalian cells (Shaltiel et al., 2004; Vaden et al., 
2001; Ye and Greenberg, 2015). VPA indirectly inhibits myo-inositol-3-phosphate 
synthase (MIPS), the enzyme responsible for the rate-limiting step of de novo synthesis 
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of inositol, suggesting that MIPS is post-translationally regulated (Ju et al., 2004).  More 
recent findings show that yeast and human MIPS are phosphorylated, (Deranieh., et al 
2013; Jesch et al., 2005) and that phosphorylation of conserved sites affects enzymatic 
activity (Deranieh., et al 2013). These findings suggest that the mechanism by which 
VPA causes inositol depletion is conserved in yeast and mammals, supporting the yeast 
model for genetic and molecular studies of the mechanism of the drug. 
In yeast, supplementation of inositol triggers a change in the expression of 
hundreds of inositol-regulated genes, including genes for lipid synthesis (Cox et al., 
1997; Chang et al., 2002; Jesch et al., 2010). Inositol containing lipids, including inositol 
phosphoinositides, glycosylphosphatidylinositol, and sphingolipids, play crucial 
structural and functional roles in regulating membrane biogenesis, membrane 
trafficking, cytoskeletal organization, and gene expression (Santiago and Mamoun, 
2003; Jesch et al., 2005; Henry et al., 2014). Hence, inositol depletion exerts profound 
effects on cellular function (Deranieh and Greenberg, 2009).  Inositol depletion not only 
alters lipid biosynthesis (Gaspar et al., 2006), but also activates stress response 
pathways, including the protein kinase C and unfolded protein response (UPR) 
pathways (Cox et al., 1997; Chang et al., 2002; Jesch et al., 2010).  Cells grown in the 
absence of inositol exhibit induction of the UPR pathway (Cox et al., 1997; Promlek et 
al., 2011), which is reversed by inositol supplementation (Jesch et al., 2005). These 
studies suggest that decreasing the intracellular levels of inositol induces the UPR 
pathway by a mechanism not yet characterized. 
 Interdependence of the UPR pathway and ceramide synthesis has been 
demonstrated in yeast and mammals. Induction of the UPR increases ceramide levels 
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and viability in yeast  (Han et al., 2010).  In mammals, activation of the UPR increases 
the expression of ceramide synthase CerS6, leading to increased synthesis of 
ceramides containing C16 fatty acids (Han et al., 2010). Perturbation of de novo 
synthesis of sphingolipids activates the UPR in yeast (Mousley et al., 2008; Epstein et 
al., 2012), and defective ceramide homeostasis leads to UPR failure (Guenther, et al 
2010). Ceramide also decreases the transcription of nutrient transporters, including 
amino acid transporter mCAT-1, glucose transporter GLUT-1 (Payet, et al., 2013), 
glucose transporter HXT4, and uracil permease FUR4 (Guenther, et al 2010). 
Therefore, the interrelationship between ceramide levels and the UPR pathway 
maintains cell homeostasis.  
In the current study, I show for the first time that VPA mediated inositol depletion 
induces the UPR pathway by increasing de novo synthesis of ceramide, especially C24-
C26 containing phytoceramide. These findings have implications for the therapeutic 
mechanism of VPA. 
MATERIALS AND METHODS 
Yeast strains, growth media and conditions 
Strains used in this study are summarized in Table 3.1.  Cells were maintained 
on YPD medium (2% glucose, 1% yeast extract, 2% bactopeptone). Deletion mutants 
were maintained on medium supplemented with G418 (200 µg/ml). Synthetic minimal 
medium without inositol (I-) contained all the essential components of Difco yeast 
nitrogen base (minus inositol), 2% glucose, 0.2% ammonium sulfate, vitamins, the four 
amino acids histidine (20 mg/liter), methionine (20 mg/liter), leucine (60 mg/liter), and 
lysine (20 mg/liter), and the nucleobase uracil (40 mg/liter). Where indicated, inositol (I) 
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was added at a concentration of 75 µM. For selection of plasmids, uracil was omitted. 
Liquid and solid media were supplemented with 0.6 mM and 1 mM VPA, respectively, 
when indicated. Fumonisin B1 (Sigma) and aureobasidin A (Clontech) were used at a 
concentration of 100 µM and 0.5 µg/µl, respectively. For solid media, 2% agar was 
added.  Absorbance was measured at 550 nm to monitor growth in liquid cultures. All 
incubations were at 30°C.  
VPA treatment 
Wild type cells were pre-cultured in synthetic minimal medium with inositol (I+), 
harvested, washed twice with sterile water, and grown in I+ until the cells reached the 
mid log phase (A550= 0.5). Cells were pelleted, washed twice with sterile water and 
inoculated in I+ or I- to a final A550 of 0.05 and cultured until the cells reached the mid 
log phase (A550= 0.5). Cells were then pelleted and suspended in fresh I- or I+ medium 
with or without 0.6 mM VPA and incubated for 5 hours.  
ino1Δ starvation 
ino1Δ cells were pre-cultured in I+, harvested, washed twice with sterile water, 
and grown in I+ until the cells reach mid log phase (A550= 0.5). Cells were pelleted, 
washed twice with sterile water and transferred to fresh I- (inositol starvation) or I+ 
(control) for 3 hours.  
Microarray analysis 
Total RNA was isolated by hot phenol extraction Kohrer and Domdey, 1991) and 
purified using an RNeasy kit from Qiagen. Quality of RNA was determined using Agilent 
2100 Bioanalyzer. RNA was labeled using the Agilent Low Input Quick-Amp labeling kit 
(Agilent Technologies). Cy3 labeled cRNA was then hybridized to the 8x15K Agilent 
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Yeast V2 Arrays (design ID 016322). Slides were scanned on an Agilent G2505B 
microarray scanner and the resulting image files were processed with Agilent Feature 
Extraction software (version 9.5.1). All procedures were carried out according to the 
manufacturer’s protocols. Subsequent analysis was performed using GeneSpring 
(v10.0) software. Microarray analysis was carried out at the Research Technology 
Support Facility in Michigan State University.   
Quantitative real time PCR (qRT-PCR) analysis 
Total RNA was extracted using the hot phenol method Kohrer and Domdey, 
1991) and purified using an RNeasy mini plus kit (Qiagen, Valencia, CA). 
Complementary DNA (cDNA) was synthesized using the first strand cDNA synthesis kit 
from Roche Applied Science as described in the manufacturer's manuals. qRT-PCR 
reactions were done in a 20 µl volume reaction using Brilliant III Ultra-Faster SYBR 
Green qPCR master mix (Agilent Technologies, Santa Clara, CA). Each reaction was 
done in triplicate. The primers used for the qRT-PCR reactions are listed in Table 3.2. 
RNA levels were normalized to ACT1 levels (internal control). Relative values of mRNA 
transcripts are shown as fold change relative to that of the indicated controls. Primers 
were validated as suggested in the Methods and Applications Guide (Agilent 
Technologies). All primers used in this study had primer efficiency between 85 and 
105%. Optimal primer concentrations were determined, and primer specificity of a single 
product was monitored by a melt curve following the amplification reaction. PCR 
reactions were initiated at 95°C for 10 min for denaturation followed by 40 cycles 
consisting of 30 s at 95°C and 60 s at 55°C. 
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Ceramide measurement 
Cells were grown and treated with VPA as described above for 5 hours, pelleted 
and stored at -80°C. Extraction of lipids from yeast pellets and lipid quantification by 
LC/MS/MS was performed as previously described (Brice et al., 2009). 
Western blot 
Cells were broken in the presence of acid-washed glass beads in lysis buffer 
containing 50 mM Tris, 125 mM sodium chloride, 1% Nonidet P-40, 2 mM EDTA, and 
1× protease inhibitor mixture (Roche Applied Science). Extracts were centrifuged twice 
for 5 min at 13,000 × g at 4°C to remove cell debris and glass beads. Protein 
concentration was determined using the Bradford assay (Pierce Protein), with bovine 
serum albumin as the standard protein. Proteins were separated on 10% SDS-PAGE 
and electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). The 
membrane was incubated with antibodies (1:3000 anti-HA; 1:3000 anti-actin; 1:10000 
appropriate secondary antibodies conjugated with HPR) and visualized using ECL Plus 
substrate (Pierce Protein), with α-actin as the loading control.  
β-Galactosidase assays 
Cells expressing the UPRE-LacZ reporter plasmid provided by Dr. Susan Henry  
(Chang et al., 2004) were precultured in Ura-I+, and grown in Ura-I+ to an A550 of 0.5, 
washed and transferred to Ura-I- medium with or without VPA for 5 hours at 30°C. Cells 
were harvested, and β-galactosidase was assayed as described (Fu and Xiao, 2006). 
RESULTS 
VPA increases the expression of fatty acid elongases 
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To determine candidate pathways that may be important for the therapeutic role 
of VPA, we performed a genome-wide microarray analysis of cells treated with 0.6 mM 
VPA for 5 hours in the presence or absence of inositol, as described under ”Material 
and methods” (Chapter 2). VPA treatment resulted in altered expression (>2-fold) of 324 
genes in the presence of inositol and 413 genes in the absence of inositol (Table 2.2). 
Interestingly, fatty acid elongase genes FEN1 and SUR4 exhibited 2-fold increased 
expression in response to VPA (Table 2.2).  qRT-PCR analysis of fatty acid elongase 
genes in  wild type cells treated with VPA validated these findings. As seen in Fig. 3.1, 
mRNA levels of FEN1 and SUR4 were increased 6- and 4-fold in the absence of 
inositol, and to a lesser extent  (3- and 2-fold) in the presence of inositol. Fen1 and Sur4 
catalyze the synthesis of very long chain fatty acids, including C22 and C24 (Fen1), and 
C24 and C26 (Sur4) (Oh et al., 1997), which are used for the synthesis of ceramide. 
Mutants fen1Δ and sur4Δ exhibited sensitivity to VPA, as did the sphinganine C4-
hydroxylase mutant, sur2Δ (Fig. 3.2). VPA sensitivity was partially rescued by inositol.  
The VPA-mediated increase in expression of these genes, and VPA sensitivity of Fen1, 
Sur4, and Sur2 mutants suggested that VPA induces an increase in ceramide 
containing C24-C26 fatty acids and PHS (phytosphingosine) (the product of Sur2). 
VPA increases ceramide levels and downregulates amino acid transporters 
To determine if VPA increases ceramide levels, DHC (dihydroceramide) and 
PHC (phytoceramide) ceramide species were analyzed by mass spectrometry. VPA 
increased PHC levels in wild type cells but did not significantly alter levels of DHC  (Fig. 
3.3). Interestingly, VPA treatment for 30 min upregulated the expression of RSB1 (data  
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Table 3.1. Yeast strains and plasmids used in this study 
Strains/Plasmid Genotype/Description Source/Ref. 
Wild type MATa, his 3Δ1, leu 2Δ0, met 
15Δ0, ura3Δ0 
Invitrogen 
fen1Δ MATa, his 3Δ1, leu 2Δ0, met 
15Δ0, ura 3Δ0, 
fen1Δ::KanMX4 
Invitrogen 
sur4Δ MATa, his 3Δ1, leu 2Δ0, met 
15Δ0, ura 3Δ0, 
sur4Δ::KanMX4 
Invitrogen 
rsb1Δ MATa, his 3Δ1, leu 2Δ0, met 
15Δ0, ura 3Δ0, 
rsb1Δ::KanMX4 
Invitrogen 
ino1Δ MATa, his 3Δ1, leu 2Δ0, met 
15Δ0, ura 3Δ0, 
ino1Δ::KanMX4 
Invitrogen 
RSB1-HA pRS316-RSB1Δ335–382-
3×HA 
Johnson et al., 2010 
UPRE-LacZ pJC104, containing UPRE-
CYC-lacZ 
Chang et al., 2004 
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Table 3.2. Real time PCR primers used in this study 
GENE Primers Sequence (5’ to 3’) 
ACT1 Forward ACGTTCCAGCCTTCTACGTTTCCA 
ACT1 Reverse ACGTGAGTAACACCATCACCGGAA 
FEN1 Forward TGGGTTCAACAACTGCCACCTTTG 
FEN1 Reverse TCATTAACCTTTGCGGCAACACCG 
SUR4 Forward TGTTATGGTACTCAGGCTGCTGCT 
SUR4 Reverse AGTAGAAGAACCGGATGCAACGGA 
RSB1 Forward TTGCCCTCTCCAATGGCGTATTCT 
RSB1 Reverse ACATGATTGCCGGTTGTTGTGGAC 
ELO1 Forward AGAAAGCCTCTAGGTTTCGCCCAA 
ELO1 Reverse AAAGGCTGCTTCCCAACGGTAAAC 
BIO5 Forward GCATCCGGACTACGAGTTAAAG 
BIO5 Reverse GGGCAACGGAGTTGAATAAATG 
AGP1 Forward GAACGATCTTACGTCGGCTATC 
AGP1 Reverse GACCTGTATTAGCGCCTATGTT 
GAP1 Forward GTGACACTCCAGGTGCTAAA 
GAP1 Reverse GCAGCAAGACCAACCAATTC 
BAP2 Forward GAGGATGGCGTTGAGTCTATC 
BAP2 Reverse GTCCCAATACCTGTCCCTAAAG 
DIP5 Forward TCATTTCTTGGGCTGGTTACA 
DIP5 Reverse GGTCCTTCATTCTTCCCTCTTC 
UGA4 Forward TGGTGGTCCAGCAACATTAG 
UGA4 Reverse AGCGGTAGGAATGGAACTTG 
CAN1 Forward GAACGCTGAAGTGAAGAGAGAG 
CAN1 Reverse GTTGGTCAGAGGTGTGGATAAA 
SAM3 Forward GATGTATCTGCCTCTCCCTTTG 
SAM3 Reverse CACAACCGCAACAAGGATAAC 
EUG1 Forward TGGTCAAGTCTATCGCGGTGTCAA 
EUG1 Reverse CATTCAAGCCTGTCAAGCCTCTGT 
JEM1 Forward TGGGACAAGGTGCATCAGAAGGAT 
JEM1 Reverse GCGTTATGCGTAGCAGCTCAGAAA 
KAR2 Forward AAAGATGGGAAGCCCGCTGTAGAA 
KAR2 Reverse ACAGCATGGGTAACCTTAGTGCCT 
LHS1 Forward GCGCGGAAGTGCTTATCCAAACAA 
LHS1 Reverse ACGCAACTCCTGACGAGCACTTAT 
SEC63 Forward AGCAAAGGGCCTAACACCTGATGA 
SEC63 Reverse TGGGCCATCTGGATGACCGTATTT 
PDI1 Forward TGCCATCCACGACATGACTGAAGA 
PDI1 Reverse ACTCCAACACGATCTTGTCGCTCA 
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Figure 3.1. VPA upregulates expression of fatty acid elongase genes.  Wild type 
cells were pre-cultured in I+ medium, harvested, washed twice with sterile water, and 
grown in I+ or I- medium until cells reached the mid log phase (A550= 0.5). Cells were 
pelleted and suspended in fresh I- medium with or without 0.6 mM VPA and incubated 
for 5 hours. mRNA levels of fatty acid elongases were quantified by qRT-PCR in wild 
type cells grown in the presence or absence of VPA. Values are reported as fold 
change in expression in cells grown in VPA relative to cells grown without VPA, in the 
absence (A) or presence of inositol (B). Expression was normalized to the mRNA levels 
of the internal control ACT1. Data shown are mean ± SD (n=6) (*, p < 0.05; **, p < 0.01; 
***, p < 0.001). 
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Figure 3.2. VPA sensitivity of fatty acid elongase and sphinganine C4-hydroxylase 
mutants. Cells were pre-cultured in I+, counted using a hemocytometer, and washed 
with sterile water. 3-µl aliquots of a series of 10-fold dilutions were spotted onto I+ or I− 
plates in the presence or absence of 1 mM VPA and incubated for 3 days at 30°C. 
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 not shown), which transports LCBs, (long chain bases) (including DHS 
(dihydrosphingosine) and PHS (phytosphingosine) across the plasma membrane 
(Kihara and Igarashi, 2002). In wild type cells, upregulation of RSB1 increases the 
transport of LCBs, reducing the intracellular levels of these ceramide precursors. 
Therefore, we measured the effect of VPA on ceramide levels in rsb1Δ cells. VPA 
increased both DHC and PHC in rsb1Δ (Fig. 3.3). Specific ceramide species were 
increased, including DHC with C16, C18:1, C20, C20:1, and C22, and PHC with C16, 
C18, C22, C22:1, C24, C26, C28 in rsb1Δ cells (Table 3.3). The highest increase was 
observed in C26 and C26:1 species of PHC, suggesting that VPA specifically increases 
levels of C26 containing PHC. 
Previous studies have shown that increased levels of ceramide cause a 
decrease in the transcription of nutrient permeases leading to reduced intake of 
nutrients and induction of stress (Guenther et al., 2008; Payet et al., 2013).  Consistent 
with this, the microarray analysis revealed decreased expression of amino acid 
transporter genes BIO5, AGP1, GAP1, BAP2, DIP5, UGA4, CAN1, and SAM3 in 
response to VPA in the absence of inositol. The expression of these transporters was 
not altered in I+ medium (Table 2.2). Decreased expression of amino acid transporters 
was confirmed by qRT-pCR in both wild type and rsb1Δ cells (Fig. 3.4). Downregulation 
was greater in rsb1Δ than in wild type cells, consistent with the increase in ceramide 
levels. To determine if decreased expression of amino acid transporters resulted from 
increased ceramide, cells were treated with 100 µM fumonisin, a ceramide synthase 
inhibitor (Wu et al., 1995; He et al., 2006; Merill et al., 2000). Fumonisin reversed the 
downregulation of the amino acid transporters in both wild type and rsb1Δ cells (Fig. 
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3.4). Taken together, these findings suggest that VPA increases levels of specific 
ceramide species, resulting in decreased expression of nutrient permeases.  
VPA induces the UPR by increasing ceramide levels 
 Decreased expression of nutrient transporters is expected to induce stress due to 
nutrient starvation (Guenther et al., 2008). In agreement with this, VPA increased the 
expression of ER chaperone genes EUG1, JEM1, KAR2, LHS1, SEC63, and PDI1 in I- 
medium (Table 2.2 and Fig. 3.5), suggesting that the UPR pathway was induced. To 
test this, we analyzed the UPR response in wild type and rsb1Δ cells expressing a 
UPRE-lacZ reporter plasmid. Increased lacZ activity was observed in response to VPA 
in I- medium (Fig. 3.6A). The increase was more pronounced in rsb1Δ than in wild type 
cells. Fumonisin restored lacZ activity to normal levels. In contrast, aureobasidin, which 
inhibits the conversion of ceramide to complex sphingolipids, did not affect UPRE 
expression (Fig. 3.6B). Increased UPRE expression was not observed in I+ medium 
(Fig. 3.6C). These findings suggest that VPA induced the UPR pathway via increased 
de novo synthesis of ceramide, and not by inhibiting the conversion of ceramide to 
complex sphingolipids. Consistent with previous reports showing that inositol starvation 
induces the UPR pathway (Cox et al., 1997; Promlek et al., 2011), UPRE expression 
was increased in inositol-starved ino1Δ mutant cells (Fig. 3.7A). Treatment with 
fumonisin decreased UPRE expression to levels observed in control cells, indicating 
that inositol starvation of ino1Δ cells induces the UPR pathway by increasing ceramide 
levels.   
Similar to VPA treatment, ino1Δ cells starved for inositol for 3 hours also 
exhibited decreased expression of amino acid transporter genes BIO5, AGP1, GAP1,  
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Figure 3.3. VPA increases levels of DHC and PHC. Wild type and rsb1Δ cells were 
grown as described in the legend of Fig. 3.1. Cells were pelleted and total DHC and 
PHC levels were quantified by mass spectrometry. Data shown are mean ± SD (n=6 *, p 
< 0.05). 
 
 
 
 
 
	  	  	  
157	  
	  
Figure 3.4. VPA downregulates expression of nutrient transporters via ceramide. 
mRNA levels of nutrient transporters were quantified by qRT-PCR in wild type (A) and 
rsb1Δ  (B)  cells grown in the presence or absence of VPA and fumonisin, as indicated. 
Values are reported as fold change in expression in cells grown in VPA relative to cells 
grown without VPA. Expression was normalized to the mRNA levels of the internal 
control ACT1. Data shown are mean ± SD (n=6) (*, p < 0.05; **, p < 0.01; ***, p < 
0.001). 
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 Table 3.3 A 
 
Wild type rsb1Δ 
Dihydroceramide -VPA +VPA -VPA +VPA 
dhC12-Cer 0.56 ± 0.23 0.82 ± 0.15 0.9 ± 0.15 1.68 ± 0.62 
dhC14-Cer 0.78 ± 0.21 1.74 ± 0.29 1.78 ± 0.34 3.9 ± 1.03 
dhC16-Cer 1.7 ± 0.11 2.48 ± 0.36 2.42 ± 0.43 5.51 ± 0.92 
dhC18-Cer 12.4 ± 1.09 16.61 ± 2.8 23.77 ± 2.19 50.76 ± 3.26 
dhC18:1-Cer 17.25± 0.98 13.73 ± 2.42 22.88 ± 0.25 37.3 ± 2.27 
dhC20-Cer 28.7± 1.48 38.69 ±6.74 56.31 ± 9.72 111.24 ± 9.93 
dhC20:1-Cer 25.04 ± 2.38 18.95 ±3.95 31.54 ± 3.24 55.81 ± 6.74 
dhC22-Cer 1.02 ± 0.04 1.39 ± 0.21 1.61 ± 0.14 3.07 ± 0.32 
dhC22:1-Cer 0.26 ± 0.04 0.31 ±0.09 0.67 ± 0.17 1.15 ± 0.12 
dhC24-Cer 0.3 ± 0.16 0.45 ± 0.05 0.55 ± 0.07 0.84 ± 0.29 
dhC24:1-Cer 0.02 ± 0.01 0.05 ± 0.031 0.05 ± 0.01 0.09 ± 0.05 
dhC26-Cer 0.8 ± 0.18 1.11 ± 0.23 2.01 ± 0.23 2.87 ± 0.37 
dhC26:1-Cer 0 ± 0 0 ± 0 0.03 ± 0.03 0 ± 0 
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Table 3.3 B 
 
Wild type   rsb1Δ 
Phytoceramide -VPA +VPA -VPA +VPA 
PhytoC14-Cer 0 ± 0 0.15 ± 0.079 0.47 ± 0.12 0.79 ± 0.03 
PhytoC16-Cer 1.76 ± 0.07 5.67 ± 1.63 5.05 ± 1.5 18.75 ± 4.24 
PhytoC18-Cer 0.14 ± 0.14 0.81 ± 0.5 1.24 ± 0.43 5.45 ± 1.2 
PhytoC18:1-Cer 0 ± 0 0.56 ± 0.33 0.44 ± 0.22 1.23 ±  0.48 
PhytoC20-Cer 0.43 ± 0.22 0.93 ± 0.31 0.27 ± 0.19 1.09 ± 0.39 
PhytoC20:1-Cer 0.83 ± 0.36 2.12 ± 0.95 1.31 ± 0.38 3.03 ± 1.25 
PhytoC22-Cer 0.66 ± 0.34 1.29 ± 0.44 0.36 ± 0.2 1.55 ± 0.33 
PhytoC22:1-Cer 0.92 ± 0.49 0.62 ± 0.33 1.28 ± 0.61 0.63 ± 0.63 
PhytoC24-Cer 1.32 ± 0.32 1.56 ± 0.71 1.24 ± 0.4 3.45 ± 0.43 
PhytoC24:1-Cer 0 ± 0 0.7 ± 0.5 0.84 ± 0.71 2.64 ± 1.03 
PhytoC26-Cer 19.63 ± 0.86 36.52 ± 11.65 70.66 ± 14.26 139.67 ± 19.08 
PhytoC26:1-Cer 9.16 ± 1.45 17.75 ± 8.32 38.5 ± 5.25 87.27 ± 16.92 
PhytoC28-Cer 6.55 ± 1.22 10.29 ± 3.06 12.63 ± 4.82 39.36 ± 6.36 
PhytoC28:1-Cer 0.25 ± 0.25 0.8 ± 0.63 0.14 ± 0.14 0.84 ± 0.42 
 
Table 3.3. VPA increases C24-C26 ceramide species. Wild type and rsb1Δ cells were 
grown as described in the legend of Fig. 3.1. Cells were pelleted and DHC (A) and PHC 
(B) species with the indicated fatty acids were quantified by mass spectrometry. Data 
shown are mean ± SD (n=6). 
 
 
 
 
 
	  	  	  
160	  
	  
 
Figure 3.5. VPA increases expression of ER chaperones.  Wild type cells were 
grown as described in Fig. 3.1. mRNA levels of chaperone genes were quantified by 
qRT-PCR in wild type cells grown in I- medium in the presence or absence of VPA. 
Values are reported as fold change in expression in cells grown in VPA relative to cells 
grown without VPA. Expression was normalized to the mRNA levels of the internal 
control ACT1. Data shown are mean ± SD (n=6). (*, p < 0.05; **, p < 0.01; ***,p < 
0.001). 
 
 
 
 
	  	  	  
161	  
	  
  
Figure 3.6. VPA upregulates UPRE expression. Wild type and rsb1Δ cells expressing 
a UPRE-lacZ plasmid were pre-cultured in Ura-I+ medium and then grown in (A,B) Ura-
I- medium  with or without 100 µM fumonisin or 0.5 µg/µl aureobasidin; or (C) Ura-I+ 
medium.  0.6 mM VPA was added when indicated. LacZ activity is quantified as 
indicated. Data shown are mean ± SD (n=6) (*, p < 0.05; **, p < 0.01). 
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BAP2, DIP5, UGA4, CAN1, and SAM3 (Fig. 3.7B). This decrease was partialy ceramide 
dependent, as it was blocked by fumonisin. Decreased expression of amino acid 
transporter genes BAP2, GAP1 and UGA4 was partially rescued by fumonisin (Fig. 
3.7B), suggesting that inositol depletion decreased the expression of amino acid 
transporter genes, at least in part, by increasing ceramide levels.  To directly test the 
hypothesis that inositol depletion decreased the expression of amino acid transporters 
and induced the UPR by increasing the intracellular ceramide levels, ino1Δ cells were 
starved for 3 hours and ceramide levels were quantified (Table 3.4). Inositol starvation 
increased levels of total DHC and PHC (Fig. 3.7C). Most notable were increases in 
DHC with C20 and PHC with C24, C26, and C26:1 (Table 3.4). The highest increase 
was observed in C26 and C26:1 species of PHC, similar to the response to VPA (Table 
3.3). Expression of fatty acid elongases FEN1 and SUR4 was also increased during 
inositol starvation (Fig. 3.7D). Taken together our findings indicate that inositol depletion 
mediated by VPA or by starvation of ino1Δ cells led to increased expression of fatty acid 
elongases (elongating C24-C26), resulting in increasing ceramide levels with C24-C26 
fatty acids. Increased ceramide synthesis led to downregulation of transporters and 
induction of the UPR pathway. These findings are the first to show that VPA mediated 
inositol depletion induces the UPR by increasing ceramide levels. 
DISCUSSION 
In this study, we show that VPA induces the UPR by increasing ceramide levels 
via inositol depletion. Our specific findings indicated that VPA: 1) increased expression 
of fatty acid elongases synthesizing C24 and C26 fatty acids; 2) increased ceramide  
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Table 3. 4 A 
Dihydroceramide ino1Δ I+ ino1Δ I- 
dhC12-Cer 1.08±0.02 0.92±0.28 
dhC14-Cer 2.40±0.34 2.10±1.08 
dhC16-Cer 2.07±0.40 1.72±0.02 
dhC18-Cer 4.15±0.36 6.99±0.24 
dhC18:1-Cer 2.85±0.27 3.51±0.16 
dhC20-Cer 7.32±1.16 15.21±0.93 
dhC20:1-Cer 4.14±0.47 4.69±0.39 
dhC22-Cer 0.20±0.06 0.33±0.14 
dhC22:1-Cer 0.05±0.01 0.064±0.02 
dhC24-Cer 0.26±0.11 0.28±0.16 
dhC24:1-Cer 0.04±0.03 0.046±0.01 
dhC26-Cer 0.62±0.28 0.80±0.36 
dhC26:1-Cer 0.03±0.02 0.02±0.008 
 
 
Table 3.4 B 
 
Phytoceramide ino1Δ I+ ino1Δ I- 
PhytoC14-Cer 0.11±0 0.23±0 
PhytoC16-Cer 0.61±0.13 1.2±0.24 
PhytoC18-Cer 0.09±0.05 0.11±0.10 
PhytoC18:1-Cer 5.66±3.52 3.52±1.26 
PhytoC20-Cer 0.26±0.14 0.85±1.13 
PhytoC20:1-Cer 6.92±4.7 5.27±2.70 
PhytoC22-Cer 0±0 0.02±0.01 
PhytoC22:1-Cer 0.04±0 0.07±0.05 
PhytoC24-Cer 0.086±0.06 0.1±0.02 
PhytoC24:1-Cer 0.25±0.11 1.19±0.13 
PhytoC26-Cer 4.39±0.77 8.41±1.51 
PhytoC26:1-Cer 9.76±3.01 26.76±2.54 
PhytoC28-Cer 0.01±0 0±0 
PhytoC28:1-Cer 0.18±0 0±0 
 
Table 3.4.  Inositol depletion increases levels of ceramide species. ino1Δ cells 
were starved for inositol as described in materials and methods. Levels of DHC (A) and 
PHC (B) species were quantified by mass spectrometry. 
 
	  	  	  
164	  
	  
 
 
Figure 3.7. VPA induces the UPR by inositol depletion. ino1Δ cells expressing the 
UPRE-lacZ reporter plasmid were pre-cultured and grown in Ura-I+ medium until the 
cells reached mid log phase (A550= 0.5). Cells were washed and transferred to Ura-I- 
medium with or without 100 µM fumonisin for 3 hours. (A) LacZ activity. Data shown are 
mean ± SD (n=6) (*, p < 0.05; **, p < 0.01; ***,p < 0.001). (B) Total DHC and PHC levels 
were quantified by mass spectrometry. Data shown are mean ± SD (n=6) (*, p < 0.05; 
**, p < 0.01; ***,p < 0.001). mRNA levels of nutrient transporters (C) and fatty acid 
elongases (D) were quantified by qRT-PCR as indicated. Values are reported as fold 
change in expression in cells grown in I- medium relative to cells grown in I+ medium. 
Expression was normalized to the mRNA levels of the internal control ACT1. Data 
shown are mean ± SD (n=6) (*, p < 0.05; **, p < 0.01; ***,p < 0.001). 
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levels, particularly PHC with C24 and C26 fatty acids; 3) decreased the expression of 
amino acid transporters; and 4) induced the UPR pathway. These outcomes were 
abrogated atleast partially by inhibition of de novo ceramide synthesis or by 
supplementation of inositol.  Ceramide can be synthesized via two pathways, de novo 
synthesis by ceramide synthase or breakdown of complex sphingolipids by inositol 
phosphosphingolipid phospholipase C. Our findings suggest that VPA induces the UPR 
pathway by increasing de novo synthesis of ceramide (Fig. 3.6) as a result of increased 
expression of fatty acid elongases, as induction did not occur in the presence of the 
ceramide synthase inhibitor fumonisin (He et al., 2006; Merill et al., 2000). In contrast, 
aureobasidin, which inhibits inositol phosphorylceramide synthase, did not affect VPA-
mediated induction of the UPR (Fig. 3.6C). Our findings are consistent with studies 
showing that inositol starvation induces the UPR. UPR target genes were found to be 
significantly upregulated in cells grown in the absence of inositol Jesch et al., 2005). In 
addition, inositol supplementation alters the expression of UPR pathway genes (Jesch 
et al., 2006).  Although initial studies showed that accumulation of unfolded proteins in 
the ER induces the UPR pathway (Cox et al., 1993; Nikawa et al., 1996; Nikawa and 
Yamashita, 1992; Sidrauski et al., 1996, Villa-Garcia et al., 2011),  it was since 
determined that Ire1p, the transmembrane kinase that senses ER stress (Cox and 
Walter, 1996; Mori et al., 2000), induces the UPR pathway in response to changes in 
membrane lipid composition (Cox and Walter, 1996; Mori et al., 2000). In this light, 
inositol starvation may trigger the UPR as a result of lipid related membrane changes in 
the ER, including perturbation of sphingolipid metabolism. The addition of inositol 
induces changes in the synthesis and levels of numerous lipids, including sphingolipids  
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Figure 3.8. Model: VPA induces the UPR pathway by increasing intracellular 
ceramide levels. In the proposed model, VPA mediated inositol depletion leads to 
increased expression of fatty acid elongases and ceramide levels, especially PHC 
containing C24-C26 fatty acids. Increased ceramide levels decrease expression of 
nutrient transporters, stressing the cell due to lack of nutrients and inducing the UPR 
pathway. 
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(Alvarez-Vasquez et al., 2005; Jesch et al., 2010). Recent studies show that 
perturbation of sphingolipid metabolism may affect ER membrane homeostasis. Mutant 
cells lacking ORM1 and ORM2, negative regulators of sphingolipid metabolism (Breslow 
et al., 2010; Han et al., 2010), exhibit constitutive induction of the UPR response (Han 
et al., 2010). In addition, orm1Δ orm2Δ cells contain elevated levels of sphingolipids 
(Breslow et al., 2010; Han et al., 2010) and are hypersensitive to stress induced by 
inositol starvation (Han et al., 2010). Similarly, UPR expression is constitutive in isc1Δ 
mutant cells, which contain elevated sphingolipids due to a block in sphingolipid 
turnover (Sawai et al., 2000; Gururaj et al., 2013). Conversely, inhibiting sphingolipid 
synthesis with myriocin treatment suppresses activation of the UPR induced by inositol 
starvation (Promlek et al., 2011). Elevated sphingolipids in the ER may lead to 
membrane aberrancy that activates the UPR pathway independent of accumulation of 
unfolded protein. The role of specific sphingolipids in activation of the UPR is not 
known. Our study suggests that accumulation of ceramide, specifically C24-C26 
containing PHC, induces the UPR upon inositol depletion. 
 We have previously shown that VPA decreases intracellular inositol levels 
(Shaltiel et al., 2004; Vaden et al., 2001; Ye and Greenberg, 2015; Ju et al., 2004).  VPA 
induction of the UPR occurred only in I- conditions, suggesting that the response to VPA 
was mediated by inositol depletion. Consistent with this, inositol starvation of ino1Δ cells 
caused similar effects, including increased expression of fatty acid elongases, increased 
intracellular levels of ceramides, especially PHC with C24 and C26, downregulation of 
nutrient transporters, and induction of the UPR. Based on these data, we propose the 
following model (Fig. 3.8). VPA decreases intracellular inositol levels causing an 
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increase in C24 and C26 PHC species as a result of upregulation of expression of fatty 
acid elongases (FEN1 and SUR4).  This results in increased ceramide synthesis, which 
causes downregulation of expression of nutrient transporters, inducing stress and the 
UPR.  
 Several studies suggest that the UPR pathway may be involved in the 
pathophysiology of BD. Lymphoblasts from bipolar patients show an aberrant ER stress 
response (Hayashi et al., 2009; So et al., 2007). Compared to cells from healthy controls, 
lymphoblasts from bipolar patients had lower expression of XBP1 (mammalian 
homologue of yeast HAC1), the spliced form of which binds the UPRE element and 
induces the UPR pathway in response to ER stress inducers (So et al., 2007). A 
polymorphism (–116CàG) in the XBP1 promoter that is associated with lower gene 
transcription was observed in BD lymphoblastoid cells (Kakiuchi et al., 2003). These 
findings suggest that the UPR pathway may be perturbed in bipolar patients, and 
activation of this pathway may be important for the therapeutic action of VPA. In this 
light, the UPR pathway may be a possible new target for BD therapy. 
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CHAPTER 4 ACUTE VALPROIC ACID TREATMENT INCREASES LEVELS OF 
PHYTOSPHINGOSINE VIA INOSITOL DEPLETION 
 
INTRODUCTION 
Valproic acid (VPA) is one of the most widely used drugs for the treatment of 
bipolar disorder (BD). Several targets are hypothesized to be important for the 
therapeutic action of VPA; however, the mechanism of action is not understood (Gould 
et al., 2004). Inositol depletion is one of the major hypotheses of the therapeutic action 
of VPA. Sir Michael Berridge first proposed the inositol depletion hypothesis in 1989, 
based on the finding that the antibipolar drug, lithium, causes inositol depletion by 
inhibiting inositol monophosphatase (IMPase) (Berridge, 1989). This was hypothesized 
to result in decreased levels of inositol, an increase in inositol phosphates, and 
subsequent downregulation of the phosphoinositide cycle.  
Although many studies showed that antibipolar drugs lead to inositol depletion, 
this hypothesis was not universally accepted (Jope, 1999; Ikonomov et al., 1999; 
Agranoff and Fisher, 2001). Several findings argue against this hypothesis. First, 
although lithium depletes inositol with acute treatment, the therapeutic effects of the 
drug are observed with chronic administration (Pollack et al., 1994; Moore et al., 1999). 
However, this does not completely oppose the hypothesis, as acute inositol depletion 
could activate downstream signaling pathways important for the therapeutic efficacy.  
Second, studies show that lithium does not deplete inositol in the temporal lobe of 
human brain (Moore et al., 1999). Third, disruption of the sodium-dependent inositol 
transporter (SMIT1), which decreases intracellular inositol levels, in mice, does not 
mimic the effects of lithium (Shaldubina et al., 2001; Shaldubina et al., 2007). Finally, it 
remains unclear how inositol depletion could treat mania and depression, two opposing 
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phases of BD. To this end, Cheng et al, have shown that VPA inhibits prolyl 
oligopeptidase enzyme activity (Cheng et al., 2005), which enhances PI signaling and 
mimics the effect of addition of exogenous inositol (Willams et al., 2002). Based on this, 
they proposed a model for the dual action of VPA. According to their proposed model, 
VPA inhibits de novo synthesis of inositol, depleting intracellular inositol, which 
stabilizes mood in the manic phase, whereas, during the depressive phase it inhibits 
prolyl oligopeptidase enzyme activity, leading to enhancement of the PI cycle (Cheng et 
al., 2005).  In summary, while many studies support inositol depletion as a therapeutic 
mechanism of action, conflicting reports challenge the significance of inositol depletion 
in the therapeutic action of BD. 
Interestingly, VPA decreases intracellular inositol levels in yeast and mammalian 
cells, although not by inhibiting IMPase (Vaden et al., 2001; Shaltiel et al., 2004; Ye and 
Greenberg, 2015). Actually, VPA indirectly inhibits the enzyme catalyzing the de 
novo synthesis of inositol, myo-inositol-3-phosphate synthase (MIPS). This suggests 
that MIPS is post-translationally regulated in response to the drug (Ju et al., 2004). 
More recent findings show that yeast and human MIPS are regulated by 
phosphorylation (Deranieh et al., 2013). The finding that lithium and VPA, two 
structurally dissimilar drugs, cause inositol depletion, albeit by affecting different 
enzymes, suggests that inositol depletion may be important for the therapeutic 
mechanism of action.  
In yeast, a decrease in intracellular inositol leads to a subsequent increase in the 
expression of INO1, which codes for MIPS (Hirsch and Henry, 1986; Henry et al., 2014).  
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Figure 4.1 Sphingolipid metabolism in yeast. Serine is condensed with palmitoyl-
CoA by serine palmitoyl transferase (SPT) to form 3-ketodihydrosphingosine, which is 
reduced to DHS. Orm1 and Orm2 negatively regulate SPT enzyme activity. DHS is 
hydroxylated on C-4 to produce PHS. Ceramide synthase catalyzes the linkage of very 
long chain fatty acids produced by fatty acid elongases to long chain bases (LCBs) DHS 
and PHS to form ceramide. DHS and PHS are also phosphorylated to DHS-1P and 
PHS-1P. Rsb1 and Yor1 transport LCBs and LCBPs, respectively, across the plasma 
membrane.  DHS-1P and PHS-1P are metabolized by Dpl1 to generate ethanolamine 
phosphate and fatty aldehydes. (Abbreviations: SPT, Serine palmitoyl transferase; DHS, 
Dihydrosphingosine; PHS, Phytosphingosine; DHS-1P, Dihydrosphingosine-1-
phosphate PHS-1P, Phytosphingosine-1-phosphate; LCB, Long chain base; LCBP, 
Long chainbase-1-phosphate)  
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Consistent with this finding, VPA causes a decrease in intracellular inositol and 
an increase in INO1 expression (Vaden et al., 2001). Inositol depletion is apparent with 
acute VPA treatment (30 minutes - 1 hour) and continues to decrease (Ju and 
Greenberg, 2003). However, the normal response of UASINO-containing genes (target of 
Ino2-Ino4) to inositol depletion is abrogated with acute VPA, as expression of INO1, 
INO2 and CHO1 decreases with acute VPA even though inositol depletion is apparent 
(Ju and Greenberg, 2003). Conversely, chronic VPA increases the expression of 
UASINO-containing genes. These results suggest that VPA exerts differential acute and 
chronic responses.  
Studies in this chapter focus on the acute response to VPA. In order to determine 
the acute effect of VPA on gene expression, I performed a genome wide microarray 
analysis (Chapter 2). In this study, I identified sphingolipid metabolism as a pathway 
that showed altered expression in response to VPA. RSB1, the transporter of long chain 
bases (LCBs), which are sphingolipid precursors, exhibited the highest upregulation in 
response to acute VPA.   
Sphingolipids play a structural role in cell membranes (Obeid et al., 2002), and 
also act as second messengers in signaling pathways (Dickson et al., 1998). 
Sphingolipid synthesis (Fig. 4.1) begins in the endoplasmic reticulum with the 
condensation of L-serine with palmitoyl-CoA, catalyzed by serine palmitoyl transferase 
(SPT), to produce 3-ketodihydrosphingosine (KDHS), which is reduced to 
dihyrdrosphingosine (DHS) (Gable et al., 2002; Hanada, 2003; Lowther et al., 2012; 
Dickson 2008; Beeler et al., 1998; Kihara and Igarashi 2004). Orm1 and Orm2 are 
negative regulators that physically interact and inhibit serine palmitoyltransferase (SPT) 
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(Han et al., 2010; Breslow et al., 2010). Phytosphingosine (PHS) is synthesized in yeast 
via hydroxylation of C-4 of DHS, catalyzed by sphinganine C4-hydroxylase (Dickson, 
2008). DHS and PHS are the two LCBs in yeast. Very long chain fatty acids synthesized 
by fatty acid elongases are linked to LCBs via an amide linkage at the C-2 position to 
form ceramide by ceramide synthase (Dickson 2008). LCBs are also phosphorylated by 
sphingolipid base kinases (Lcb4 and Lcb5) to DHS-1P and PHS-1P (Nagiec et al., 
1998). Rsb1 and Yor1 transport LCBs and LCBPs, respectively, across the plasma 
membrane, which maintains normal intracellular levels of these metabolites (Kihara and 
Igarashi 2002; Boujaoude et al., 2001).  DHS-1P and PHS-1P are cleaved by the 
sphingolipid lyase, Dpl1, to generate ethanolamine phosphate and fatty aldehydes 
(Saba et al., 1997). 
There are no published studies to date indicating that VPA affects sphingolipids. 
The current study shows for the first time that acute VPA-mediated inositol depletion 
decreases levels of Orm proteins, inhibitors of de novo synthesis of LCBs and fatty acid 
elongases, thereby increasing intracellular PHS levels.   
MATERIALS AND METHODS 
Yeast strains, growth medium and conditions  
Strains used in this study are summarized in Table 4.1.  Cells were maintained 
on YPD medium (2% glucose, 1% yeast extract, 2% bactopeptone). Deletion mutants 
were maintained on medium supplemented with G418 (200 µg/ml). Synthetic minimal 
medium without inositol (I-) contained all the essential components of Difco yeast 
nitrogen base (minus inositol), 2% glucose, 0.2% ammonium sulfate, vitamins, the four 
amino acids histidine (20 mg/liter), methionine (20 mg/liter), leucine (60 mg/liter), and 
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lysine (20 mg/liter), and the nucleobase uracil (40 mg/liter). Where indicated, inositol (I) 
was added at a concentration of 75 µM. For selection of plasmids, uracil was omitted. 
Liquid and solid medium were supplemented with 0.6 mM and 1 mM VPA, respectively, 
when indicated. For solid media, 2% agar was added.  Absorbance was measured at 
550 nm to monitor growth in liquid cultures. All incubations were at 30°C.  
VPA treatment 
Wild type cells were precultured in synthetic minimal medium with inositol (I+), 
harvested, washed twice with sterile water, and grown in I+ until the cells reached the 
mid log phase (A550= 0.5). Cells were pelleted, washed twice with sterile water and 
inoculated in I+ or I- to a final A550 of 0.05 and cultured until the cells reached the mid 
log phase (A550= 0.5). Cells were then pelleted and suspended in fresh I- or I+ medium 
with or without 0.6 mM VPA and incubated for 30 minutes.  
ino1Δ starvation 
ino1Δ cells were precultured in I+ medium, harvested, washed twice with sterile 
water, and grown in I+ until the cells reached the mid log phase (A550= 0.5). Cells were 
pelleted, washed twice with sterile water and cultivated in fresh I- (inositol starvation) or 
I+ (control) for 30 minutes.  
Microarray analysis 
Total RNA was isolated by hot phenol extraction (Kohrer and Domdey, 1991) and 
purified using an RNeasy kit from Qiagen. Quality of RNA was determined using Agilent 
2100 Bioanalyzer. RNA was labeled using the Agilent Low Input Quick-Amp labeling kit 
(Agilent Technologies). Cy3 labeled cRNA was then hybridized to the 8x15K Agilent 
Yeast V2 Arrays (design ID 016322). Slides were scanned on an Agilent G2505B 
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microarray scanner and the resulting image files were processed with Agilent Feature 
Extraction software (version 9.5.1). All procedures were carried out according to the 
manufacturer’s protocols. Subsequent analysis was performed using GeneSpring 
(v10.0) software. Microarray analysis was carried out at the Research Technology 
Support Facility in Michigan State University.   
Quantitative real time PCR (qRT-PCR) analysis 
Total RNA was extracted using the hot phenol method (Kohrer and Domdey, 
1991) and purified using an RNeasy mini plus kit (Qiagen, Valencia, CA). 
Complementary DNA (cDNA) was synthesized using the first strand cDNA synthesis kit 
from Roche Applied Science as described in the manufacturer's manuals. qRT-PCR 
reactions were done in a 20 µl volume reaction using Brilliant III Ultra-Faster SYBR 
Green qPCR master mix (Agilent Technologies, Santa Clara, CA). Each reaction was 
done in triplicate. The primers used for the qRT-PCR reactions are listed in Table 4.2. 
RNA levels were normalized to ACT1 levels (internal control). Relative values of mRNA 
transcripts are shown as fold change relative to that of the indicated controls. Primers 
were validated as suggested in the Methods and Applications Guide (Agilent 
Technologies). All primers used in this study had primer efficiency between 85 and 
105%. Optimal primer concentrations were determined, and primer specificity of a single 
product was monitored by a melt curve following the amplification reaction. PCR 
reactions were initiated at 95°C for 10 minutes for denaturation followed by 40 cycles 
consisting of 30 s at 95°C and 60 s at 55°C. 
Long chain base measurement 
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Cells were grown and treated with VPA as mentioned in the above section for 30 
minutes, pelleted and stored at -80°C. Extraction of lipids from yeast pellets and lipid 
quantification by LC/MS/MS was performed as previously described (Brice et al., 2009). 
LC/MS/MS experiments were performed by Dr. Ashley Cowart, Medical University of 
South Carolina.  
Western blot 
Cells were broken in the presence of acid-washed glass beads in lysis buffer containing 
50 mM Tris, 125 mM sodium chloride, 1% Nonidet P-40, 2 mM EDTA, and 1× protease 
inhibitor mixture (Roche Applied Science). Extracts were centrifuged twice for 5 minutes 
at 13,000 × g at 4°C to remove cell debris and glass beads. Protein concentration was 
determined using the Bradford assay (Pierce Protein), with bovine serum albumin as the 
standard protein. Proteins were separated on 10% SDS-PAGE and electrotransferred to 
a polyvinylidene difluoride (PVDF) membrane (Millipore). The membrane was incubated 
with antibodies (1:3000 anti-HA; 1:3000 anti-actin; 1:10000 appropriate secondary 
antibodies conjugated with HPR) and visualized using ECL Plus substrate (Pierce 
Protein), with α-actin as the loading control.  
RESULTS 
Acute VPA increases the expression of RSB1  
In order to identify pathways that are affected by acute VPA treatment, I carried 
out a genome wide microarray study of cells treated with 0.6 mM VPA for 30 minutes in 
the presence or absence of inositol (Chapter 2). After acute VPA treatment, 592 genes 
exhibited more than two-fold change in gene expression when grown in the absence of 
inositol and 542 genes in the presence of inositol, as summarized in Table 2.1. VPA  
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Table 4.1. Yeast strains and plasmids used in this study 
Strains/Plasmid Genotype/Description Source/Ref. 
Wild type MATa, his 3Δ1, leu 2Δ0, met 15Δ0, 
ura3Δ0 
 
Invitrogen 
rsb1Δ MATa, his 3Δ1, leu 2Δ0, met 15Δ0, 
ura 3Δ0, rsb1Δ::KanMX4 
 
Invitrogen 
ino1Δ MATa, his 3Δ1, leu 2Δ0, met 15Δ0, 
ura 3Δ0, ino1Δ::KanMX4 
 
Invitrogen 
3xFlag-Orm1 / 
3xHA-Orm2 
 
BY4741; 3xFlag-ORM13xHA-ORM2 
 
Breslow et al., 2010  
 
3xFlag-Orm2 / 
3xHA-Orm1 
 
BY4741; 3xFlag-ORM2 3xHA-
ORM1 
 
Breslow et al., 2010  
 
RSB1-HA pRS316-RSB1Δ335–382-3XHA Johnson et al., 2010 
pRS316 pRS316 Johnson et al., 2010 
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Table 4.2. Real time PCR primers used in this study 
GENE Primers Sequence (5’ to 3’) 
ACT1 Forward ACGTTCCAGCCTTCTACGTTTCCA 
ACT1 Reverse ACGTGAGTAACACCATCACCGGAA 
FEN1 Forward TGGGTTCAACAACTGCCACCTTTG 
FEN1 Reverse TCATTAACCTTTGCGGCAACACCG 
SUR4 Forward TGTTATGGTACTCAGGCTGCTGCT 
SUR4 Reverse AGTAGAAGAACCGGATGCAACGGA 
RSB1 Forward TTGCCCTCTCCAATGGCGTATTCT  
RSB1 Reverse ACATGATTGCCGGTTGTTGTGGAC 
ELO1 Forward AGAAAGCCTCTAGGTTTCGCCCAA 
ELO1 Reverse AAAGGCTGCTTCCCAACGGTAAAC 
YOR1 Forward TCTCCCAAGGCATCTGCTTCTTCA  
YOR1 Reverse TGCACACCAGTCAGTTGGGATGTA  
DPL1 Forward TTGTCGTAGGTTGTTGGGCCACTA 
DPL1 Reverse  TTGCTGCACCGACTATTTCTTGGC 
ORM1 Forward GGCGTTCTTCCAGCATAATTTC 
ORM1 Reverse TTGGTCTACCCAAGTAGCATTC 
ORM2 Forward GACGGTCATCCAGCGTAATATC 
ORM2 Reverse CCCACGTAGCGTTCATGTT 
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treatment perturbed sphingolipid metabolism genes, as shown in Table 2.1. 
Interestingly, RSB1 exhibited the highest upregulation in response to VPA, showing 
158-fold and 108-fold upregulation in I- and I+ medium, respectively. qRT-PCR analysis 
of RSB1 in wild type cells treated with VPA confirmed the increased expression, as 
mRNA levels of RSB1 were increased 47-fold in I- (Fig. 4.2A), and 13-fold in I+ medium 
(Fig. 4.2B). The greater increase in I- than in I+ medium suggests that the induction was 
at least partially a response to inositol limitation. To determine if increased RNA levels 
resulted in increased protein, wild type cells harboring a plasmid expressing the RSB1 
gene, a transporter of LCBs with an HA tag were treated with VPA. Similar to the mRNA 
increase, Rsb1 protein levels were increased to a greater extent in I- than I+ (Fig. 4.2 
C). Increased intracellular levels of LCBs are toxic to yeast cells, which respond by 
inducing Rsb1 (Kihara and Igarashi, 2002). Increased levels of Rsb1 suggest that VPA 
increases intracellular levels of LCBs.  
Acute VPA increases PHS levels 
Increased intracellular levels of LCBs are expected to increase sensitivity to 
added PHS. To determine if VPA increases the sensitivity to PHS, wild type and rsb1Δ 
cells expressing a plasmid containing RSB1 or empty vector were grown in the 
presence or absence of VPA and plated on synthetic medium with or without 20 µM 
PHS. Wild type cells did not exhibit sensitivity to PHS in the presence of VPA, 
suggesting that Rsb1 maintains sub-toxic levels of PHS. However, VPA caused an 
increase in sensitivity of rsb1Δ cells to PHS, which was rescued by overexpression of 
RSB1 (Fig. 4.3). These findings are consistent with increased intracellular levels of PHS 
in VPA treated cells.  
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In order to directly determine if VPA increases the levels of LCBs, I measured 
LCBs and LCBPs in cells treated with VPA using mass spectrometry. Wild type cells 
showed a slight increase in PHS levels in response to VPA (Fig. 4.4A), and rsb1Δ cells 
exhibited an increase in PHS and PHS-1P. DHS-1P levels were decreased in rsb1Δ 
cells (Fig. 4.4B). These findings showed that levels of PHS increase in response to 
acute VPA, suggesting that VPA may increase de novo synthesis of PHS. 
Acute VPA increases the expression of genes that aid in maintaining sub-toxic 
PHS levels 
Acute VPA led to a small increase in PHS levels relative to the increase in Rsb1 
levels. In addition to exporting LCBs by Rsb1, cells maintain low levels of LCBs by 
metabolizing them to other species and transporting them across the plasma 
membrane. Thus, as mentioned in the Introduction, LCBs are phosphorylated to LCBPs 
(DHS-1P and PHS-1P) by sphingolipid base kinases (Nagiec et al., 1998). LCBPs are 
cleaved by a lyase encoded by Dpl1 to generate fatty aldehyde and ethanolamine 
phosphate (Saba et al., 1997). Yor1, a transporter protein that belongs to the ATP 
binding cassette family, transports LCBPs across the plasma membrane (Fig. 4.1). 
Interestingly, VPA increased expression of YOR1 and DPL1 by 11-fold and 6-fold, 
respectively in I-. In the presence of inositol, the increase in expression was somewhat 
less, 6-fold and 3-fold in YOR1 and DPL1, respectively (Fig. 4.5). This suggests that 
VPA induces expression of YOR1 and DPL1 in response to increased levels of LCBs to 
maintain low PHS levels. 
VPA decreases ORMs and fatty acid elongases  
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 Orm proteins negatively regulate LCB synthesis by physically interacting with 
and inhibiting SPT (Fig.4.1) (Han et al., 2010; Breslow et al., 2010). Phosphorylation of 
Orm proteins inhibits their association with SPT and increases the de novo synthesis of 
LCBs (Liu et al., 2012; Roelants et al., 2011). VPA decreased the expression of ORM1 
and ORM2 in I-, and to a lesser extent in I+  (Fig. 4.6).  In addition, VPA decreased the 
protein levels of Orm2 in I- (Fig. 4.6 C).  
 In addition to Orm negative regulators, LCB levels are also controlled by Fen1 
and Sur4, which catalyze the synthesis of very long chain fatty acids of C24-C26 (Oh et 
al., 1997). Mutants of these fatty acid elongases (fen1Δ and sur4Δ) accumulate LCBs 
(Oh et al., 1997).   As stated earlier (Chapter 3), fen1Δ and sur4Δ mutants exhibited 
VPA sensitivity. Here I showed that acute VPA downregulated the expression of FEN1 
and SUR4 in I- medium, and to a lesser extent also in I+ (Fig. 4.7). Fatty acid elongases 
catalyze the synthesis of fatty acids that are linked to an LCB by ceramide synthase to 
synthesize ceramide. Downregulation of the fatty acid elongases by VPA may account 
for the observed increase in PHS (Fig. 4.4) as a result of decreased fatty acids required 
for ceramide synthesis. These results suggest that acute VPA decreases ORM levels 
and fatty acid elongases, which lead to an increase in PHS levels.  
Inositol depletion downregulates the expression of ORM and fatty acid elongase 
genes and upregulates PHS and PHS-1P transporters 
 VPA affects the expression of sphingolipid metabolism genes to a greater extent 
in I- compared to I+, suggesting that VPA exerts effects on sphingolipid metabolism via 
inositol depletion. To test the effects of inositol depletion on sphingolipid gene 
expression, ino1Δ cells were cultured in I+ media, transferred to I- media for 30 minutes, 
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and gene expression was quantified. Acute inositol starvation of ino1Δ cells decreased 
expression of fatty acid elongases (FEN1 and SUR4) and Orm genes (ORM1 and 
ORM2) (Fig. 4.7). In addition, inositol starvation of ino1Δ cells increased expression of 
RSB1 and YOR1. These results suggest that the effects of VPA on sphingolipid 
metabolism genes can be explained by inositol depletion.  
DISCUSSION 
This study shows that acute VPA increases de novo synthesis of PHS by inositol 
depletion. Our specific findings indicated that acute VPA: 1) decreased expression of 
ORM and fatty acid elongase genes, 2) increased levels of PHS, and 3) increased 
expression of genes that transport (RSB1, YOR1) and metabolize (DPL1) PHS. These 
outcomes were partially dependent on supplementation of inositol.  
My findings are consistent with studies showing that cells lacking ORM1 and 
ORM2 exhibit increased levels of the LCB, PHS and Rsb1 protein (Han et al., 2010). A 
greater increase in PHS levels in the rsb1Δ mutant compared to wild type (Fig. 4.3), and 
rescue of this phenotype by overexpression of RSB1 (Fig. 4.2), further support a 
mechanism whereby VPA increases PHS levels and induces RSB1 by decreasing ORM 
expression. Mutants of fatty acid elongases fen1Δ and sur4Δ are known to accumulate 
high levels of PHS (Oh et al., 1997). Decreased expression of FEN1 and SUR4 in VPA 
treated cells is also consistent with increased PHS levels. In summary, acute VPA 
increases PHS levels by downregulation of two key regulators of PHS, ORM and fatty 
acid elongase genes.  
ORM2 is a UASINO-containing gene, whose expression is controlled by inositol  
(Han et al., 2010). Chronic VPA-mediated inositol depletion increases expression of 
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genes containing UASINO in their promoters (Ju and Greenberg, 2003).  However, acute 
VPA-mediated inositol depletion decreases expression of UASINO-containing genes, 
including INO1 and INO2 (Ju and Greenberg, 2003). The current study shows that 
acute VPA downregulates the expression of ORM genes, similar to other UASINO-
containing genes, via acute inositol depletion. This confirms the earlier finding that acute 
and chronic VPA-mediated inositol depletion differentially regulate expression of 
UASINO-containing genes (Ju and Greenberg, 2003).  
Lithium, another antibipolar drug that also causes inositol depletion, does not 
decrease INO1 expression in response to acute treatment. This suggests that the 
decrease in expression of UASINO-containing genes may be mediated via a mechanism 
other than inositol depletion. Ju and Greenberg (2003) proposed a mechanism to 
explain this abrogated expression in response to acute VPA. Their study showed that 
acute VPA causes a decrease in the level of phosphatidylserine, a protein kinase C 
activator. Decreased activity of PKC causes an increase in unphosphorylated Opi1 
(active), which leads to a decrease in INO1 expression (Sreenivas et al., 2001). 
Consistent with this, acute VPA does not affect expression of UASINO-containing genes 
in opi1Δ mutant cells.  This model is consistent with my observations and suggests that 
acute VPA may downregulate expression of Orm2, a UASINO-containing gene, via Opi1. 
Acute VPA decreases the expression of ORM and fatty acid elongase genes and 
increases the expression of RSB1, YOR1, and DPL1.  The fold change of expression is 
greater in I- than in I+ medium, suggesting that the response to VPA was partially 
mediated by inositol depletion. Consistent with this, acute inositol starvation of ino1Δ 
cells caused similar effects, including decreased expression of ORM, FEN1, and SUR4 
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genes and increased expression of RSB1 and YOR1. Based on these data, I propose 
that the VPA-mediated decrease in intracellular inositol levels causes a decrease in the 
expression of fatty acid elongase (FEN1 and SUR4) and ORM genes, decreased Orm2 
protein levels, and an increase in levels of PHS. To remediate the toxic effects of PHS, 
expression of RSB1, YOR1, and DPL1 is increased, and PHS is either transported from 
the cell or degraded to other metabolites (Fig. 4.8).  
This study shows for the first time that acute VPA-mediated inositol starvation 
increases intracellular levels of the signaling sphingolipid molecule, PHS, which 
regulates actin cytoskeleton, heat stress, and endocytosis (Hannun and Obeid, 2008). 
Heat stress induces a transient 2-3-fold increase in the levels of C18 PHS and a 100-
fold increase in levels of C20 PHS (Dickson et al., 1997; Jenkins et al., 1997). PHS is 
required for regulation of actin cytoskeleton organization (Schmelze et al., 2002) and 
endocytosis (deHart et al., 2002). PHS also inhibits uptake of uracil and amino acids 
tryptophan, leucine, and histidine (Chung et al., 2001). The exact role of PHS in the 
regulation of amino acid transport remains unknown; however, PHS is important for 
ubiquitin-mediated breakdown of the uracil transporter Fur4 (Chung et al., 2000). 
Sphingosine, the  mammalian equivalent of PHS, activates synaptobrevin in synaptic 
vesicles, facilitating SNARE complex assembly and membrane fusion. In addition, 
sphingosine plays a crucial role in increasing synaptic vesicle exocytosis at nerve 
terminals and neuromuscular junctions (Darios et al., 2009). In summary, PHS is an 
important signaling lipid crucial for maintaining actin cytoskeleton, heat stress, 
endocytosis and exocytosis, and neurotransmitter release in mammals. Perturbation of 
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PHS/sphingosine by VPA might affect neurotransmitter release and other processes 
that affect neural function and may, thus, be a novel mechanism of action of VPA. 
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Figure 4.2. VPA increases the levels of RSB1. RSB1 mRNA levels were 
quantified by qRT-PCR from wild type cells grown in the presence or absence of 
VPA for 30 minutes. Values are reported as fold change in expression of cells 
grown in the presence of VPA compared to cells grown in the absence of VPA, in 
I+ (A) or I- (B). Expression was normalized to the mRNA levels of ACT1 (internal 
control). Data shown are mean of ± SD (n=6). C, Western blot analysis of Rsb1 
protein. rsb1Δ cells expressing a plasmid containing RSB1 tagged with HA were 
grown in the presence and absence of inositol and VPA, harvested and lysed for 
protein extraction. 30 µg total cell extract from each sample were subjected to 
Western blot analysis using 10% SDS-PAGE gel. Data shown are mean ± SD 
(n=6). 
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Figure 4.3. VPA increases sensitivity of rsb1Δ to PHS.  Wild type and rsb1Δ 
cells expressing a plasmid containing RSB1 or empty vector (EV) were 
precultured in I+ medium, diluted, and spotted on I- medium containing VPA 
(1mM) or PHS (20 µM) as indicated. 
 
 
 
 
 
 
 
 
	  	  	  
188	  
	  
  
 
 
 
Figure 4.4. VPA increases levels of PHS. Wild type (A) and rsb1Δ (B) cells were 
pre-cultured in I+ medium, harvested, washed twice with sterile water, and grown in I- 
medium until cells reached the mid log phase (A550= 0.5). Cells were pelleted and 
suspended in fresh I- medium with or without 0.6 mM VPA and incubated for 30 
minutes. Cells were pelleted and DHS, PHS, DHS-1P, and PHS-1P levels were 
quantified by mass spectrometry. Data shown are mean ± SD (n=6 *, *, p < 0.05; **, p 
< 0.01; ***, p < 0.001).  
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Figure 4.5. VPA increases the expression of YOR1 and DPL1.  mRNA levels were 
quantified by qRT-PCR from wild type cells grown in the presence or absence of VPA. 
Values are reported as fold change in expression in cells grown in the presence of VPA 
compared to cells grown in the absence of VPA, in I- and I+ medium, for YOR1 (A) and 
DPL1 (B). Expression was normalized to the mRNA levels of ACT1 (internal control). 
Data shown are mean ± SD (n=6). 
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Figure 4.6. VPA affects ORM expression. (A) ORM1 and ORM2 mRNA levels were 
quantified by qRT-PCR from wild type cells grown in the presence or absence of VPA 
in I- (top) or I+ (bottom). Values are reported as fold change in expression in cells 
grown in the presence of VPA compared to cells grown in the absence of VPA. 
Expression was normalized to the mRNA levels of ACT1 (internal control). Data 
shown are mean ± SD (n=6). (B) Western blot analysis of Orm2 protein levels in wild 
type cells expressing ORM2 tagged with HA. Cells were grown in the presence and 
absence of VPA in I-, harvested and lysed for protein extraction. 60 µg total cell 
extract from each sample were subjected to Western blot analysis using 12% SDS-
PAGE gel. 
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Figure 4.7. VPA decreases the levels of FEN1 and SUR4.  mRNA levelFEN1 and 
SUR4 were quantified by qRT-PCR from wild type cells grown in the presence or 
absence of VPA in I- (top) or I+ (bottom), as described in Fig. 4.2. 
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Figure 4.8. Inositol depletion downregulates ORM and fatty acid elongase 
genes and upregulates RSB1 and YOR1. ino1Δ cells were precultured in I+ 
medium, harvested, washed twice with sterile water, and grown in I+ until the 
cells reached the mid log phase (A550= 0.5). Cells were pelleted, washed twice 
with sterile water and cultivated in fresh I- (inositol starvation) or I+ (control) for 
30 minutes. mRNA levels were quantified by  qRT-PCR as described in Fig. 4.2.  
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Figure 4.9. Proposed model. In the proposed model, acute VPA mediated 
inositol depletion leads to decreased expression of fatty acid elongases (FEN1 and 
SUR4) and ORM genes. This increases the de novo synthesis and accumulation 
of the signaling sphingolipid molecule, PHS, which is toxic at high levels. Cells 
respond by increasing expression of RSB1 (transporter of PHS), YOR1 
(transporter of PHS-1P), and DPL1 (breaks down PHS-1P), which aid in 
maintaining non-toxic levels of PHS. (Abbreviations: SPT, Serine palmitoyl 
transferase; DHS, Dihydrosphingosine; PHS, Phytosphingosine; DHS-1P, 
Dihydrosphingosine-1-phosphate PHS-1P, Phytosphingosine-1-phosphate) 
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CHAPTER 5 FUTURE DIRECTIONS 
The studies in this thesis identified and characterized sphingolipid metabolism as 
a new target of VPA, which could be important in the therapeutic action of the drug. 
While my work has shed light on the effect of VPA on sphingolipid metabolism, a 
number of fascinating unanswered questions remain to be explored. In this chapter, I 
suggest challenging and interesting directions for future studies that could lead to a 
better understanding of the mechanisms underlying the therapeutic action of VPA. 
Does VPA induce the UPR pathway in mammals?  
In Chapter 3, I showed that, in yeast, chronic VPA-mediated inositol depletion 
induces the UPR by increasing intracellular ceramide levels. This major finding identifies 
the UPR as a possible new target of VPA. However, It is not known if VPA induces the 
UPR pathway in mammals.  
VPA is known to cause inositol depletion in yeast as well as mammalian cells 
(Vaden et al., 2001; Shaltiel et al., 2004; Ye and Greenberg, 2015). I suggest future 
experiments to determine if VPA induces the UPR pathway in mammalian cells, as 
determined by the effect of VPA on: 1) intracellular levels of ceramide, 2) induction of 
the UPR pathway, and 3) the role of ceramide in UPR induction. 
  My findings demonstrate that chronic VPA specifically increases levels of C24- 
and C26-containing phytoceramide. Future experiments should determine if VPA 
specifically increases C24-C26-ceramides in mammalian cells. 
 If experiments confirm the findings in yeast and reveal that VPA induces the 
UPR pathway in mammals, this will suggest that the UPR pathway is an important 
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target of VPA. Drugs that induce the UPR pathway can be tested for their antibipolar 
efficacy.  
What is the mechanism that causes inositol depletion to increase ceramide levels 
and induce the UPR? 
As stated previously, I showed that chronic VPA causes inositol depletion, which 
increases ceramide levels and induces the UPR pathway. However, the mechanism by 
which inositol depletion leads to increased ceramide levels remains unknown. VPA 
mediated inositol starvation increased the expression of fatty acid elongases FEN1 and 
SUR4, which catalyze the synthesis of C24-C26 fatty acids and levels of C24- and C26-
containing phytoceramide. I suggest future experiments to determine the effect of VPA 
and inositol starvation on the enzyme activity of fatty acid elongases and ceramide 
synthase. Solving this mystery will not only aid in elucidating the mechanism by which 
VPA increases ceramide levels, but also uncover a novel regulatory mechanism of 
ceramide synthesis.  
What is the mechanism that causes acute VPA to increase PHS levels? 
In Chapter 4, I showed that acute VPA-mediated inositol depletion increases de 
novo synthesis of PHS. However, the mechanism by which VPA increases PHS levels 
is not known. My studies revealed that acute VPA decreases expression of ORM and 
fatty acid elongases, suggesting that VPA increases de novo synthesis of PHS. I 
suggest further studies to determine if VPA: 1) increases the activity of serine palmitoyl 
transferase (SPT), the enzyme catalyzing de novo synthesis of PHS; 2) increases 
phosphorylation of Orm proteins, which regulate SPT activity; 3) decreases activity of 
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fatty acid elongases; and/ or 4) decreases ceramide synthase activity, which is 
expected to cause accumulation of the precursor, PHS.  
PHS acts as a second messenger that controls a wide range of cellular 
processes, including growth, cell wall integrity, stress resistance, endocytosis, and 
aging (Liu et al., 2005). Future experiments should determine if VPA increases levels of 
sphingosine, the homolog of PHS in mammals.  Further, characterizing the effect of 
acute VPA on: 1) sphingosine levels, 2) Orm protein and phosphorylation levels, 3) SPT 
activity, and 4) fatty acid elongation in mammalian cells would aid in determining if acute 
effects of VPA are conserved in yeast and mammals. Determining this will not only aid 
in elucidating the mechanism by which acute VPA mediated inositol depletion increases 
PHS levels, but may also uncover a novel regulatory mechanism of PHS synthesis via 
inositol.  
Identify new targets of VPA that could play a role in the therapeutic action of the 
drug 
In order to identify targets of VPA, I performed a genome wide microarray 
analysis with acute and chronic VPA treatment, as described in Chapter 2.  Previous 
studies showed that acute VPA decreases and chronic VPA increases expression of 
INO1 (Ju and Greenberg, 2003), which was confirmed by my microarray study. This 
indicates that VPA exhibits differential perturbation of gene expression in response to 
acute vs. chronic VPA treatment.  
 I focused my studies on the effect of VPA on sphingolipid metabolism. However, 
the screen revealed that VPA affects a number of pathways, including lipid metabolism, 
glycolysis, amino acid metabolism, and transmembrane transport as potential targets of 
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VPA.  Further experiments to characterize the effect of VPA on these cellular pathways 
remain to be done. As an example, Michael Salsaa’ has systematically analyzed this 
microarray data and determined that chronic VPA increases glycolytic genes in I- 
medium. His observations led to the exciting hypothesis that VPA-mediated inositol 
depletion diverts glucose-6-phosphate from inositol synthesis to glycolysis. I am certain 
that his hypothesis will result in a fascinating dissertation project. I invite my colleagues 
to continue to mine my microarray database to further explore the mechanism of action 
of VPA. 
In conclusion, VPA is a drug that has been used for the treatment of BD for 
years, in spite of not understanding the molecular mechanism that elicits its therapeutic 
mode of action. The identification and characterization of cellular targets will aid in 
understanding the mechanisms of action of VPA and the pathophysiology of BD, which 
remains poorly understood.  
Now that we are at the end of this thesis, we have certainly not finished 
identifying all the targets of VPA, nor do we completely understand the molecular 
mechanism of the drug. I am sure my lab mates will continue to explore and contribute 
to the understanding of VPA as a bipolar drug.  I hope you enjoy the research and time 
in the lab as I did. Good luck!!! 
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APPENDIX 
IDENTIFICATION OF SYNTHETIC GENETIC INTERACTIONS OF LCB4 
INTRODUCTION 
Sphingolipids are primarily found in the plasma membrane and can be 
metabolized to signaling molecules (Pitman et al., 2015). Among these, sphingosine-1-
phosphate (S1P) is a signaling molecule that is known to play a role in the development 
of cancer, obesity, anxiety disorders, diabetes, and cardiovascular disorders (Pyne et 
al., 2016). S1P is synthesized by phosphorylation of sphingosine, catalyzed by 
sphingosine kinases SphK1 and SphK2 (Pitman et al., 2015). S1P regulates several 
important cellular functions, including cell proliferation, cell survival, cell migration, and 
neurotransmitter release (Okada et al., 2009; Zhang et al., 2001; Spiegel and Merrill, 
1996; Spiegel et al., 1996; Meyer zu Heringdorf et al., 1999). The functional roles of 
S1P were discovered in the last several years and remain an exciting focus of current 
research.  
Sphingolipid synthesis and metabolism are complex. The sphingolipid synthesis 
pathway is highly conserved in yeast and mammals (Epstein and Riezman, 2013). The 
two major yeast long chain bases (LCBs), dihydrosphingosine (DHS) and 
phytosphingosine (PHS), are homologous to mammalian sphingosine (Nagiec et al., 
1998). DHS and PHS are phosphorylated to DHS phosphate (DHS-1P) or PHS 
phosphate (PHS-1P) by sphingolipid base kinases Lcb4 and Lcb5, which account for 
97% and 3% of sphingolipid base kinase activity, respectively (Nagiec et al., 1998).  In 
this study, I carried out a genetic screen to elucidate functions of LCB4 by identifying 
synthetic lethal interactions of the lcb4Δ mutant. Synthetic lethality is a genetic 
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phenomenon in which deletion of two or more genes causes lethality, while deletion of 
only one gene is viable. Synthetic lethality suggests that the gene products carry out 
similar functions in a common pathway or in alternative pathways. The genetic screen 
known as Synthetic Genetic Array (SGA), currently possible only in yeast, identifies 
genetic interactions with all non-essential yeast genes (Tong et al., 2006).  
Using the SGA approach, I identified genetically interacting mutants in several 
functional categories. Among these, especially interesting was ER-Golgi transport, 
suggesting for the first time that LCBPs generated by Lcb4 may play a role in this 
process. In addition to ER-Golgi transport, carbohydrate metabolism, cell cycle, 
cytoskeletal organization, cellular amino acid metabolic processes, and transmembrane 
transport mutants exhibited synthetic interactions with lcb4Δ. Synthetic interaction 
suggests a possible overlapping role of Lcb4 in these cellular functions. 
MATERIALS AND METHODS 
Growth medium 
Synthetic complete medium contained adenine (20.25mg/l), arginine (20mg/l), 
histidine (20mg/l), leucine (60mg/l), lysine (200mg/l), methionine (20mg/l), threonine 
(300mg/l), tryptophan (20mg/l) and uracil (20mg/l), vitamin mix, yeast base (Difco), 
ammonium sulphate 5gm/l, glucose 20gm/l, 75µM inositol. Synthetic drop out medium 
contained all these components but lacked the indicated amino acid. G418 (400mg/ml) 
and 5-fluoroorotic acid (FOA) (2gm/l) were added when indicated. Sporulation medium 
contained yeast extract (1.25gm/l), glucose (1gm/l), potassium acetate (10gm/l), leucine 
(60mg/l), uracil 920mg/l), histidine (20mg/l), tryptophan (20mg/l) and methionine 
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(20mg/l). YPD medium contained yeast extract (1%), peptone (2%), and glucose (2%).  
Agar (2%) was added in solid medium. 
Construction of the starting strain for the synthetic lethality screen 
The starting strain was constructed in three steps: disruption of LCB4, 
confirmation of disruption by PCR, and genetic analysis of the phenotype. The 
disruption cassette containing the URA marker was amplified from the pUGK plasmid 
using forward primer 
5’AGGTTATCAAGAACACAAAAGTCTAGCAGCGAAAAGTACGCGAAGAATCTACTAT
AGATACAGCTGAAGCTTCGTACGC3’ and reverse primer 
5’TTTCGATGTAGTATTTCTTTTTACAAAAAAATCATTTTTGAAGGAAAATATAACG3’ 
using polymerase chain reaction (PCR). The PCR product was electrophoresed on an 
agarose gel and cleaned using a Qiagen gel purification kit. The wild type SGA strain 
Matαcan1Δ::STE2pr-LEU2 lyp1Δhis3Δleu2Δura3ΔmetΔ (Tong and Boone, 2006) was 
transformed with the purified PCR product by electroporation and recombinants were 
selected on Ura- medium. Disruption of the LCB4 gene and insertion of the URA 
cassette were confirmed by PCR (Fig. A.1). The recombinants were also tested for 
mating type (Matα) and Ura+, Leu-, Met-, and His- phenotypes. 
SGA design 
 The MATα can1Δlcb4Δ was crossed to the array of deletion mutants in the 
MATa background, in which the deletions are linked to the dominant selectable marker 
for geneticin resistance, KanMx4. Diploids were selected on Ura- G418 medium and 
sporulation was induced. Haploid spore progeny were transferred to synthetic medium 
lacking leucine, which allowed for selective germination of MATa cells by virtue of the 
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STE2pr-LEU2 reporter. Following two rounds of selection on Leu- G418 medium, double 
mutant MATa progeny were selected on Leu- medium supplemented with G418. 
Synthetic interaction between lcb4Δ and deletion mutants was determined by examining 
growth of the double mutant on Leu- Ura- G418 compared to that of wild type and to 
single mutants on Leu- FOA.  Mutants that exhibited growth on Leu- FOA but exhibited 
no growth or less growth on Leu- Ura- G418 were categorized as synthetically lethal or 
sick.   
RESULTS AND DISCUSSION 
 An SGA screen was performed to identify mutants that synthetically interact with 
the lcb4Δ mutant in order to identify pathways that share a common or overlapping 
function with LCB4. As expected, the SGA screen identified a large number of synthetic 
interactions. Fifteen mutants showed a sick interaction with lcb4Δ at 30°C and one 
hundred and twenty four mutants at 37°C (Tables A.1 and A.2). Interacting genes were 
grouped based on their associated cellular processes (Tables A.3 and A.4) using the 
GO Slim Mapper program available on the Saccharomyces Genome Database (SGD). 
Previous studies have shown that sphingosine kinase may play a role in ER-
Golgi transport. Consistent with these studies, lcb4Δ interacted with genes involved in 
this process (Table A.5). ECM21 was the only gene that showed a synthetic sick 
interaction at the optimal growth temperature of 30°C, suggesting that an essential 
function is not compensated by other genes in cells lacking Lcb4 and Ecm21. Mutants 
of ERV15, VPS54, GGA1, EMP24, SLY41, ECM21, SUR7, CSR2, STP22, VPS54, and  
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Figure A.1. PCR confirmation of the SGA query strain. Query strain DNA was 
subjected to PCR amplification using the following primers 1: primers for LCB4; 2: 
forward primer upstream and reverse primer downstream of LCB4; 3: forward primer 
upstream of LCB4 and reverse primer within the gene; 4: forward primer upstream of 
the LCB4 and reverse primer within the URA cassette; 5: primers for the CAN1 gene.  
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Figure A.2. Synthetic genetic array (SGA)  (modified from Tong et al., 2001). 
Matαcan1Δ::STE2pr-LEU2 lyp1Δhis3Δleu2Δura3ΔmetΔlcb4Δ::URA3 was crossed to 
about 4,800 MATa yeast deletion mutants, each carrying a deletion mutation linked to a 
kanamycin-resistance marker (KanMX), to form diploids. Haploid meiotic spores were 
formed following transfer of heterozygous diploids to sporulation medium. Haploid spore 
progeny were transferred to synthetic medium lacking leucine, which allows for selective 
germination of MATa cells because these cells express the STE2pr-LEU2 reporter. The 
selected MATa meiotic progeny were transferred to Leu- G418-containing medium. 
Leucine auxotrophy and kanamycin resistance identified the double mutant progeny. 
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GGA1 were synthetic sick at the stress temperature of 39°C. These genes function in 
ER-Golgi transport. Synthetic lethality of lcb4Δ and genes encoding for ER-Golgi 
transport proteins suggest that Lcb4 generated LCBP is required for efficient ER-Golgi 
transport.Ceramide is synthesized in the ER and transported to the Golgi by ER-Golgi 
transport proteins. Deletion of genes for ER-Golgi transport increases ceramide levels in 
the ER, resulting in ceramide induced apoptosis. S1P is known to rescue cells from 
ceramide-induced apoptosis (Cuvillier et al., 1996). In addition, overexpression of 
sphingosine kinase 1 (SphK1) rescues defective ER-Golgi protein trafficking (Veret at 
al., 2013), suggesting that S1P is required for efficient ER-Golgi transport.  However, 
the mechanism by which S1P rescues defective ER-Golgi trafficking remains unknown. 
Lcb4 and ER-Golgi transport proteins may genetically interact because deletion of LCB4 
decreases S1P levels and deletion of ER-Golgi transport proteins increases ceramide 
levels inducing apoptosis. I hypothesize that S1P inhibits accumulation of ceramide in 
the ER by promoting its efficient transport to Golgi or by decreasing ceramide synthesis. 
This would identify a novel function of S1P.  
	  	  	  
207	  
	  
 
Table A.1. Genes showing synthetic interaction with lcb4Δ at 30°C 
(Gene descriptions are from Saccharomyces Genome Database) 
 
ORF GENE FUNCTION 
YOR302W Orf  verified 
CPA1 uORF; Arginine attenuator peptide, regulates 
translation of the CPA1 mRNA 
YOR342C Orf  verified 
Protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to the cytoplasm and the 
nucleus 
YLR014C PPR1 
Zinc finger transcription factor; contains a Zn(2)-Cys(6) 
binuclear cluster domain, positively regulates 
transcription of URA1, URA3, URA4, and URA10, 
which are involved in de novo pyrimidine biosynthesis, 
in response to pyrimidine starvation; activity may be 
modulated by interaction with Tup1p 
YDR132C S000002539 
Protein of unknown function; protein increases in 
abundance and relative distribution to the nucleus 
increases upon DNA replication stress 
YLR384C IKI3 
Subunit of Elongator complex; Elongator is required for 
modification of wobble nucleosides in tRNA; maintains 
structural integrity of Elongator 
YML094W GIM5 
Subunit of the heterohexameric cochaperone prefoldin 
complex; prefoldin binds specifically to cytosolic 
chaperonin and transfers target proteins to it 
YPR060C ARO7 
Chorismate mutase; catalyzes the conversion of 
chorismate to prephenate to initiate the 
tyrosine/phenylalanine-specific branch of aromatic 
amino acid biosynthesis 
YBL101C ECM21 
Protein involved in regulating endocytosis of plasma 
membrane proteins; identified as a substrate for 
ubiquitination by Rsp5p and deubiquitination by Ubp2p 
YML027W YOX1 
Homeobox transcriptional repressor; binds to Mcm1p 
and to early cell cycle boxes (ECBs) in the promoters 
of cell cycle-regulated genes expressed in M/G1 
phase; expression is cell cycle-regulated; potential 
Cdc28p substrate 
YGL159W S00000317 
Putative protein of unknown function; deletion mutant 
has no detectable phenotype 
YGL157W ARI1 
NADPH-dependent aldehyde reductase; utilizes 
aromatic and alophatic aldehyde substrates; member 
of the short-chain dehydrogenase/reductase 
superfamily 
YGL156W AMS1 
Vacuolar alpha mannosidase; involved in free 
oligosaccharide (fOS) degradation 
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YER149C PEA2 
Coiled-coil 12S polarisome subunit; required for polarity 
establishment, apical bud growth, shmoo formation, 
filamentous differentiation; involved in Bni1p 
localization at sites of polarized growth, controlling 
polarized assembly of actin cables  
YER109C FLO8 
Transcription factor; required for flocculation, diploid 
filamentous growth, and haploid invasive growth; forms 
a heterodimer with Mss1p that interacts with the 
Swi/Snf complex during transcriptional activation of 
FLO1, FLO11, and STA1 
YER110C KAP123 
Karyopherin beta; mediates nuclear import of ribosomal 
proteins prior to assembly into ribosomes and import of 
histones H3 and H4 
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Table A.2. Genes showing synthetic interaction with lcb4Δ at 39°C 
(Gene descriptions are from Saccharomyces Genome Database) 
 
ORF GENE FUNCTION 
YLL032C ORF, verified Protein of unknown function 
YLR046C 
ORF, 
Uncharacteri
zed 
Putative membrane protein; member of the fungal lipid-
translocating exporter (LTE) family of proteins 
YLR062C 
 
BUD28 Dubious open reading frame 
YLR092W SUL2 High affinity sulfate permease 
 
 
YLR063W BMT6 
Methyltransferase required for m3U2843 methylation of 
the 25S rRNA 
YML052W SUR7 
Plasma membrane protein of unknown function involved 
with endocytosis 
YMR157C AIM36 Protein of unknown function 
YMR25W GTO3 
Omega class glutathione transferase; putative cytosolic 
localization 
YMR282C AEP2 
Mitochondrial protein; likely involved in translation of the 
mitochondrial OLI1 mRNA;  
YOL054W PSH1 
E3 ubiquitin ligase targeting centromere-binding protein 
Cse4p 
YPL261C 
ORF, 
verified 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental and 
comparative sequence data 
YPL254W HFI1 
Adaptor protein required for structural integrity of the 
SAGA complex 
YPL244C HUT1 
Protein with a role in UDP-galactose transport to the 
Golgi lumen 
YPL198W 
 
 
RPL7B 
Ribosomal 60S subunit protein L7B; required for 
processing of 27SA3 pre-rRNA to 27SB pre-rRNA during 
assembly of large ribosomal subunit; depletion leads to a 
turnover of pre-rRNA 
YPL186C UIP4 
Protein that interacts with Ulp1p; a Ubl (ubiquitin-like 
protein)-specific protease for Smt3p protein conjugates 
YPL192C PRM3 
Protein required for nuclear envelope fusion during 
karyogamy 
YPL141C 
 
FRK1 
Protein kinase of unknown cellular role; green 
fluorescent protein (GFP)-fusion protein localizes to the 
cytoplasm 
YBR197C 
ORF, 
Verified 
Protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to the cytoplasm and 
nucleus 
YBR199W KTR4 Putative mannosyltransferase involved in protein 
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glycosylation 
YBR210W ERV15 
Protein involved in export of proteins from the 
endoplasmic reticulum; ERV15 has a paralog, ERV14, 
that arose from the whole genome duplication 
YOR307C SLY41 Protein involved in ER-to-Golgi transport 
YOR323C PRO2 
Gamma-glutamyl phosphate reductase; catalyzes the 
second step in proline biosynthesis 
YOR343C 
ORF, 
verified 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental and 
comparative sequence data 
YOL006C TOP1 
Topoisomerase I; nuclear enzyme that relieves torsional 
strain in DNA by cleaving and re-sealing the 
phosphodiester backbone 
YOL007C CSI2 Protein of unknown function 
YOL014W YOL014W Putative protein of unknown function 
YOL015W IRC10 Putative protein of unknown function 
YPL261C S000006182 Dubious open reading frame 
YPL244C HUT1 
Protein with a role in UDP-galactose transport to the 
Golgi lumen 
YPL240C HSP82 Hsp90 chaperone; redundant in function with Hsc82p 
YPL178W CBC2 
Small subunit of the heterodimeric cap binding complex 
with Sto1p 
YPL136W S000006057 Dubious open reading frame 
YPL106C SSE1 
ATPase component of heat shock protein Hsp90 
chaperone complex; plays a role in determining prion 
variants 
YPL192C PRM3 
Protein required for nuclear envelope fusion during 
karyogamy 
YPL186C UIP4 
Protein that interacts with Ulp1p; a Ubl (ubiquitin-like 
protein)-specific protease for Smt3p protein conjugates 
YDR358W GGA1 Golgi-localized protein with homology to gamma-adaptin 
YDR359C EAF1 
Component of the NuA4 histone acetyltransferase 
complex 
YDR363W ESC2 
Sumo-like domain protein; prevents accumulation of toxic 
intermediates during replication-associated 
recombinational repair; roles in silencing, lifespan, 
chromatid cohesion and the intra-S-phase DNA damage 
checkpoint; RENi family member 
YCL008C STP22 
Component of the ESCRT-I complex; ESCRT-I is 
involved in ubiquitin-dependent sorting of proteins into 
the endosome; prevents polyubiquitination of the 
arrestin-related protein Rim8p, thereby directing its 
monoubiquitination by Rsp5p 
YLR219W MSC3 Protein of unknown function 
YKL177W S000001660 Dubious open reading frame 
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YOR137C SIA1 Protein of unassigned function 
YGR055W MUP1 
High affinity methionine permease; integral membrane 
protein with 13 putative membrane-spanning regions; 
also involved in cysteine uptake 
YOR258W HNT3 
DNA 5' AMP hydrolase involved in DNA repair; member 
of the histidine triad (HIT) superfamily of nucleotide-
binding proteins 
YJL170C ASG7 
Protein that regulates signaling from G protein beta 
subunit Ste4p 
YLR357W RSC2 Component of the RSC chromatin remodeling complex 
YLR362W STE11 Signal transducing MEK kinase 
YLR384C IKI3 
Subunit of Elongator complex; Elongator is required for 
modification of wobble nucleosides in tRNA 
YLR377C FBP1 
Fructose-1,6-bisphosphatase; key regulatory enzyme in 
the gluconeogenesis pathway, required for glucose 
metabolism 
YLR308W CDA2 
Chitin deacetylase; together with Cda1p involved in the 
biosynthesis ascospore wall component, chitosan 
YLR322W VPS65 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental and 
comparative sequence data 
YGL196W DSD1 D-serine dehydratase (aka D-serine ammonia-lyase) 
YDR227W SIR4 
SIR protein involved in assembly of silent chromatin 
domains; silent information regulator (SIR) along with 
SIR2 and SIR3 
YGL200C EMP24 
Component of the p24 complex; role in misfolded protein 
quality control 
YGL214W S000003182 
Dubious open reading frame; unlikely to encode a 
functional protein 
YGL222C EDC1 
RNA-binding protein that activates mRNA decapping 
directly; binds to mRNA substrate and enhances activity 
of decapping proteins Dcp1p and Dcp2p; has a role in 
translation during heat stress 
YGL256W ADH4 
Alcohol dehydrogenase isoenzyme type IV; dimeric 
enzyme demonstrated to be zinc-dependent despite 
sequence similarity to iron-activated alcohol 
dehydrogenases 
YPL088W S000006009 Putative aryl alcohol dehydrogenase 
YPL037C EGD1 
Subunit beta1 of the nascent polypeptide-associated 
complex (NAC); involved in protein targeting, associated 
with cytoplasmic ribosomes 
YPL065W VPS28 
Component of the ESCRT-I complex; complex is 
involved in ubiquitin-dependent sorting of proteins into 
the endosome 
YPL006W NCR1 Vacuolar membrane protein 
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YBL053W S000000149 Dubious open reading frame 
YGL081W S000003049 Putative protein of unknown function 
YDR248C S000002656 
Putative gluconokinase; sequence similarity to bacterial 
and human gluconokinase 
YKR033C S000001741 Dubious open reading frame 
YDR276C PMP3 Small plasma membrane protein 
YDR314C RAD34 
Protein involved in nucleotide excision repair (NER); 
homologous to RAD4 
YDR335W MSN5 
Karyopherin; involved in nuclear import and export of 
proteins, including import of replication protein A and 
export of Far1p and transcription factors Swi5p, Swi6p, 
Msn2p, and Pho4p 
YFL026W STE2 
Receptor for alpha-factor pheromone; seven 
transmembrane-domain GPCR that interacts with both 
pheromone and a heterotrimeric G protein to initiate the 
signaling response that leads to mating between haploid 
a and alpha cells 
YFL054C S000001840 Putative channel-like protein; similar to Fps1p 
YOL095C HMI1 
Mitochondrial inner membrane localized ATP-dependent 
DNA helicase 
YOL115W PAP2 
Non-canonical poly(A) polymerase; involved in nuclear 
RNA degradation as a component of TRAMP; catalyzes 
polyadenylation of hypomodified tRNAs, and snoRNA 
and rRNA precursors; required for mRNA surveillance 
and maintenance of genome integrity, serving as a link 
between RNA and DNA metabolism 
YLL049W LDB18 
Component of the dynactin complex; dynactin is required 
for dynein activity 
YMR312
W ELP6 
Subunit of hexameric RecA-like ATPase Elp456 
Elongator subcomplex; which is required for modification 
of wobble nucleosides in tRNA 
YMR316C
-A S000004933 Protein of unknown function 
YMR316C
-B S000004934 Dubious open reading frame 
YML094W GIM5 
Subunit of the heterohexameric cochaperone prefoldin 
complex 
YMR004
W MVP1 
Protein required for sorting proteins to the vacuole; 
Mvp1p and Vps1p act in concert to promote membrane 
traffic to the vacuole; participates in transcription initiation 
and/or early elongation of specific genes 
YMR121C RPL15B 
Ribosomal 60S subunit protein L15B; binds to 5.8 S 
rRNA; homologous to mammalian ribosomal protein L15, 
no bacterial homolog 
YPR027C S000006231 Putative protein of unknown function 
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YML117W
-A S000004586 Putative protein of unknown function 
YPR030W CSR2 
Nuclear ubiquitin protein ligase binding protein; may 
regulate utilization of nonfermentable carbon sources 
and endocytosis of plasma membrane proteins 
YPR075C OPY2 
Integral membrane protein that acts as a membrane 
anchor for Ste50p; involved in the signaling branch of the 
high-osmolarity glycerol (HOG) pathway and as a 
regulator of the filamentous growth pathway 
YJL030W MAD2 
Component of the spindle-assembly checkpoint complex; 
delays onset of anaphase in cells with defects in mitotic 
spindle assembly; forms a complex with Mad1p 
YJR108W ABM1 Protein of unknown function 
YLR436C ECM30 Putative protein of unknown function 
YAL047C SPC72 
Component of the cytoplasmic Tub4p (gamma-tubulin) 
complex 
YDL243C AAD4 
Putative aryl-alcohol dehydrogenase; involved in 
oxidative stress response 
YMR136
W GAT2 Protein containing GATA family zinc finger motifs 
YDR042C S000002449 
Putative protein of unknown function; expression is 
increased in ssu72-ts69 mutant 
YDR027C VPS54 
Component of the GARP (Golgi-associated retrograde 
protein) complex; GARP is required for the recycling of 
proteins from endosomes to the late Golgi, and for 
mitosis after DNA damage induced checkpoint arrest 
YJL007C S000003544 Dubious open reading frame 
YJR035W RAD26 
Protein involved in transcription-coupled nucleotide 
excision repair; repairs UV-induced DNA lesions 
YDL109C S000002267 
Putative lipase; involved in lipid metabolism; not an 
essential gene 
YDL136W RPL35B 
Ribosomal 60S subunit protein L35B; homologous to 
mammalian ribosomal protein L35 and bacterial L29 
YDL155W CLB3 
B-type cyclin involved in cell cycle progression; activates 
Cdc28p to promote the G2/M transition; may be involved 
in DNA replication and spindle assembly 
YDL184C RPL41A 
Ribosomal 60S subunit protein L41A; comprises only 25 
amino acids; rpl41a rpl41b double null mutant is viable; 
homologous to mammalian ribosomal protein L41, no 
bacterial homolog; RPL41A has a paralog, RPL41B, that 
arose from the whole genome duplication 
YBL101C ECM21 
Protein involved in regulating endocytosis of plasma 
membrane proteins 
YBR019C GAL10 
UDP-glucose-4-epimerase; catalyzes the interconversion 
of UDP-galactose and UDP-D-glucose in galactose 
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metabolism 
YBR030W RKM3 Ribosomal lysine methyltransferase 
YBR065C ECM2 Pre-mRNA splicing factor 
YBR069C TAT1 
Amino acid transporter for valine, leucine, isoleucine, and 
tyrosine 
YIL110W HPM1 
AdoMet-dependent methyltransferase; involved in a 
novel 3-methylhistidine modification of ribosomal protein 
Rpl3p 
YIL099W SGA1 Intracellular sporulation-specific glucoamylase 
YNL072W RNH201 Ribonuclease H2 catalytic subunit 
YNL097C PHO23 
Component of the Rpd3L histone deacetylase complex; 
involved in transcriptional regulation of PHO5 
YFR013W IOC3 
Subunit of the Isw1a complex; Isw1a has nucleosome-
stimulated ATPase activity and represses transcription 
initiation by specific positioning of a promoter proximal 
dinucleosome 
YJL160C PIR5 Putative protein of unknown function 
YJL213W S000003749 
Protein of unknown function that may interact with 
ribosomes 
YBR169C SSE2 
Member of the heat shock protein 70 (HSP70) family; 
may be involved in protein folding; localized to the 
cytoplasm; SSE2 has a paralog, SSE1, that arose from 
the whole genome duplication 
YDL002C NHP10 
Non-essential INO80 chromatin remodeling complex 
subunit; preferentially binds DNA ends, protecting them 
from exonucleatic cleavage 
YDL001W RMD1 Cytoplasmic protein required for sporulation 
YDL026W S000002184 Dubious open reading frame 
YDL027C S000002185 Putative protein of unknown function 
YDL041W S000002199 Dubious open reading frame 
YDL077C VAM6 
Vacuolar protein involved in vacuolar membrane fusion 
tethering 
YDR440W DOT1 Nucleosomal histone H3-Lys79 methylase 
YGL101W S000003069 Protein of unknown function 
YGL109W S000003077 Dubious open reading frame 
YGL110C CUE3 Protein of unknown function 
YGL147C RPL9A Ribosomal 60S subunit protein L9A 
YGL157W ARI1 NADPH-dependent aldehyde reductase 
YGL159W S000003127 Putative protein of unknown function 
YER149C PEA2 
Coiled-coil 12S polarisome subunit; required for polarity 
establishment, apical bud growth, shmoo formation, 
filamentous differentiation; involved in Bni1p localization 
at sites of polarized growth, controlling polarized 
assembly of actin cables 
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YDR483W KRE2 Alpha1,2-mannosyltransferase of the Golgi 
YJL028W S000003565 Protein of unknown function 
YIL066C RNR3 
Minor isoform of large subunit of ribonucleotide-
diphosphate reductase 
YML110C COQ5 
2-hexaprenyl-6-methoxy-1,4-benzoquinone 
methyltransferase 
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Table A.3. Genes classified based on the cell process showing synthetic 
interaction with lcb4Δ at 30°C 
 
GO term Frequency 
 
Gene(s) 
 
Transcription from RNA 
polymerase II promoter 
33.30% FLO8,PPR1,IKI3,YOX1,GIM
5 
Pseudohyphal growth 20% FLO8,KAP123,PEA2 
Carbohydrate metabolic 
process 
13.30% FLO8,AMS1 
Mitotic cell cycle 13.30% PEA2,YOX1 
DNA-templated transcription, 
elongation 
6.70% GIM5 
Cytoskeleton organization 6.70% PEA2 
Cytokinesis 6.70% PEA2 
Cellular amino acid metabolic 
process 
6.70% ARO7 
Cell morphogenesis 6.70% PEA2 
RNA modification 6.70% IKI3 
Nucleobase-containing small 
molecule metabolic process 
6.70% PPR1 
Protein complex biogenesis 6.70% GIM5 
Nuclear transport 6.70% KAP123 
Response to chemical 6.70% PEA2 
Invasive growth in response to 
glucose limitation 
6.70% FLO8 
Cell budding 6.70% PEA2 
Endocytosis 6.70% ECM21 
Regulation of organelle 
organization 
6.70% PEA2 
Oligosaccharide metabolic 
process 
6.70% AMS1 
Conjugation 6.70% PEA2 
Regulation of translation 6.70% YOR302W 
tRNA processing 6.70% IKI3 
Protein targeting 6.70% KAP123 
biological process unknown 26.70% YDR132C,ARI1,YGL159W,
YOR342C 
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Table A.4. Genes classified based on the cell process showing synthetic 
interaction with lcb4Δ at 39°C 
 
GO term 
 
Frequency 
 
Gene(s) 
 
Chromatin organization 8.10% NHP10,SIR4,EAF1,DOT1,IOC3,RA
D26,RSC2,PHO23,TOP1,HFI1 
Mitotic cell cycle 8.10% SPC72,ERV15,CLB3,ESC2,DOT1,
PEA2,MAD2,LDB18,BUD28,TOP1 
Cellular response to DNA 
damage stimulus 
7.30% NHP10,RAD34,EAF1,ESC2,DOT1,
RAD26,RSC2,PAP2,HNT3 
Transcription from RNA 
polymerase II promoter 
7.30% RSC2,IKI3,GIM5,GAT2,ELP6,PHO
23,TOP1,HFI1,CSR2 
DNA repair 6.50% NHP10,RAD34,EAF1,ESC2,DOT1,
RAD26,RSC2,PAP2 
Regulation of organelle 
organization 
5.60% SPC72,VAM6,CLB3,DOT1,PEA2,M
AD2,HSP82 
Protein targeting 5.60% STP22,GGA1,VPS65,MVP1,EGD1,
VPS28,HSP82 
DNA recombination 5.60% NHP10,ESC2,DOT1,MSC3,RSC2,T
OP1,PAP2 
Organelle fission 5.60% SPC72,ESC2,DOT1,MAD2,MSC3,
TOP1,PAP2 
Regulation of cell cycle 4.80% SPC72,CLB3,ESC2,DOT1,MAD2,O
PY2 
Conjugation 4.80% PEA2,STE2,ASG7,STE11,PRM3,O
PY2 
Protein complex biogenesis 4.80% SPC72,VAM6,EAF1,STE2,GIM5,H
SP82 
Meiotic cell cycle 4.80% VPS54,DOT1,MSC3,CDA2,SUR7,P
AP2 
Ion transport 4.80% TAT1,PMP3,MUP1,SUL2,SIA1,HU
T1 
Cytoskeleton organization 4.00% SPC72,CLB3,PEA2,ABM1,LDB18 
Carbohydrate metabolic 
process 
4.00% GAL10,KTR4,KRE2,SGA1,FBP1 
Response to chemical 4.00% PMP3,PEA2,STE2,STE11,OPY2 
Cell wall organization or 
biogenesis 
4.00% VPS54,KRE2,CDA2,STE11,CSR2 
Chromosome segregation 4.00% SPC72,ESC2,MAD2,RSC2,TOP1 
Proteolysis involved in 
cellular protein catabolic 
process 
4.00% STP22,GGA1,MAD2,PSH1,VPS28 
Cytoplasmic translation 4.00% RPL35B,RPL41A,RPL9A,RPL15B,
RPL7B 
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Golgi vesicle transport 4.00% ERV15,VPS54,GGA1,EMP24,SLY4
1 
RNA modification 3.20% BMT6,IKI3,ELP6,PAP2 
Regulation of protein 
modification process 
3.20% STP22,CLB3,ESC2,STE11 
Cellular amino acid 
metabolic process 
3.20% DSD1,ADH4,GTO3,PRO2 
Protein folding 3.20% SSE2,EGD1,SSE1,HSP82 
Protein modification by 
small protein conjugation or 
removal 
3.20% STP22,ESC2,ELP6,PSH1 
Protein phosphorylation 2.40% CLB3,STE11,FRK1 
Endosomal transport 2.40% STP22,VPS54,GGA1 
RNA catabolic process 2.40% EDC1,RNH201,PAP2 
DNA replication 2.40% RNH201,TOP1,HSP82 
Peptidyl-amino acid 
modification 
2.40% RKM3,HPM1,HFI1 
Response to osmotic stress 2.40% STE11,HSP82,OPY2 
Cytokinesis 2.40% ERV15,PEA2,BUD28 
Protein alkylation 2.40% RKM3,DOT1,HPM1 
Generation of precursor 
metabolites and energy 
2.40% ADH4,SGA1,COQ5 
Regulation of DNA 
metabolic process 
2.40% TOP1,PAP2,HSP82 
Sporulation 2.40% VPS54,CDA2,SUR7 
Mitochondrion organization 2.40% AEP2,HMI1,HSP82 
tRNA processing 2.40% IKI3,ELP6,PAP2 
DNA-templated 
transcription, elongation 
2.40% RSC2,GIM5,TOP1 
rRNA processing 2.40% RPL35B,BMT6,RPL7B 
Endocytosis 2.40% ECM21,SUR7,CSR2 
Signaling 2.40% STE2,STE11,OPY2 
mRNA processing 1.60% ECM2,CBC2 
RNA splicing 1.60% ECM2,CBC2 
Transmembrane transport 1.60% TAT1,YFL054C 
Histone modification 1.60% DOT1,HFI1 
Protein glycosylation 1.60% KTR4,KRE2 
Lipid metabolic process 1.60% YDL109C,NCR1 
Cell budding 1.60% ERV15,PEA2 
Nucleobase-containing 
compound transport 
1.60% MSN5,HUT1 
Vesicle organization 1.60% VAM6,EMP24 
Pseudohyphal growth 1.60% PEA2,STE11 
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Invasive growth in response 
to glucose limitation 
1.60% STE11,PHO23 
Response to heat 1.60% STE11,PHO23 
Amino acid transport 1.60% TAT1,MUP1 
Ribosomal large subunit 
biogenesis 
1.60% RPL35B,RPL7B 
Telomere organization 1.60% NHP10,HSP82 
Organelle fusion 1.60% VAM6,PRM3 
Membrane fusion 1.60% VAM6,PRM3 
Translational initiation 0.80% AEP2 
Nucleus organization 0.80% PRM3 
Cell morphogenesis 0.80% PEA2 
Membrane invagination 0.80% VAM6 
Nuclear transport 0.80% MSN5 
Transposition 0.80% STE11 
 snoRNA processing 0.80% PAP2 
Response to starvation 0.80% OPY2 
Transcription from RNA 
polymerase I promoter 
0.80% PHO23 
Cellular respiration 0.80% COQ5 
Vacuole organization 0.80% VAM6 
Mitochondrial translation 0.80% AEP2 
Oligosaccharide metabolic 
process 
0.80% KRE2 
Cofactor metabolic process 0.80% COQ5 
 Regulation of transport 0.80% VAM6 
Protein maturation 0.80% MAD2 
 Protein acylation 0.80% HFI1 
Nucleobase-containing 
small molecule metabolic 
process 
0.80% RNR3 
Regulation of translation 0.80% EDC1 
Biological process unknown 29.00% YBL053W,YBR197C,RMD1,YDL02
6W,YDL027C,YDL041W,YDR042
C,YDR248C,YGL081W,YGL101W,
YGL109W,CUE3,ARI1,YGL159W,
YGL214W,YJL007C,YJL028W,YJL
160C,YJL213W,YKL177W,YKR03
3C,YLL032C,YLR046C,ECM30,Y
ML116W-A,AIM36,YMR316C-
A,YMR316C- 
B,CSI2,YOL014W,IRC10,YOR343
C,YPL136W,UIP4,YPL261C,YPR0
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27C 
Other 1.60% AAD4,YPL088W 
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Table A.5. LCB4 interacts with genes involved in ER-Golgi transport 
 
 
Function Interaction at 30°C Interaction at 39°C 
Golgi vesicle 
transport 
  ERV15,VPS54,GGA1,EMP2
4, SLY41 
Endocytosis ECM21 ECM21,SUR7,CSR2 
Endosomal transport   STP22,VPS54,GGA1 
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  Bipolar disorder (BD), which is characterized by depression and mania, affects 
about 1% of the total world population. Current treatments are effective in only 40-60% of 
cases and cause severe side effects. Valproic acid (VPA), a branched short-chain fatty 
acid, is one of the most widely used drugs for the treatment of BD. Although many 
hypotheses have been postulated to explain the molecular mechanism of action of this 
drug in BD, the therapeutic mechanism is not understood. This knowledge gap has 
hampered the development of new drugs to treat this disorder. To identify candidate 
pathways affected by VPA, I performed a genome wide expression analysis in yeast cells 
grown in the presence or absence of the drug. Many genes and pathways showed altered 
expression in response to VPA. Among these, sphingolipid metabolism genes showed 
altered expression in response to both chronic and acute VPA treatment.  
Chronic VPA caused upregulation of FEN1 and SUR4, encoding fatty acid 
elongases that catalyze the synthesis of very long chain fatty acids (C24 to C26) 
required for the synthesis of ceramide. Interestingly, fen1Δ and sur4Δ mutants exhibited 
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VPA sensitivity. Consistent with this, VPA increased levels of ceramides, especially 
those that contain C24 and C26 fatty acids. As expected with an increase in ceramide, 
VPA decreased the expression of amino acid transporters, increased the expression of 
ER chaperones, and activated the unfolded protein response element (UPRE), 
suggesting that VPA induces the UPR pathway. These effects are rescued by 
supplementation of inositol and are similarly observed in inositol-starved ino1Δ cells. 
Starvation of ino1Δ cells increased expression of FEN1 and SUR4, increased ceramide 
levels, decreased expression of nutrient transporters, and induced the UPR. These 
findings suggest that VPA-mediated inositol depletion induces the UPR by increasing 
the de novo synthesis of ceramide.  
  In response to acute VPA, the gene that exhibited the highest upregulation was 
RSB1, which encodes a transporter of the long chain bases (LCBs) dihydrosphingosine 
(DHS) and phytosphingosine (PHS).  In addition to increased mRNA, acute VPA 
increased Rsb1 protein levels. The rsb1Δ mutant exhibited increased sensitivity to PHS in 
the presence of VPA, suggesting that VPA increases PHS levels. Consistent with this, 
acute VPA increased PHS levels, especially in rsb1Δ cells. LCBs are precursors of 
ceramide synthesis, which begins in the endoplasmic reticulum by the conversion of 
palmitoyl-CoA to PHS or DHS. These intermediates are converted to ceramide via 
ceramide synthase by addition of a fatty acid synthesized by the fatty acid elongation 
pathway. Orm proteins are negative regulators of de novo synthesis of PHS, which was 
shown to function as a signaling molecule.  My findings indicate that acute VPA 
downregulates ORM and fatty acid elongases FEN1 and SUR4. This leads to increased 
PHS levels and increased expression of RSB1 as well as genes that transport and 
	  	  	  
262	  
	  
metabolize PHS, including YOR1 and DPL1. Inositol starvation of the ino1Δ mutant for 30 
minutes increased expression of RSB1 and YOR1 and decreased expression of FEN1, 
SUR4, ORM1, and ORM2. This study shows for the first time that acute VPA-mediated 
inositol depletion increases levels of PHS. 
  In summary, I identified sphingolipid metabolism as a new target of VPA. My 
studies showed that VPA exerts inositol depletion-mediated differential effects on 
sphingolipid species. Chronic VPA increases ceramide levels and induces the UPR 
pathway, whereas, acute VPA increases the levels of PHS. These findings suggest that 
sphingolipid metabolism is a potential target of VPA that could be important for the 
therapeutic action of this drug.  
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